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Resistance to platinum is a major problem in the treatment of ovarian cancer. 
Molecular profiling of isogenic ovarian cancer cell line pairs derived from tumour 
cells pre- and post- clinical resistance, identified that histone deacetylase 4 
(HDAC4) is over-expressed in cisplatin-resistant cells relative to sensitive 
derivatives. HDAC4 siRNA and HDACi treatment resensitised resistant cells to 
cisplatin. Furthermore, up-regulation of HDAC4 in cisplatin-resistant ovarian cell 
lines and tumour sections identified HDAC4 as a potential biomarker of cisplatin-
resistance. It was observed that HDAC4 interacts with another mediator of 
platinum resistance, the transcription factor STAT1, and that knockdown of 
HDAC4 increased acetylation levels of STAT1 protein in platinum resistant cells. 
Consequent decrease in cisplatin mediated phosphorylation of STAT1 and 
nuclear translocation of STAT1 were observed. However, STAT1 was found to 
be acetylated and inactive in platinum sensitive cells, expressing lower levels of 
HDAC4. Microarray analysis of the platinum resistant cells has identified 
differentially regulated genes following HDAC4 knockdown. The UCHL1 promoter 
is methylated in both cisplatin sensitive and resistant paired cells and yet is re-
expressed in resistant cells following HDAC4 knockdown. The methylation levels 
at the UCHL1 promoter were analysed by pyrosequencing method and do not 
appear to significantly change the methylation level after HDAC4 knockdown. 
However, ChIP analysis revealed an increase in acetylation at the UCHL1 
promoter after HDAC4 knockdown. Conversely, P21 is down-regulated by 
HDAC4 knockdown in resistant PEO4 cells in contrast to reports of P21 over-
expression as a biomarker of HDAC inhibition. Strikingly however, it is up-
regulated after HDAC4 knockdown in cisplatin-sensitive paired PEO1 cells 
suggesting that, like STAT1, a fundamental change in its control occurs on 
acquisition of platinum resistance. This study provides evidence that HDAC4 is 
required for platinum mediated STAT1 activation; a phenomenon associated with 
clinical platinum resistance, and identifies frequent HDAC4 over-expression in 
platinum resistant tumour biopsies. Pharmacological modulation of this pathway 
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is shown to restore sensitivity to cisplatin. Microarray analysis revealed HDAC4 
regulated target genes. These studies identify new and clinically relevant insights 
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1.1 Ovarian cancer 
 
Ovarian cancer is the leading cause of death arising from gynaecological 
malignancies and the fourth most common form of cancer in women in developed 
countries, after breast, lung, and colorectal cancer (Gayther and Pharoah, 2010; 
Permuth-Wey and Sellers, 2009).  In 2008, the number of women who died from 
ovarian cancer worldwide and in the UK was 140,000 and 4,373 respectively. 
Each year 204,000 new cases of ovarian cancer are diagnosed worldwide with 
Europe accounting for 43,000 and the UK for 6,600 of these cases. The lifetime 
risk of developing ovarian cancer is approximately 1 in 50 for women in the UK 
(CancerStats, Ovarian Cancer. Cancer Research UK, 2011) and the disease is 
predominantly of older, post-menopausal women with over 80% of cases being 
diagnosed in women over 50 years of age (Herzog and Pothuri, 2006). The 
highest incidence areas are in the USA and Northern Europe and the lowest 
rates occur in Africa and Asia (Parkin et al. 2005). In Europe, high incidences 
occur in Denmark, Finland, Iceland, Norway, Sweden and the United Kingdom 
(Bray et al. 2005). Ovarian cancer be divided into three subtypes based on the 
cell type that these tumours arise from; epithelial tumours, germ cell (ova) 
tumours and the sex cord (stromal) tumours (Kurian, Balise et al. 2005). Ovarian 
cancer is divided into three histological subtypes based on where the cells arise 
from. Briefly, the female reproductive system consists of two ovaries. Each ovary 
is covered with germinal epithelium cells and divided into two regions; cortical 
and medullar. The cortex contains ovarian follicles in different stages of 
development (oogenesis). The medulla contains blood vessels, lymphatic vessels 
and nerves (Figure 1; Naora and Montell 2005). Every histologic subtype of 


















Figure 1: The structure of the human adult ovary showing the cortical and the medullar 
regions.  Inside the cortex, there are number of follicles in various stages of development. 
It starts from primordial follicle, then the primary follicle where the thecal cells and 
granulosa cells form a layer surrounding the follicle that contains the oocyte, then the 
secondary follicle, and finally the mature vesicular follicle that will rupture to release the 
ovulated ovum. The remaining part of the follicle in the ovary is transformed to corpus 
luteum. The medulla includes blood vessels, lymphatic vessels and nerves. The ovary is 
covered with epithelial cells where most ovarian cancer arises from. Adapted from 






Epithelial ovarian cancer, the focus of this study, is the most common type of 
malignant ovarian tumour, occurring in 90% of cases.  Epithelial ovarian cancer is 
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divided based on their morphological features into four distinct subtypes; serous 
is the most malignant tumour of the epithelial ovarian cancer followed by 
endometrioid, clear cell and mucinous (Bowtell, 2010). Ovarian serous cancer is 
usually high stage, however, ovarian endometrioid and clear cell cancer often are 
low-stage lesions. Mucinous ovarian cancer is frequently low stage and is 
considered a rare type of ovarian epithelial cancer (Soslow 2008). Although, 
ovarian cancer has been reported to occur most frequently in industrial countries, 
Japan has a low overall incidence. However, clear cell ovarian cancer incidence 
is higher in Japanese women than in women in American or Europe (Omura, 
Brady et al. 1991; O'Brien, Schofield et al. 1993; Sugiyama, Kamura et al. 2000) 
indicating a possible link between the histological subtype of epithelial ovarian 
cancer and geographic location. Moreover, the environmental factors are 
considered as one of the risk factors that might increase the chance of 
developing of ovarian cancer. A study of Japanese migrant populations with a 
low-risk incidence of ovarian cancer that moved to the United States (a high 
incidence rate country) showed that the ovarian cancer incidence and mortality 
rates for the Japanese women have increased (Locke and King, 1980). This 
suggests some dietary, behavioural or environmental factor differences occurring 
in the higher incidence countries and also might explain why the Incidence rates 
have been slowly increasing in France, Spain, and Japan (Parkin et al. 2005; 
Sagae and Mori, 2001) where the people may have started to adopt the same 
lifestyle as those in the countries with the highest incidence. Diet has been 
shown to play a role in the aetiology of ovarian cancer. A case-controlled study 
has shown the link between ovarian cancer and diet.  The consumption of a wide 
range of food groups was been investigated and positive relations were observed 
with fats and proteins (Bosetti et al. 2001). However, the estimated risk of 
developing ovarian cancer in monozygotic twin of an affected patient is twice the 
sibling risk, implying that familial risk of ovarian cancer may be more strongly 
related to genetic factors than to share environmental effects (Gayther 2007). 
The lowest rates of ovarian cancer are found in the developing countries (Beral, 
Fraser et al. 1978). The reason that might contribute to differences between 
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underdeveloped and industrialized countries is the life expectancy. Life 
expectancy is higher in the industrialized countries, resulting in greater 
proportions of elderly women in the population of these countries who are at risk 
of developing ovarian cancer. In addition, the environmental factors, such as the 
exposure to carcinogens associated with industries, may contribute to these 
variations in the rate of ovarian cancer. There are number of factors associated 
with the reduction in ovarian cancer such as parity, oral contraception, 
oophorectomy and abortion. A study has found that increased parity, use of oral 
contraception and oophorectomy reduce ovarian cancer risk (Permuth-Wey and 
Sellers, 2009). In addition, induced abortions were associated with slight 
reductions in the risk of ovarian cancer (Dick, Siskind et al. 2009). Neither the 
age at first live birth nor the age at first pregnancy is strongly associated with 
ovarian cancer (Shu et al. 1989). However, the risk factors associated with 
ovarian cancer are family history, infertility, and increasing age (Cetin et al.  2008; 
Tortolero-Luna and Mitchell, 1995).  
 1.1.1 Symptoms: 
 
There are no specific clinical symptoms associated with ovarian cancer when the 
disease spreads within the peritoneal cavity but some of the most common 
symptoms are abdominal discomfort and bloating. Other symptoms such as 
vaginal bleeding, gastrointestinal discomfort, and urinary tract symptoms 
(Friedlander, 1998) are also among the symptoms that ovarian cancer patients 
suffer from before they are diagnosed with the disease.  However, all of these 
symptoms might also be associated with other diseases. Furthermore, it has 
been reported that over 95% of epithelial ovarian cancer patients experience 
abdominal complaints for many months prior to their diagnosis (Goff et al. 2007; 
Lowe et al. 2009) suggesting that these clinical symptoms can be used to detect 
ovarian cancer.   
1.1.2  Detection and diagnosis: 
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Pelvic examination, ultrasound examination, computed tomography scans, X-
rays, and a blood test for cancer antigen 125 (CA 125), are used to detect 
ovarian cancer but none of these techniques can be reliably used for early 
detection. CA-125 is produced by ovarian cancer cells and is usually present at 
higher levels in women with ovarian cancer. The only validated marker for 
ovarian cancer. A study has shown that CA-125 was detectable in the serum 
of >80% of women with ovarian carcinomas (Niloff et al. 1984).  However, its 
clinical value as a marker of ovarian cancer is low due to its expression in a 
number of relatively benign conditions and several diseases of the ovary as well 
as pregnancy (Marsden et al. 2000; Meyer and Rustin, 2000; Tuxen et al. 1995). 
Thus, a high level of CA-125 does not necessarily mean that ovarian cancer is 
present.  Nevertheless, CA-125 can be used in monitoring response to treatment 
or disease recurrence (Karam and Karlan, 2010). A prospective case-control 
study which included 254 healthy women at high risk from disease because of 
family history, and 75 women with ovarian cancer was conducted by (Andersen 
et al. 2008) to determine whether an index based on the specific pattern of 
symptoms commonly reported by women with ovarian cancer could be used in 
combination with CA-125 to improve the sensitivity of screening for ovarian 
cancer. The study showed that the symptom index with CA-125 created a 
combination guide with a greater sensitivity for the detection of ovarian cancer 
than using CA-125 alone.  
1.1.3 Ovarian cancer FIGO Classification: 
 
According to the International Federation of Gynecology and Obstetrics (FIGO) 
staging system, ovarian cancer has four surgical stages: 
 Stage I ovarian cancer limited to one or both ovaries  
 Stage II the cancer has grown outside the ovary or ovaries, but it is inside 
the pelvis 
 Stage III the cancer has grown outside the pelvis into the abdominal cavity 
or there is cancer in the lymph nodes in the upper abdomen, groin or 
behind the womb  
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 Stage IV the cancer has spread into other body organs such as the liver or 
outside the peritoneal cavity 
There are also three histological grades for ovarian cancer:  
 Grade 1 (low-grade) the cancer cells look like the normal epithelial cells of 
the ovary. They usually grow slowly and are less likely to spread.  
 Grade 2 (moderate-grade) the cells look more abnormal than low-grade 
cells.  
 Grade 3 (high-grade) the cells look very abnormal or undifferentiated. 
They are likely to grow and spread rapidly. 
 
The stages of the disease, age at diagnosis, histological subtype and molecular 
characteristics have been reported to be associated with patient outcome. For 
example, patients with stage one ovarian cancers, where the tumours are limited 
to the ovaries at time of diagnosis, can be successfully cured using standard 
therapies (Bast et al. 2009). Nevertheless, once cancer has spread beyond the 
peritoneal cavity (stage 3 or 4), the cure rate decreases.  
  
1.2 The biology of epithelial ovarian cancer: 
 
Most ovarian cancers are believed to arise from the surface epithelium (Piek, 
Dorsman et al. 2004). However, the biological mechanism behind this 
transformation remains unknown. The first theory introduced to explain the 
development of ovarian cancer is the incessant ovulation theory. The repeated 
disruption of the ovarian epithelium was suggested to lead to malignant 
transformation of the epithelial cells therefore incessant ovulation is associated 
with the process of ovarian carcinogenesis (Booth et al. 1989; Fathalla, 1971; 
Parazzini et al. 1991). This hypothesis is supported by the fact that all the factors 
suppress the incessant ovulation such as pregnancy, use of contraceptive are 
linked with reduce the risk of developing ovarian cancer. It has been reported that 
gonadotropin level is elevated with age and increased during the menopause. As 
a result, the excessive gonadotropin secretion might mediate the hormonal 
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stimulation of ovarian epithelial cells on the surface of the ovary or within ovarian 
inclusion cysts. This may increase the risk of malignant alterations in the ovaries 
by stimulating the growth of ovarian epithelial cells (Risch 1998).  
 
Another hypothesis about the sex steroid hormone, suggests that extreme 
androgen stimulation of the ovarian surface epithelial is associated with 
increased risk of cancer. Circulating androgens have been suggested to be 
involved in the development of ovarian cancer. It has been suggested that high 
androgen serum levels may increase risk of ovarian cancer. It has been reported 
that 90% of ovarian cancer tissue were shown to be positive for the androgen 
receptor (Wang and Chang, 2004). However, a recent study showed no 
association between serum levels of androgens and ovarian cancer risk in a 
case-controlled study (Rinaldi, Dossus et al. 2007). Each of these hypothesises 
might contribute to the development of ovarian cancer, however, it seems likely 
that there are other, as yet unidentified, factors that could also be involved in the 
development of ovarian cancer.   
 
 1.2.1 Familial ovarian cancer:  
 
Ovarian cancer is a multi-factorial disease and its development involves the 
accumulation of several genetic alterations many of which either activate 
oncogenes or silence tumour suppressor genes (Gayther et al. 1997; Schuijer 
and Berns, 2003). Inherited ovarian cancer accounts for about 5 to 15 % of 
ovarian cancer (Boyd 1998). The BRCA1 and BRCA2 tumour suppressor genes 
are the most important predisposition genes to ovarian cancer and germ line 
mutation in BRCA1 and BRCA2 is associated with the hereditary breast and 
ovarian cancer syndrome (Prat, Ribe et al. 2005).  Germ line mutations in BRCA1 
and BRCA2 genes account for about 90% of the ovarian cancers in the 
hereditary breast and ovarian cancer syndrome (Gayther, Mangion et al. 1997; 
Stratton, Gayther et al. 1997; Wooster et al.1994). Women with germ line 
mutations in BRCA1 or, BRCA2 are at a higher risk (about 60% to 80% higher) of 
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developing ovarian cancer than women in the general population (Narod and 
Boyd 2002; Malander, Rambech et al. 2006). The risk of ovarian cancer is higher 
for BRCA1 mutation carriers (50%) than for BRCA2 mutation carriers (20%). 
BRCA1 and BRCA2 are key proteins that are involved in the process of 
homologous recombination which mediates DNA double-strand break repair and 
are also involved in the transcriptional regulation of gene expression (D'Andrea 
and Grompe, 2003). There are well defined mutations in BRCA1 and BRCA2 
carried in closed population like Ashkenazi Jews. These specific mutations in 
BRCA1 and BRCA2 are called founder mutations such as 185delAG and 
5382insC mutations in BRCA1 gene and 6174delT in BRCA2 gene increase the 
risk of developing ovarian cancer in Ashkenazi Jews (Dunning, Chiano et al. 
1997; King, Marks et al. 2003). A particular mutation (999del5) in BRCA2 
accounts for about 7.9% of ovarian cancer in Iceland (Johannesdottir, 
Gudmundsson et al. 1996). Thus, there are different mutations that could 
increase the risk of ovarian cancer depending on the population group. Germ line 
mutations in the DNA mismatch repair (MMR) genes (hMLH1, hMSH2, hMSH6, 
PMS1, PMS2) which are commonly associated with nonpolyposis colorectal 
cancer (HNPCC) are also associated with ovarian cancer. Ovarian cancer risk in 
HNPCC families is more than 12%.  In general, hereditary ovarian cancers are 
diagnosed at a young age. Thus, they get earlier treatment than sporadic cancers. 
This might explain why hereditary ovarian cancer patients have longer overall 
survival and better clinical outcome than sporadic cancers. 
 1.2.2 Sporadic ovarian cancers:  
 
The majority of ovarian cancer occurs sporadically, however, the genes 
associated with familial ovarian cancer such as BRCA1 and BRCA2 also appear 





























Table 1: Some of the putative oncogenes and tumour suppressor genes investigated in 
ovarian cancer Adapted from (Schuijer and Berns, 2003) showing the function and the 











Mutations in BRCA1 and BRCA2 are more likely to lead to the development of 
serous cancers than mucinous (Narod and Boyd 2002). The frequency of 
Oncogenes function Spectrum mutation 
CMYC Transcription factor Amplification, overexpression 
K-RAS Signal transduction Simple(codon12,13 and codon 
61) 
AKT2 Serine-threonine protein kinase Amplification, overexpression 
Tumour suppressor 
genes 
function Spectrum mutation 
PTEN Phosphatase Multiple mutations 
TP53 Cell cycle regulator; DNA repair 
and apoptosis 
Multiple mutations and 
overexpression 
BRCA1 Transcription factor Multiple mutations 
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mutations in DNA mismatch repair (MMR) genes has also been shown by 
immunostaining with antibodies against MMR proteins to be higher in the 
mucinous and endometrioid adenocarcinoma compared to clear cell and serous 
adenocarcinoma (Domanska et al. 2007). The tumour suppressor gene p53 
encodes a transcription factor that has a role in regulating cell cycle progression, 
DNA repair, and cell death. A mutation of the p53 gene, which maps to 17p13.1, 
is the most common genetic alteration in epithelial ovarian cancers. It has been 
shown that the majority of serous carcinomas have mutant p53 (Palmer et al. 
2008). Recently, (Ahmed et al. 2010) showed that p53 dysfunction rate 
approached 100% in high-grade pelvic serous carcinoma.  Mutation of p53 was 
found in both early and advanced stage serous ovarian cancers (Havrilesky et al. 
2003; Leitao et al. 2004). Nevertheless, the incidence of p53 mutations in the 
other histological subtypes of epithelial ovarian cancer; endometrioid, clear cell 
and mucinous is much lower (Leitao et al. 2004; Schuijer and Berns, 2003). 
 
PTEN tumour suppressor (phosphatase and tensin homolog) is one of the 
mutated tumour suppressor genes in ovarian cancer and has a role in cell 
proliferation and migration (Kolasa, Rembiszewska et al. 2006). The primary 
target for PTEN is the PIP3, the product of the phosphatidylinositol 3-kinase 
(PI3K) (Salmena, Carracedo et al. 2008). It has been reported that PTEN and the 
PI3K/Akt pathway might be implicated in the regulation of cell proliferation and 
apoptosis (Goff et al. 2007). Transfected PTEN into ovarian cancer cell resulted 
in migration inhibition (Saga, Mizukami et al. 2003) and enhanced the sensitivity 
to anticancer drugs; cisplatin, paclitaxel, SN-38, (active metabolite of irinotecan 
and topoisomerase I inhibitor), and gemcitabine (Saga, Mizukami et al. 2002). 
 
The RAS family are involved in the transduction of external stimuli which is most 
likely induced by growth factors. This family consists of three functional genes, H-
ras, K-ras, and N-ras. Activation of Rat sarcoma viral oncogene (RAS) signalling 
causes cell growth, differentiation and survival (Bar-Sagi, 1989). K-ras mutation 
is one of the most frequent genetic abnormalities in ovarian mucinous carcinoma. 
 27 
K-ras mutations in codon 12 and 13 were analysed in frozen and formalin-fixed 
paraffin-embedded (FFPE) tissues of 381 malignant samples. The rate of K-ras 
mutations was much higher in mucinous tumours compared with other histotypes. 
Thus, K-ras mutation is a common feature in ovarian mucinous carcinomas 
(Auner et al.  2009). 
 
The combination of activating mutations in the oncogenic K-ras gene and 
deletion of the PTEN tumour suppressor within the cells of the ovarian surface 
epithelium has been shown to play a role in the development of endometrioid 
epithelial ovarian cancer (Dinulescu et al. 2005). In addition, recurrent somatic 
mutations in the PTEN gene and loss of heterozygosity at the 10q23 PTEN locus 
in endometrioid ovarian cancer indicated the importance of PTEN in the aetiology 
of endometrioid ovarian cancer especially with the absence of such mutations in 
other histological subtypes. PTEN is considered as a part of the PI3K/AKT 
pathway (Paez and Sellers, 2003). Furthermore, the phosphatidylinositol 3-
kinase (PI3K)/AKT signalling pathway is involved in cellular functions such as cell 
growth, proliferation, differentiation, and survival, which in turn are involved in 
cancer. The activation of PI3K/AKT cascade has also been reported to be highly 
specific to endometrioid carcinomas (Obata et al.1998; Sato et al. 2000). The c-
MYC proto-oncogene, which participates in the regulation of cellular proliferation, 
apoptosis and cell differentiation, has also been shown to be overexpressed in 
endometrioid and clear cell carcinomas (Plisiecka-Halasa  et al.  2003). Taken 
together, these data suggest that mutations in certain genes are associated with 
particular subtypes of epithelial ovarian cancer, which might help in diagnosis. 
Several studies have been conducted with the aim of identifying common 
molecular changes that characterize each histological subtype of epithelial 
ovarian tumour by utilizing gene expression technology. A number of microarrays 
have been conducted to determine the genes associated with specific histological 
subtype of ovarian cancer for example microarray gene expression profile of 285 
serous and endometrioid tumours of the ovary, peritoneum, and fallopian tube 
was performed to identify novel molecular subtypes of ovarian cancer. It was 
 28 
found that serous and endometrioid subtypes can display a large degree of 
molecular heterogeneity that divided into six subgroups, each associated with 
specific molecular and histopathologic characteristics, and patient survival. The 
genes related to the WNT/b-catenin and cadherin signalling pathways were 
overexpressed in high-grade serous tumours, including N-cadherin and P-
cadherin (Tothill, Tinker et al. 2008). This shows that each subtype of ovarian 
cancer has distinct expression profiles that can be used to understand its biology. 
Gene-expression analyses of ovarian carcinomas have shown that each 
histological subtype of epithelial ovarian tumour can be distinguished from other 
histological subtypes based on their global gene-expression profiles (reviewed by 
Cho and Shih, 2009; Gomez-Raposo et al.  2010). However, the mechanisms of 
how these genes, individually or in combination is involved with distinct epithelial 
ovarian tumour subtypes is not clear as yet. 
1.3 Treatment of ovarian cancer: 
 
In the treatment of ovarian cancer, there are three main approaches: surgery, 
radiotherapy and chemotherapy. Treatment depends upon a number of factors 
such as stage, grade of the disease and how far it has spread, the 
histopathologic type, patient's age, patient’s desire to have children and overall 
health. The most common treatment for ovarian cancer involves surgery and 
chemotherapy (Cannistra, 2004).  
1.3.1 Surgery: 
 
Reduction of tumour by surgery is always essential in the treatment of ovarian 
cancer. Nevertheless, surgery prior to chemotherapy depends on the size of the 
tumour and the patient condition. Platinum-based chemotherapy has been used 
to reduce the size of the tumour before surgery (neo-adjuvant chemotherapy) 
which reduces the tumour burden and makes surgical operation easier. However, 
reduction of the tumour bulk by surgery prior to chemotherapy might reduce the 
chance of developing chemo-resistance (Morrison et al. 2007). This might be due 
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to decrease the number of ovarian cancer cells in the body that are likely to 
develop chemoresistance.  Several studies have reported the impact that surgery 
has on the survival for women with ovarian cancer (Bristow et al.  2002; Eisenkop 
and Spirtos, 2001; Griffiths, 1975). The smaller (less than 1 cm) the residual 
tumour volume, the more effective chemotherapy and the better the survival 
(Bristow et al.  2002; Hogberg, 1995). This suggest that surgical debulk status 
has huge effect in the survival of ovarian cancer patients. In addition, the tumour 
biology of the ovarian cancer plays an important role in the survival rate 
(Eisenkop and Spirtos, 2001).                                                                       
1.3.2 Radiation therapy: 
 
Radiation therapy is rarely used for ovarian cancer because the majority of the 
patients diagnosed are at an advanced stage where the tumours have spread 
widely within the abdominal cavity (Ito et al. 2004). Radiotherapy can be used to 
treat residual cancer after cytoreductive surgery and chemotherapy (Bese et al. 
2009). But, it may occasionally be used if the tumours are confined to one or both 
ovaries without spreading to abdominal organs or pelvic lymph nodes. It has 
been shown that the whole abdomen radiotherapy which is a technique that 
targets the anatomic sites at highest risk has an effective adjuvant treatment 
modality in early ovarian cancer.  However; the size and the site of residual 
disease and tumour grade determine the successful outcome (Dembo, 1983; 
Einhorn et al. 2003). A study was conducted to investigate the effect of 
radiotherapy in advanced ovarian cancer patients comparing seventy-five 
patients with stage IIb-IV ovarian cancer treated with a combination of surgery, 
radiotherapy and chemotherapy (melphalan then doxorubicin and later cisplatin) 
with 98 patients treated with surgery and chemotherapy only. The study showed 
that radiotherapy could enhance survival rate (Einhorn et al.1999). Although 
radiotherapy may be useful to shrink tumours and to reduce symptoms in 
advanced ovarian cancer, nonetheless, due to the acute toxicity of the 




Chemotherapy is required for most ovarian cancer patients either after or before 
the surgery. Chemotherapy drugs are categorised into several groups based on 
their chemical structure and mechanism of action:  
 Anti-metabolite drugs that interfere with DNA and RNA synthesis such as 
5 – fluorouracil.  
  Anti-tumor antibiotics that inhibit DNA and RNA synthesis, including 
enzymes such topoiosomerase II (which is inhibited by doxorubicin) 
leading to cell death.  
 Plant-based compounds are natural products of plant alkaloids that can 
inhibit mitosis or enzymes, thereby preventing protein synthesis 
necessary for cell like etoposide and taxanes 
 Alkylating agents that interfere with DNA thus prevent the cancer cells 
growth.  
Platinum-based agents, such as cisplatin and carboplatin, are the most effective 
chemotherapy for ovarian cancer on whole, showing high response rates and 
long survival for advanced ovarian cancer patients (Dunton 1997; Piccart, Lamb 
et al. 2001). Platinum-based agents are the first-line choice drugs.  Carboplatin is 
more favourable in clinic than cisplatin due to it being considerably less 
nephrotoxic. The standard treatment for ovarian cancer patients is combination 
therapy using carboplatin and paclitaxel due to its effectiveness and favourable 
toxicity profile (Ozols, Bundy et al. 2003). Platinum-based agents are usually 
administered intravenously every 3 weeks for six cycles as standard treatment 
duration. A decision about the use of combination therapy versus single-agent 
platinum therapy has to be made depending on the stage of the disease and the 
overall health of the patient. It has been reported that the response rate to 
combination chemotherapy is higher than to single-agent carboplatin (Ozols 
2005). Therefore, the use of combination chemotherapy is more preferable for 
women with residual tumour after surgery. Regardless of the effectiveness of the 
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combination chemotherapy, many women relapse following the first line 
chemotherapy, therefore, strategies for second-line therapy are required to many 
ovarian cancer patients. Ovarian cancer patients can be divided after relapse into: 
1) refractory to a platinum; those who progress on first-line therapy or relapse 
within 3 months, 2) platinum resistant; those who respond to primary treatment 
and relapse within 6 months and 3) platinum sensitive; those who relapse more 
than 6 months after completion of initial therapy (Markman et al.1991; Teneriello 
et al. 2009). Chemotherapy can be administered intravenously (i.v.), 
intraperitonealy (IP) or orally. It is difficult to identify the optimal way to deliver the 
chemotherapy to all advanced cases of ovarian cancers because each patient 
must be assessed individually to decide optimal therapy in terms of recurrence, 
sensitivity to platinum, toxicity, way of administration, and patient preference. In 
ovarian cancer tumour, growth is often limited to the abdominal (peritoneal) cavity. 
Infusion of chemotherapy drugs into the peritoneal space, where they will come 
into direct contact with the cancer cells is called IP (Robinson, Coberly et al. 
2008). IP chemotherapy has been extensively investigated both preclinically and 
clinically to examine the survival advantage over intravenous therapy. Three U.S. 
National Cancer Institute cooperative group randomized phase three trials have 
shown that the IP delivery of cisplatin-based chemotherapy as primary treatment 
of small-volume residual in advanced ovarian cancer improves survival compared 
to the administration of the agents by the intravenous route (reviewed in Alberts 
et al.1996; Markman, 1994; Markman et al. 2001). The advantage of IP therapy 
compared to the i.v. route is that higher doses of the drugs can be given directly 
to the areas at highest risk for tumour involvement, a more prolonged tumour 
exposure and reduced systemic toxicities (Fujiwara et al. 2005). It has been 
shown that IP chemotherapy improved the progression-free survival (Armstrong 
and Brady, 2006; Markman, 2001). However, some patients do not complete the 
entire course of IP treatment because of side effects. The side effects of IP 
therapy can be severe such as the toxicity, catheter-related problems, abdominal 
pain, bloating, fatigue, infection and gastrointestinal disturbance (Fung-Kee-Fung 
et al. 2007; Walker et al. 2006).  IP chemotherapy as a first-line treatment is 
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important option for optimally debulked patients, but, it is more complicated than 
IV chemotherapy and it requires skill and experience to avoid major 
complications. To date, i.v. is the conventional delivery method for platinum-
based agents although a study has been shown that not all patients are good 
candidates for IP chemotherapy (Robinson, Coberly et al. 2008).   
1.3.4 Platinum-based chemotherapy: 
 
The majority of ovarian cancer patients are diagnosed at advanced stage of the 
disease which makes the survival rate very low. However, the survival rate has 
increased in the last three decades as a result of advances in both surgery and 
chemotherapy to five years for around 40% of women diagnosed with ovarian 
cancer (Armstrong et al. 2006; Cannistra, 1993; Gondos et al. 2009; Verdecchia 
et al. 2009; Herzog and Pothuri, 2006).  Although platinum based therapy has 
significant response in ovarian cancer patients resistance to platinum drugs is a 
significant and largely unresolved the obstacle in the treatment of ovarian cancer. 
The inorganic compound cis-diamminedichloroplatinum (II) or cis-DDP is a DNA-
damaging agent that is effective in ovarian, head, neck, bladder cancer 
(Prestayko et al.1979). Platinum is the first-line choice chemotherapeutic agent 
for ovarian cancer treatment. The platinum analogues, cisplatin and carboplatin 
are platinum (II) complexes with two ammonia groups in the cis position (Figure 
2). The cis isomer is the only potent anticancer agent because it forms covalent 
adducts with DNA; intrastrand 1, 2-d (GpG), 1, 2- d (ApG), 1, 3-d (GpNpG), and 
interstrand cross-links. Whereas the trans-isomer of transplatin (Figure 2) is 
clinically inactive because it is unable to form 1, 2-intrastrand cross-links which 
are considered the most important adducts that cis isomer forms to target DNA 
(Lippert, 1996; Pinto and Lippard, 1985). Cisplatin has two chloride atoms; 
carboplatin possesses a cyclobutane moiety (Pasco JM and Roberts JJ. 1974; 
Figure 2). Cisplatin is administered to cancer patients i.v. as a sterile saline 
solution. When cisplatin enters the cells, its chloride ligands are replaced by 
water molecules, generating a positively charged species, due to lower chloride 
concentration in the cytoplasm. The aquated platinum complex can then react 
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with a variety of macromolecules including nucleic acids. Cisplatin binds to RNA 
more than DNA and to DNA more than to protein (Baik et al. 2003; Pascoe and 
Roberts, 1974) however cisplatin-DNA binding has been shown to be the key 
toxic lesion underlying cisplatin’s antitumour activity (Baik et al. 2003). Cisplatin-
RNA and cisplatin-protein effects are not considered essential in cisplatin 
mechanism of action against cancer (Akaboshi et al.1992). Bartz SR et al. 2006 
showed that silencing BRCA1 and BRCA2 genes, which are involved in DNA 
repair pathways, enhanced cisplatin cytotoxcity in cervical cancer-HeLa, 
adenocarcinomic human-A549, and the epithelial ovarian cancer cell line, 
TOV21G. It has been reported that newly manufactured material replaces 
cisplatin-mediated damage to RNA and protein, and that glutathione eliminate 
cisplatin-protein adducts (Peleg-Shulman and Gibson, 2001). In cisplatin-DNA 
interaction, the N7 atoms of guanine and adenine are the main binding sites for 
platinum complexes in DNA (Lippard, 1985). Interaction between cisplatin and 
DNA can result in mono- and bifunctional adducts, as well as form DNA–protein 
crosslinks. The bifunctional adducts, take two forms either intra- or interstrand 
crosslinks that can result in local distortions of the DNA structure. As mentioned 
earlier the most common adducts formed between DNA and cisplatin are 1, 2-
intrastrand d (GpG) crosslinks and d (ApG) crosslinks with small amounts of 1, 3-
d (GpNpG) (Fichtinger-Schepman et al.1985; Yang and Wang, 1996). DNA-
platinum covalent adducts inhibit DNA replication and RNA transcription that 
interfere with cell proliferation, induce cell cycle arrest and eventually leading to 


















Figure 2: The chemical structures of active platinum compounds cis and carbo-diamine-













The structure of cisplatin remains intact in the patient bloodstream due to the 
high concentration of chloride ions.  The main mechanism of cellular uptake of 
cisplatin is considered to be through passive diffusion (Ghezzi et al. 2004). Other 
studies have suggested that cisplatin enters cells via the copper transporter, 
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CTR1, in the plasma membrane as an alternative way of cisplatin uptake   
(Holzer et al. 2004; Ishida et al. 2002; Sakamoto et al. 2001).  It has been shown 
that knockout of CTR1 in yeast and mammalian (mouse) cells strikingly reduce 
cisplatin uptake (Lin et al. 2002), suggesting that cisplatin may be transported 
into cells by both passive uptake and through the copper transporter. One of the 
major limitations to platinum based therapy is the toxic side effects. Cisplatin is 
commonly associated with anaemia, vomiting, neuropathy, kidney damage and 
hearing loss (Feng et al.1996). Due to the toxic effect of cisplatin, carboplatin was 
developed to maintain the activity but reduce the toxicity of cisplatin. Therefore, 
clinically, carboplatin is less toxic than cisplatin. Both carboplatin and cisplatin 
exhibit their therapeutic effects by forming intrastrand DNA adducts with adjacent 
guanine residues of the DNA inside the tumour cell. However, carboplatin has 
carboxylate groups which form more stable adducts than the chloride groups of 
cisplatin. This decreases the chemical reactivity of carboplatin compared to 
cisplatin and extends the time required for its aquation and the consequent DNA-
adduct formation (Alberts and Dorr, 1998). Thus, carboplatin is more stable and 
still has equivalent therapeutic activity to cisplatin (Ozols, Bundy et al. 2003).  
1.4 Platinum resistance and  its molecular mechanisms:  
 
Platinum based therapy is very effective in the treatment of ovarian cancer. 
However, patients frequently develop platinum-resistance.  Resistance can be 
either acquired, when the patients respond to the chemotherapy but then develop 
resistance afterward or intrinsic, when the patients are unaffected by platinum 
treatment at first exposure (refractory). Drug resistance is a multi-factorial 
phenomenon involving various mechanisms.  These mechanisms can be divided 
to five groups:  
1. Decreased platinum accumulation by decreased uptake  
2. Increased efflux of cisplatin inactivation by cellular glutathione or 
metallothionein 
3. Increased platinum-DNA adduct repair,  
4. Increased platinum-DNA damage tolerance  
 36 
5. Alterations in the signalling pathways affecting apoptosis (Kartalou and 
Essigmann, 2001; Ohmichi et al.  2005; Wernyj and Morin, 2004; Figure 3). 
1.4.1 Decreased platinum accumulation: 
 
Decreased intracellular platinum concentrations by decreased uptake or 
increased efflux of cisplatin are a significant mechanism of cisplatin resistance 
(Nitiss, 2002). It has been reported that following incubation with cisplatin, the 
platinum resistant human ovarian A2780/A2780cis and cervical HeLa/HeLaCK 
cancer cell lines exhibit lower intracellular platinum concentrations and lower 
levels of CTR1 than their respective parental cells with no change in efflux. This 
shows that among the three copper transporters (CTR1, ATP7A and ATP7B) 
CTR1 is the most important copper transporter in cisplatin resistance since there 
is a clear link between lower CTR1 expression and intracellular concentration 
(Zisowsky et al. 2007). The main multidrug resistance efflux pump, P-
glycoprotein, is not usually over expressed in cisplatin resistant epithelial ovarian 
cancer cell lines (Ren et al. 2007; Yang and Page, 1995).  Moreover, P-
glycoprotein expression was evaluated in frozen sections from 57 patients with 
epithelial ovarian cancer. P-glycoprotein expression was observed in 4 out of 21 
cisplatin resistant and 5 out of 36 cisplatin sensitive patients. It has been reported 
that P-glycoprotein is not involved in cisplatin transportation (Gibalova et al. 
2009).  Thus, P-glycoprotein might play a minor role in the development of 
cisplatin-resistance in ovarian tumours (Murphy et al.1992) and it is possible that 
both CTR1 and multidrug resistance proteins have a role in the cellular response 
to cisplatin. Nevertheless, these proteins are not considered as good predictors 








Figure 3: Illustration of possible drug resistance mechanisms in cancer cells; decreased 
platinum accumulation which may arise by 1- decreased uptake or 2-increased efflux. 3- 
Cellular detoxification.  4- Enhanced repair of cisplatin mechanism. 5- Bypass of 








The copper efflux transporters ATP7A and ATP7B are associated with cisplatin 
resistance. ATP7A has been reported to be over-expressed in ovarian cancer 
cells and enhanced resistance to cisplatin, carboplatin, and oxaliplatin (Samimi et 
al. 2004). Another study has shown that  higher ATP7A and ATP7B expression in 
platinum-resistant cells compared with sensitive cells and knockdown of ATP7B 
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but not ATP7A  was resulted in 2.5-fold decrease in cisplatin IC50 levels and 
enhanced the formation of DNA adduct in cisplatin-resistant cells; A2780-CP20 
and RMG2 (Mangala et al. 2009). Therefore, ATP7A and ATP7B might mediate 
cisplatin resistance in ovarian cancer.                                                                      
                                                                                                             
1.4.2 Drug inactivation:  
 
One of the cisplatin-resistance mechanisms that have been proposed is strong 
binding to inactivating (detoxifiying) cytoplasmic thiolate ligands inside the cell, 
such as glutathione, a tripeptide thiol, and metallothionein, a cysteine-containing 
molecule. When glutathione binds to cisplatin, it forms a glutathione-cisplatin 
chelate complex, which is then exported through a glutathione S-conjugate 
export pump (Ishikawa, 1989). Overexpression of either glutathione or the export 
pump has been reported in acquired cisplatin resistance in human ovarian cancer 
cells (Chen et al.1995). Moreover, the expression of the enzymes involved in 
glutathione biosynthesis, such as γ-glutamylcysteine synthetase (GCS) and γ-
glutamyl transpeptidase, are overexpressed in human ovarian cancer, cisplatin-
resistant cells (Godwin et al.1992; Mistry et al.1991). This highlights the 
importance of elevated glutathione in cisplatin resistance. A positive correlation 
has also been demonstrated between over-expression of nuclear metallothionein 
and cisplatin resistance in ovarian cancer cells (Andrews et al.1987).  Nuclear 
metallothionein seems to protect DNA from the toxic effects of the drug 
(Surowiak et al. 2007). However, analysis of the amount of metallothionein in 
samples from ovarian cancer patients before and after chemotherapy revealed 
that metallothionein content is not a major determinant of sensitivity to cisplatin-
based chemotherapy (Murphy et al.1992) suggesting that metallothionein 
expression cannot be used as a predictor of response to chemotherapy. 
1.4.3 Platinum DNA adduct repair: 
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Mammalian cells utilize five major DNA repair pathways: Nucleotide Excision 
Repair (NER); Mismatch repair (MMR), Base Excision Repair (BER), 
Homologous Recombination (HRR); and Non-homologous End Joining (NHEJ; 
Kunz et al. 2009). NER, MMR and BER pathways are excision repair processes 
that depend on complementary DNA strands to direct their replacement of 
excised bases (Figure 3). Nucleotide excision repair (NER) is thought to be the 
main process by which platinum adducts is removed from DNA (Figure 4) 
(Leibeling et al. 2006). Defects in NER underline xeroderma pigmentosum (XP), 
an autosomal-recessive syndrome.  Xeroderma pigmentosum human fibroblast 
cells deficient in nucleotide excision repair are more sensitive to cisplatin than the 
corresponding wild type cells. Excision repair cross-complementation group 1 
(ERCC1), a DNA repair gene in the NER  pathway. It has been reported that 
ERCC1 is activated in response to DNA adducts formed by platinum-based 
agents.  ERCC1 expression has been correlated with cisplatin resistance in 
patients’ ovarian tumour samples and cells (Altaha et al. 2004; Dabholkar et 
al.1994). It has been shown that disturbing the NER pathway in cisplatin-resistant 
ovarian cancer cells by targeting ERCC1 enhanced the cisplatin cytotoxicity and 
sensitized the highly resistant OVCAR10 cell line to cisplatin (Selvakumaran et al. 
2003). In addition, cell lines that developed resistance in vitro  following cisplatin 
treatment were found to have increased expression of ERCC1 (Ferry et al. 2000). 
Thus, these indicate the important role of ERCC1 in cisplatin resistance in 












Figure 4: Nucleotide excision repair system starts with damage recognition and 
assembly of a pre-incision complex, followed by excision of the damaged strand and the 
gap is repaired by DNA polymerase I and DNA ligase enzyme. Adapted from (de Laat, 







CHEK2 is a cell cycle checkpoint regulator that is activated following DNA 
damage and involved in NER pathway (Matsuoka et al.1998) it considered as a 
tumour-suppressor gene due to  its essential role in the DNA damage checkpoint 
response process  (Jin et al. 2006). This protein also has been reported to be 
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involved in cisplatin resistance ovarian cancer. An in vitro study has shown that 
Chk2 and ERCC1 have a key role in the DNA-adduct repair pathway that 
mediates acquired cisplatin resistance and the down-regulation of those two 
critical genes may reverse cisplatin resistance in the treatment of human ovarian 
cancer (Yu et al. 2009). The DNA mismatch repair system (MMR) is one of the 
most important guardians of genomic DNA, which corrects errors occurring 
during DNA replication to improve the fidelity of DNA replication (Figure 5).  MMR 
defects in humans leads to cancer of the colon, endometrium and ovary (Jiricny, 
2006). MMR also has an important role in cisplatin resistant ovarian cancer. The 
cytotoxicities of mitomycin C, chloroethylcyclohexyl nitrosourea, melphalan, 
psoralen-UVA, etoposide, camptothecin, ionizing radiation, and (cisplatin) in a 
strictly isogenic system was examined in human embryonic kidney 293T cells. 
The study showed that MMR deficiency desensitized human cells solely to 
cisplatin (Papouli et al. 2004) giving evidence that MMR plays an essential role in 
cisplatin resistance.  Martin et al showed that the platinum damaged DNA is 
recognized through functional MMR system (Martin et al. 2008) and later it was 
shown that cells deficient in MMR might carry on proliferating regardless of 
damaged DNA which results in genomic instability leading to resistance 
phenotype.  The defects in MMR genes are also associated with sporadic ovarian 
cancer. It has also been reported that ovarian cancer patients with hMSH2 
mutation, one of the DNA mismatch repair genes, develop aggressive and rapid 
recurrence following surgical debulking and platinum based chemotherapy 
(Marcelis et al. 2001).   Another study has shown that loss of hMLH1 expression 
occurs in 9 out of 10 independent cisplatin resistant derivatives of a human 









Figure 5: DNA mismatch proteins, formed when an incorrectly matched base is 
incorporated into a newly synthesized DNA, distort the double helix. This distortion is 
then recognized by the DNA mismatch repair proteins, which then remove the newly 
synthesized DNA. The gap in the newly synthesized DNA is replaced by a DNA 









A study determined the incidence of MMR inactivation in ovarian cancer and its 
association with resistance to platinum-based chemotherapy. The results of the 
study showed that microsatellite instability, a marker of MMR inactivation, was 
detected in three of the eight cell lines. No methylation at the MLH1 promoter 
was detected in the eight ovarian cancer cell lines and seven of the 75 ovarian 
cancer patients showed methylation at MLH1 promoter but none showed 
microsatellite instability (Helleman, van Staveren et al. 2006). The BER process 
is dependent upon specific N-glycosylases to recognize mismatches or damaged 
bases which it then removed using a family of DNA glycosylases. Such 
corrections result in the formation of an apurinic/apyrimidinic (AP) site. DNA 
polymerase beta mediates single nucleotide BER and is required for efficient 
DNA strand break repair (Figure 6). It has been demonstrated that enhanced 
activity and expression of the DNA polymerase beta occurs in cisplatin-resistant 
human ovarian tumour cells (Bergoglio et al. 2001). However, no clinical studies 
were found to support the correlation between the expression of DNA 
polymerase beta and cisplatin-resistance in ovarian cancer. Another gene 
involved in DNA repair is N-methylpurine-DNA glycosylase (MPG). MPG, a 
ubiquitous DNA repair enzyme, is responsible for the removal of a wide variety of 
alkylated base lesions in DNA. Most of the repair that are initiated by MPG, occur 
using short patch BER whereby one nucleotide is replaced. The overexpression 
of MPG and inhibition of BER pathway by methoxyamine dramatically increase 
the sensitivity of ovarian cancer cells and the amount of DNA double strand DNA 
breaks (DSB) following temozolomide treatment (an alkylating DNA-damaging 
agent) (Fishel et al. 2007). This suggests that MPG can be used as predictor for 



















Figure 6: The base excision repair (BER) system repairs the damage to a single base 
caused by oxidation, alkylation, or deamination.  The BER system is divided into two sub 
pathways, both initiated by a DNA glycosylase. Glycosylase action produces an 
apyrimidinic/apurinic (AP) site, which is processed by an AP endonuclease. In the short-
patch repair system, a single nucleotide is added, followed by DNA ligation. In the long-
patch system, DNA synthesis of multiple nucleotides occurs and the displaced 








Repair of DSB is mediated by homologous recombination (HRR) or non-
homologous end joining (NHEJ) pathways. HRR corrects chromosome breaks 
that occur during the S and G2 phases of the cell cycle and also repair DSBs 
resulting from unrepaired single-strand break (Figure 7). The MRN complex 
(Mre11, Rad50 and Nbs1) recognises the double strand breaks by recruiting the 
Ataxia telangiectasia (ATM) protein which regulates HRR and cell-cycle 
checkpoints. ATM deficient cells are highly sensitive to direct DSB forming 
agents such as IR or DSBs caused indirectly by alkylating agents (Kelley and 
Fishel, 2008).  Both BRCA1 and BRCA2 also play key roles in the repair of DSBs 
by HRR. It has been reported that mouse cells homozygous for mutated BRCA2 
have an increased sensitivity to mitomycin C treatment. This phenotype is related 
to abnormal homologous recombination.  The interstrand DNA crosslinks induced 
by Mitomycin C are reported to be repaired by a homologous-recombination-
dependent mechanism. This involves gene exchange between sister chromatids 
as well as sister-chromatid exchange (Tutt and Ashworth, 2002). Ovarian cancer 
patients with germ line mutations in either BRCA1 or BRCA2 genes display 
impaired ability to repair DSB by HR. This may explain why such patients are 
more sensitive to platinum treatment compared to nonhereditary ovarian cancer 
patients (Tan et al. 2008). Furthermore, BRCA1/2-deficient cancer cells show 
high sensitivity in response to poly (ADP-ribose) polymerase inhibitors (PARP; a 
nuclear enzyme which plays an important role in the recognition and repair of 
single-strand DNA breaks via the base excision repair pathway) (Curtin, 2005). 
However, acquired resistance to platinum in patients carrying frame-shift 
BRCA1/2 mutation is associated with restored BRCA1/2 function and HRR 
function due to secondary mutations that correct the open reading frames of 
mutated BRCA1/2 (Sakai et al. 2008; Swisher et al. 2008). Those patients who 
have mutational reversion to BRCA functionality are likely to develop resistance 






Figure 7: DNA double strand break by homologous recombination: The red and black 
dsDNA represent homologous sequence. The double strand break site is on the red is 
forming 3′ single strand DNA tails, that invade the homologous intact sequences in black. 
Then the DNA strand exchange tracks and produces a recombined molecule between 
damaged and undamaged duplex DNAs. The missing sequence information at the 
double strand break site is restored by DNA synthesis. The interlinked molecules are 
then processed by branch migration, Holliday junction resolution and DNA ligation. 






Therefore, the BRCA1 and BRCA2 mutations could be used to distinguish 
between platinum sensitivity and platinum resistance as the study proved in 8 of 
10 tumour specimens correlating the presence of a mutation with a functional 
BRCA gene.  5 of 6 tumours with the mutated BRCA1/2 were platinum sensitive, 
whereas three of four tumours with the BRCA1/2 revertant mutation were 
platinum resistant (Konstantinopoulos et al. 2010). This suggests that PARP 
inhibitors may be particularly useful for the treatment of women with hereditary 
BRCA1/2-associated ovarian cancer mutation that cause sensitivity to the PARP 
inhibitor (Gien and Mackay, 2010) and consider the BRCA1/2 reversed mutation 
as an important mechanism in both sensitivity to PARP inhibitors and cisplatin. 
Unlike HRR which requires sequence homology to guide repair, the NHEJ is a 
pathway that repairs DNA double-strand breaks in the absence of sequence 
homology at the ends of the broken DNA (Belzile et al. 2006). The NHEJ 
pathway is cell cycle independent that mainly repairs ionizing radiation -induced 
DSBs and linked to cisplatin sensitization (Nojima et al. 2005). DNA-dependent 
protein kinase (DNA-PK) is one of the key protein complexes in the NHEJ 
pathway. DNA-PK, a member of the phosphatidylinositol 3-kinase related family, 
consists of Ku70/80 heterodimer and a catalytic subunit of DNA –PK (Figure 8) 
(Meek et al. 2004).  DNA-PK has been suggested to play a role in cell signalling 
following DNA damage. Knockdown of DNA-PK significantly increases sensitivity 
to cisplatin in MDA-MB-231 human breast adenocarcinoma cells, A2780 ovarian 
adenocarcinoma cells and HeLa S3 cells.  In addition, after cisplatin-induced 
DNA damage, the phosphorylation of DNA-PK at Ser2056 was detected by 
immunoblotting.  However, pre-treatment with NU7026, a DNA-PK   inhibitor 
prevented cisplatin-induced DNA-PK activation suggesting that the sensitivity of 
tumour cells to cisplatin is enhanced by inhibition of DNA-PK (Dejmek et al. 2009) 
and revealing the important role of DNA-PK in cisplatin sensitivity in ovarian 
cancer cells. Thus, the link between DNA-PK and cisplatin sensitivity can be 






Figure 8: Non Homologous End Joining in DNA double-strand break repair: DSBs are 
recognised by Ku70/80 binding to free DNA ends at DSB site. Ku70/80 then recruits 
DNA-PKs, forming the DNA-PK complex. Afterwards, the Ligase IV/XRCC4 complex is 






1.4.4 Increased platinum-DNA damage tolerance: 
 
Platinum resistance can also be associated with the ability to remove potentially 
toxic DNA lesions. Increased DNA damage tolerance proposes a different way to 
resistance in ovarian cancer. The formation and removal of platinum-DNA 
adducts was examined in platinum-resistant cell lines. Increased removal of 
platinum-DNA adducts was associated with increased platinum resistance 
(Johnson et al.1994). Another study conducted to  determine the mechanism 
associated with  platinum resistance in  ovarian cancer cell lines was performed 
by assessing cellular platinum accumulation through measuring glutathione 
levels, platinum-DNA adduct formation, platinum-DNA adduct removal, and 
platinum-DNA damage tolerance. The analysis revealed that of these resistance 
mechanisms, platinum-DNA damage tolerance correlates strongly with cisplatin 
resistance whereas platinum accumulation, cellular glutathione levels, and 
platinum-DNA adduct removal had an insignificant effect (Johnson et al.1994). 
This indicates that platinum-DNA damage tolerance plays role in ovarian cancer 
resistance. 
1.4.5 Alteration in the apoptosis signalling pathways: 
 
Alteration of one or more components of apoptosis process can lead to the 
cisplatin resistance phenotype. The B-cell lymphoma 2 (Bcl-2) is a family of 
apoptosis regulatory proteins that is divided into groups; pro-apoptotic such as 
Bax, BAD, Bak and Bok and anti-apoptotic such as Bcl-2 proper, Bcl-xl, and Bcl-
w (Segal-Bendirdjian et al.1998). Immunohistochemical analysis was conducted 
to evaluate the expression of Bax- and Bcl-2 genes, using tumour tissue from 
215 patients with ovarian cancer. The study showed an association between Bcl-
2-expression (30%) and good prognosis. However; Bax-expression (47%) was 
related to bad clinical outcome (Marx et al.1997). In patients with Bcl-2-positive 
and Bax-negative tumours, overall survival was much longer than in patients with 
Bcl-2- and Bax-negative tumours. However, expression of Bax without Bcl-2-
expression was correlated with poor clinical outcome. This demonstrated that 
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alteration of the Bax and Bcl-2 balance may affect sensitivity to chemotherapy. 
Moreover, the expression of Bcl-xL in epithelial ovarian cancers from 28 patients 
at the time of initial staging and in recurrent tumours in the same patients 
following treatment with platinum-based was analysed using 
immunohistochemistery. It has been reported that the patients who express Bcl-
xL in their primary tumours have considerably shorter disease-free interval 
compared with patients who did not express Bcl-xL in their tumours. In addition, 
in vitro stably transfected A2780 ovarian cancer cells with Bcl-xL conferred 
resistance to cisplatin, paclitaxel, topotecan, and gemcitabine. Furthermore, in a 
xenograft model, Bcl-xL expressing tumours continued to grow following 
chemotherapy treatment, in contrast to control tumours which disappeared. This 
shows that Bcl-xL protects ovarian cancer cells from apoptotic cell death when 
exposed to cisplatin and other chemotherapeutic agents (Williams et al. 2005) 
making these apoptosis regulator proteins as promising target candidates for 
resistance modulation, reviewed in (Stewart 2007). 
 
1.5 The biological function of histone deacetylases 
(HDACs): 
 
Transcription in eukaryotic cells is influenced by the manner in which DNA is 
packaged. DNA is packaged into chromatin, a highly organized protein DNA 
complex. The basic units of the chromatin are nucleosomes.  It is comprised of 
four histones; two H2A, H2B dimmers and H3, H4 tetramer. The presence of 
acetylated lysine residues in histone tails is associated with a more relaxed 
chromatin state and gene-transcription activation, while the deacetylation of 
lysine residues is associated with a more condensed chromatin state and 
transcriptional gene silencing (figure 9) (Strahl and Allis, 2000). Thus, the 
balance between histone acetyltransferase (HAT) and histone deacetylase 
(HDAC) activities play a crucial role in chromatin remodelling and in the 













Figure 9: Histone acetylation/deacetylation regulates transcription: The balance between 
the acetylated and deacetylated states of histones is mediated by two different sets of 
enzymes: histone acetyltransferases (HATs) and histone deacetylases (HDACs). 
Acetylation of the histone tails is associated with an open chromatin structure and active 
transcription. Conversely, removing the acetyl groups on the histone tails by HDAC 
enzyme activity is associated with condensed chromatin structure and transcriptional 









These HDAC enzymes divided into four classes based on sequence similarity to 
the yeast (Figure 10). The class I, II, and IV HDACs are zinc-dependent and 
class III HDACs (SIRT1–SIRT7) are NAD+ dependent in their enzymatic activity 
(Blander and Guarente, 2004) Class I HDACs include HDAC1, 2, 3, and 8. They 
are 400 residues in length and are considered as nuclear proteins, however, 
HDAC3 has the ability to shuttle between the nucleus and the cytoplasm. Class II 
HDACs include HDAC4, 5, 6, 7, 9, and10. These enzymes have the ability to 
shuttle between the nucleus and cytoplasm. In addition, class II HDACs enzymes 
are grouped into class IIa (HDAC4, 5, 7, and 9) and IIb (HDAC6 and 10) because 
class IIa enzymes have N-terminal extension of 600 residues that are thought to 
have distinctive function but class IIb enzymes have two catalytic domains. Class 
IV, share the common properties between class I and class II HDACs and 
includes HDAC11 as reviewed in Verdin et al. 2003.  Class I enzymes are 
ubiquitously expressed in humans, whereas class II enzymes show tissue 
specific expression. Three of the class IIa HDACs, HDAC4, 5 and 9, show 
highest expression in heart, skeletal muscle and brain. The highest expression of 
HDAC7 is in heart and lung tissues. HDAC6 is predominantly expressed in testis 
while HDAC10 is expressed in liver, spleen and kidney (Verdin et al. 2003). The 
HDACs are not redundant in their biological activity. Knockout mouse 
experiments demonstrated a different function for each HDAC. The class I genes 
HDAC1 or HDAC2 knockout in mice resulted in embryonic or perinatal lethality, 
respectively. However, class II HDAC knockout mice were viable and fertile, but 
all display developmental abnormalities. HDAC7 null mouse embryos have 
defects in blood vessel development and integrity. HDAC9 null mice display 
defects in cardiac muscle development, reviewed in (Lane and Chabner 2009).  
Both class I and class II HDACs act on histone substrates and on non-histone 
proteins which play important roles in the regulation of various cellular processes. 
HDAC1 has been reported to affect the deacetylation of the transcription factor 
p53 while HDAC6 deacetylate -tubulin and heat-shock protein 90 (HSP90) 









Figure 10: Schematic representation of class I; HDAC1, 2, 3 and 8, class IIa; HDAC4, 5, 
7 and 9, class IIb; HDAC6 and 10 and class IV; HDAC11.  HDAC enzymes with the 
structural and the functional domains included the capacity of the structurally diverse 
HDAC inhibitors to inhibit the activity of each HDAC classes or specific isoform HDACs 
are shown. Taken from (Bolden et al. 2006).  
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HDAC enzymes exist in multi-protein complexes and recruited to certain 
promoters by interaction with specific transcription factors although these 
enzymes are unable to bind directly to DNA. For example, HDAC1 and HDAC2 
are thought to be found together in multi-protein complexes, and a number of 
transcription factors target these two enzymes to specific promoters to suppress 
transcription (MacDonald and Roskams 2008).  Among all HDAC enzymes, only 
HDAC3 has the ability to interact with class I and II HDACs.  HDAC3 interacts 
with HDAC4, SMRT (silencing mediator for retinoid and thyroid receptors) and N-
CoR (nuclear receptor co-repressor) complexes to repress transcription. The 
suppression of HDAC4 binding to SMRT and N-CoR and to HDAC3 lead to a 
loss of enzymatic activity related to HDAC4. It has been reported that class II 
HDACs require an enzymatically active SMRT/N-CoR-HDAC3 complex to 
regulate transcription (Fischle et al. 2002; Grozinger et al.1999) with  the 
exception of HDAC6 which contains an internal dimer including two functional 
catalytic domains and  thus does not require another HDAC  enzyme for its 
activity (Grozinger et al.1999). HDAC6 has been shown to specifically 
deacetylate -tubulin at lysine 40. Therefore, this lysine has been used as a 
marker of microtubule stability (Piperno et al.1987). Sirt1, a Class III HDAC, has 
been reported to deacetylate the p53 gene and to inhibit the transcriptional 
activity and apoptosis mediated by this gene (Cheng et al. 2003). Class II HDACs 
can deacetylate the four core histones and act like transcriptional corepressors.  
These enzymes either act through transcriptional corepressors or bind directly to 
sequence-specific transcription factors, such as myocyte enhancer factor-2 
(MEF2). The MEF2 family of transcription factors is one of the important targets 
of class IIa HDACs. MEF2, major transcriptional activators for the expression of 
muscle-specific genes, also regulate other cellular programs, including neuronal 
survival, T-cell apoptosis, and growth factor responsiveness. When class IIa 
HDACs bind to MEF2, it change MEF2 from being transcriptional activators into 
repressors. The MEF2-binding site is conserved among all four class IIa HDACs 
enzymes (Gregoire and Yang, 2005). 
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The homodimeric and heterodimeric interactions of HDAC might indicate that 
these interactions are important for the regulation of HDAC activity. Histones not 
only undergo acetylation and decetylation but undergo different post-translational 
modifications such as; phosphorylation, methylation, ubquitination and 
sumoylation which are thought to influence the chromatin structure, DNA 
accessibility and gene expression regulation (Struhl, 1998).  
1.5.1 The role of HDACs in cancer: 
 
The role of the individual histone deacetylases (HDACs) in the regulation of 
cancer cell proliferation was investigated using siRNA-mediated knockdown 
(HDAC1, HDAC2, HDAC3, HDAC4 and HDAC7) in HeLa cells. Proliferation 
analysis showed that knockdown of HDAC1 and HDAC3 resulted in slower cell 
growth compared with HDAC4 and HDAC7 and that only HDAC1 and HDAC3 
are important in cellular proliferation (Glaser et al. 2003). Another study showed 
that siRNA knockdown of HDAC2 can arrest the cell cycle either at the G (1) 
phase or during G (2)/M transition, resulting in the loss of mitotic cells and cell 
growth inhibition. In contrast, HDAC2 knockdown showed no effect on cell 
proliferation (Senese et al. 2007). Furthermore, HDACs 1 and 2 share a high 
degree of homology and coexist within the same protein complexes. In spite of 
their close association, each possesses unique functions. High expression of 
HDAC2 has been seen in colorectal cancer at polyp stage ( more than HDAC1 
expression) suggesting that HDAC2 might be involved in the early events of 
cancer development (Huang, Laban et al. 2005).  The up-regulation of HDAC3 
protein expression has been reported in human colon tumours and knocking 
down of HDAC3 expression by RNA interference in colon cancer cell lines 
resulted in growth inhibition, a decrease in cell survival and increased apoptosis. 
Similar effects were observed for HDAC2 and, to a lesser extent, for HDAC1 
(Wilson et al. 2006). HDAC8 has been implicated in smooth muscle cell 
contractility (Waltergny D, et al. 2005) although its knockdown by RNA 
interference inhibits growth of human lung, colon, and cervical cancer cell lines 
(Vannini et al. 2004). This shows that class I HDACs are essential for cell cycle 
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regulation, proliferation and survival with the exception of HDAC2 which is 
involved in the regulation of apoptosis in tumour cells. Altered expression of 
certain HDACs has been reported in tumours compared with normal cells. 
Increased expression of HDAC1 has been found in gastric cancers, esophageal 
squamous cell carcinoma, hormone-refractory prostate cancer, and colon cancer 
(Choi et al. 2001; Wilson et al. 2006). HDAC2 expression is increased in human 
colon cancer (Zhu et al. 2004). HDAC3 expression is increased in human tumour 
samples of colon cancer compared with normal tissue (Shebzukhov et al. 2005). 
HDAC5 is down-regulated in colon cancer (Scanlan et al. 2002).  Class I HDACs 
have been shown to be expressed at significantly higher levels in ovarian 
cancers in comparison to normal ovarian tissues, with no significant difference in 
Class II HDAC expression between the two groups (Khabele et al. 2007). 
Furthermore, the high expression of class 1 HDACs (HDAC1, 2, and 3) has been 
associated with poor prognosis in endometrioid subtypes of ovarian and 
endometrial carcinomas (Weichert et al.  2008).  In addition, the expression 
levels were considerably different in specific tumour histological subtypes with 
mucinous carcinomas showing the highest positivity rates (71%); followed by 
high-grade serous (64%), clear cell (54%) and endometrioid subtypes (36%). 
HDAC class I expression was generally higher in strongly proliferating tumours 
(Khabele et al. 2007; Weichert et al. 2008).  A recent study using 115 ovarian 
tumour tissues confirmed that expression of nuclear HDAC1, HDAC2 and 
HDAC3 proteins increased stepwise in benign, borderline and malignant tumours. 
Analysis of the effect of specific isoforms of HDACs using siRNA against HDAC1, 
HDAC2 and HDAC3 on the ovarian carcinoma cell lines, SKOV3, OVCAR3, 
IGROV-1, ES-2, TOV112D, A2780 and A2780/CDDP showed that knockdown of 
HDAC1 considerably reduced the proliferation of ovarian carcinoma cells, while, 
knockdown of HDAC3 reduced cell migration (Hayashi et al. 2010). This indicates 
that HDAC enzymes especially class I have important roles in ovarian 
carcinogenesis which provides a rationale for targeted inhibition of HDAC 
enzyme in the treatment of ovarian cancer.  
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1.5.2 Therapeutic implications of HDAC inhibitors: 
 
HDAC inhibitors are amongst the most promising therapeutic targets for cancer 
treatment due to their critical role in the regulation of transcription of key genes 
controlling important cellular functions such as cell proliferation, cell-cycle 
regulation and apoptosis. The balance between histone acetylation and 
deacetylation is required for active gene expression (Secrist et al. 2003).  The 
catalytic domain of HDAC is closely conserved from bacteria to humans and the 
knowledge of its crystal structure has helped in the development of potent HDAC 
inhibitors (HDACi) based on the molecular mode of action of HDAC. HDAC 
inhibitor usually consist of a metal-binding moiety that binds the catalytic metal 
atom within the HDAC active site and a capping group that interacts with the 
residues at the entrance of the active site (Marks et al. 2001; Figure11). A linker 
correctly positions the metal-binding moiety and capping group for interactions in 
the active site. Crystallographic studies have revealed that SAHA 
(suberoylanilide hydroxamic acid or vorinostat) inhibits HDAC activity by binding 
to the active site of the enzyme (Finnin et al.1999; Marks et al. 2001). A number 
of natural and synthetic compounds have been shown to be able to inhibit the 
activity of class I, II, and IV HDACs. HDACi can be divided into several classes: 
hydroxamic acids e.g., trichostatin A (TSA) and suberoyl anilide bishydroxamic 
acid (SAHA), short-chain fatty acids e.g., sodium butyrate (NaB), cyclic 
tetrapeptides (e.g., traposin), and benzamides (e.g., MS-275) (Villar-Garea and 
Esteller, 2004). The efficacy of HDAC inhibitors as anticancer agents has been 
demonstrated in a wide range of haematological and solid tumour cell lines and 
in experimental animal models (Drummond et al.  2005; Saito et al.1999).  SAHA 
has been approved by the U.S. Food and Drug Administration for the treatment 
of cutaneous T-cell lymphoma (CTCL), a form of non-Hodgkin's lymphoma.  
Romidepsin is the second HDAC inhibitor to be approved by the FDA for the 
treatment of CTCL. Romidepsin has a very different chemical structure compared 
to vorinostat.  Romidepsin is a selective inhibitor for class I HDACs whereas; 
vorinostat is a pan-HDAC inhibitor (Campas-Moya, 2009). Most HDACi are not 
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specific to subclasses of HDAC enzymes. They inhibit many of the known 
mammalian HDACs. There has been increased attention over the past several 
years to create selective HDAC inhibitor. Given that specific HDAC isoform has 
specific function in cancer, selective HDAC inhibitors will be very useful in cancer 
treatment. This led to several class-selective and some isoform-selective 
inhibitors such as MS-275.  MS-275 is more active against HDAC1 than against 
HDAC3 (Hu et al. 2003). Depsipeptide is more potent against HDAC1 and 
HDAC2 than against HDAC4 and HDAC6 (Furumai et al. 2002). 2f-MC1568 and 
4a-MC1511 HDAC inhibitors are derivative of aroyl-pyrrolyl-hydroxyamides 
(APHAs) 2f-MC1568 was selective to class II but with poor inhibitory activity, 
however, 4a-MC1511 showed effective inhibitory activity against class II and to 
less extent to class I (Mai et al. 2005). Therefore, further studies are necessary in 
order to create HDAC isoform specific inhibitors. The effect of HDACi in the 
treatment of epithelial ovarian cancer has been reported by (Takai, Ueda et al. 
2006). The study investigated the effect of scriptaid, a member of the hydroxamic 
class of HDAC inhibitors that is selective for class I HDACs on Ishikawa 
endometrial cancer cell line, SKOV-3 ovarian cancer cell line, and normal human 
endometrial epithelial cells. The data showed that Scriptaid induced growth 
inhibition and increased acetylation of H3 and H4 histone for both endometrial 
and ovarian cancer cell lines.  While normal endometrial epithelial cells were 
viable following treatment with similar doses of Scriptaid.  The study showed the 
effectiveness of HDACi in mediating tumour cell selective killing compared with 
the normal cell. This may be because cancer cells have several genetic defects 














Figure 11: Vorinostat inhibits HDAC activity by binding to the pocket of the 
catalytic site. The hydroxamic acid moiety of vorinostat binds to a zinc atom 
(pink), this allow the rest of the molecule to lie along the surface of the HDLP 










Vorinostat has been reported to induce cell death and increase caspase-3 activity 
in three ovarian cancer cell lines (OVCAR-3, SK-OV-3, and A2780) and in 
primary ovarian cancer cells isolated from malignant ascites collected from five 
patients with stage III ovarian carcinomas.  Furthermore, 2780AD, a doxorubicin-
resistant ovarian cancer cell line cells were responsive to varinostat (Sonnemann 
et al. 2006). Pre-treatment with Vorinostat and trichostatin A (TSA) has been 
shown to enhance the cytotoxicity of DNA-targeting agents such as VP-16, 
ellipticine, doxorubicin, and cisplatin but not that of drugs which do not target the 
DNA, like the antimetabolite 5-fluorouracil (Kim et al. 2003).  In addition, valproic 
acid (2-propylpentanoic acid; VPA),  an HDAC inhibitor that inhibits both class I 
and II HDACs,  has been reported to have synergistic cytotoxicity with cisplatin in 
human ovarian carcinoma cells (SK-OV-3, OVCAR-3, TOV-21G, A2780 and 
A2780/CP70) and can restore platinum sensitivity in the acquired cisplatin-
resistance cells (Lin et al. 2008). Pre-clinical in vitro studies on the effect of 
PXD101, a class I and II HDAC inhibitor showed this HDACi exhibit single-agent 
antitumour activity on human A2780 ovarian cancer xenografts. This effect 
improved when combined with carboplatin treatment (Qian et al. 2006).  Clinical 
trials showed the limited therapeutic of some of HDACi such as TSA and trapoxin 
because they have poor bioavailability and toxic side effects at high doses. Other 
HDACi are degraded after i.v. administration like sodium butyrate and 
phenylbutyrate thus requiring high doses to achieve maximum tumour killing 
(Warrell et al.1998).  It has been shown that vorinostat treated ovarian cancer cell 
lines and in primary cancer cells derived from malignant ascites obtained from 
five patients with stage III ovarian cancer had cytotoxic effect as a single agent 
(Sonnemann et al. 2006). A phase II trial of vorinostat in platinum-
resistant/refractory epithelial ovarian patients showed progression-free survival 
over 6 months, with few having a partial response. However, vorinostat has toxic 
effects such as thrombocytopenia, neurologic complaints and pain which limit its 
effectiveness (Modesitt et al. 2008). This provides an evidence that HDAC 
inhibitors could have a potential role in the treatment of ovarian cancer but there 
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is need to develop HDAC inhibitor that has a tolerable side effect and efficient in 
destroying cancer cells.  
 
1.5.2.1 HDAC inhibitors and apoptosis: 
 
HDAC inhibitors are suggested exhibit the anticancer effects through regulation 
of gene expression by histone acetylation and through increasing acetylation of 
other cellular proteins. The molecular pathways that trigger cell death by HDAC 
inhibitor in ovarian cancer are not fully understood. But there are a number of 
genes identified to be either up or down-regulated following HDACi treatment 
(Table 2). These genes involved in a variety of cellular processes and networks 
such as those involving the proapoptotic proteins; Fas, Fas ligand, Bak, Bax, Bim,  
BLxl, Bcl2, Caspase 3, and the  cell cycle regulation proteins such as p21 and 
p27 (Drummond et al. 2005). HDACi treatment has been reported to activate 
caspase-9, caspase-3, and caspase-8 and inhibit anti-apoptotic Bcl-2 family 
members (Bcl-2 and Bcl-XL)  in breast, colon, hematopoietic, lung, melanoma, 
ovarian, prostatic, renal, and stomach cancer cell lines using a novel 
hydroxamate-based HDACI, CG0006 (Hwang et al. 2009). BcL2 proteins control 
the intrinsic pathway of apoptosis at the mitochondria by preventing the release 
of the cytochrome c. Therefore, the inhibition of Bcl-2 and Bcl-XL by HDACi 
treatment promotes the release of cytochrome c followed by caspase-9 and 
caspase-3 activation leading to apoptosis. As discussed previously, the 
expression of Bcl2 has been shown to protect ovarian cancer cells from the toxic 
effect of cisplatin (Hwang et al. 2009). Thus, HDACi could play role in cisplatin 
resistance in ovarian cancer by modifying the expression of the genes could 
confer resistance to cisplatin.  It has been shown that HDACi treatment induced 
the accumulation of both proteins p21 and p27, which express in low level in 
untreated ovarian cancer cell lines and have important role in cell cycle regulation 
(Hwang et al. 2009). Moreover, specific knockdown by siRNA against HDAC4 in 
ovarian carcinoma IGROV-1 induced the expression of p21 (Mottet et al. 2009). 
The up-regulated p21 and p27 bind to cyclin-CDK complexes to inhibit their 
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catalytic activity and induce cell cycle arrest in cancer cells. The study showed 
that over-expression of P21 and p27 correlates with increased apoptosis, 
demonstrating that p21 and p27 levels might be essential for HDACi -induced 
apoptosis (Abukhdeir and Park, 2008).  
 
This is just one of the possible pathways that HDACi utilize to arrest cancer cell 
growth. It has also been demonstrated that histone deacetylase inhibitors exhibit 
anti-cancer activity and induces apoptosis in ovarian cancer cells via up-
regulation of E-cadherin expression and accumulation of acetylated histones H3 
and H4 (Figure 12). The study examined the effect of HDACi (SAHA, VPA, TSA, 
and NaB) using human ovarian cancer cell lines (SKOV-3, OVCAR-3, TOV-21G, 
OV-90, TOV-112D, OVCA420, OVCA429, OVCA432, and OVCA433) (Takai et al. 
2004). Hayashi A, et al. 2010 has reported that knockdown of HDAC3 by siRNA 
reduced the cell migration with elevated E-cadherin expression in ovarian cancer 
cells. E-cadherin is one of the important molecules for adhesion between 
adjacent epithelial cells.  When the ovarian epithelial cell undergoes 
transformation, the cell can detach from the original basement membrane and 
metastasize throughout the peritoneal cavity. E-cadherin is membrane 
glycoproteins that mediate adhesion between cells which is an important event in 
metastasis. Loss of E-cadherin has been associated with ovarian cancer 
metastasis (Sawada et al. 2008).  E-cadherin might have tumour suppressor 
function in ovarian carcinoma because it has been reported to be silenced by 
















Regulated protein Function (oncogenic or tumour suppressing) 
Down regulated by HDAC inhibitors 
Thioedoxn 
Disulfdereductas , cytokine activity 
 can inhibit apoptosis 
Telomerae Prevents telomere erosion 
REK Regulates matrix metalloproteinases 
VEGF Angiogenc factor 
Bfgf Angiognic factor 
Myb/c-MyBL2 
Oncogenic transription factor 
regulation of transformation and differentiation 
raf-1 Effector of Ras 
cyclin A Cell cycle regulator 
cyclin B Cell cycle regulator 
Abl 
Growth factor receptor, component of bcr/abl 
chimeric kinase 
Regulated protein Function 
Upregulated by HDAC inhibitors 
Fas/Fas ligand Proapoptotic 
Bcl2 Proapoptotic 
p53 Proapoptotic 
Bak, Bax, Bim Proapoptotic 
c-myc Inhibitor of differentiation 
Caspase 3 




Carboxypeptidase, putative role in regulating 
differentiation 
RECK Negatively regulates matrix metalloproteinases 
p21WAF1/Cip1 Cell cycle regulation 
 
Table 2: The genes whose transcriptional expression is changed after HDAC inhibitor 
treatment in ovarian cancer cells either by increased their expression or decrease the 













The up-regulated E-cadherin after HDACi treatment in ovarian carcinoma cells 
indicate that this gene also involved in HDACi meditating cell death in ovarian 
cancer (Takai and Narahara, 2007). The generation of reactive oxygen species 
(ROS) is another phenomenon observed in HDAC inhibitor treated cells.  It has 
been reported that HDAC inhibitors; TSA, MS-275, FK228 and HC toxin promote 
the induction of DNA damage by a variety of anticancer agents; doxorubicin, 
paclitaxel, Etoposide, cisplatin, bleomycin, Mitomycin-C and topotecan, which 
resulted in enhanced generation of ROS, then cell death in human ovarian 
cancer cell lines; OVCAR-3, OVCAR-4, OVCAR-5, OVCAR-8, SKOV-3, and 
TYK-nu (Ozaki et al. 2008). This showed that increased generation of ROS play 
a role in HDAC-mediated cell death.  
 
It seems that HDACi induced cell death is through extrinsic apoptotic pathway, 
which involves the cross-linking of certain death-inducing receptors like Fas by 
their legends (Drummond et al. 2005) and consequent activation of caspases 3, 8 
and 9. In addition to this HDACi utilize the intrinsic apoptotic pathway through the 
disruption of outer mitochondrial membrane integrity and later release of 
cytochrome c and other pro-apoptotic molecules. The involvement of these 
factors and pathways in the antic cancer activity of HDACi need to be 
investigated. In addition, the effects of HDACi can be cell-type-dependent, and 
different HDACi can have different effects in the same cell type as shown by 
Ozaki K et al. 2008. This possibly relate to the HDAC-specificity profiles of the 
different compounds and HDACs profile in different cell lines. Since different 














Figure 12: Postulated mechanisms of action of HDAC inhibitors in ovarian cancer 
Adapted from (Drummond et al. 2005).  The global change in gene transcription 
following HDACi treatment is limited to certain number of genes about 2–5% of 
expressed genes in cancer (VanLint, Emiliani et al. 1996). Among these genes, p21 and 
p27, their expression increased which lead to cell cycle arrest. Another mechanism is the 
repression of anti-apoptotic genes such as bcl-2 and bcl-xL that block of the release of 
cytochrome c, the activation of Caspase-3 and initiation of apoptosis. Increase the 








1.5.3 Histone deacetylase 4 (HDAC4): 
 
Histone deacetylase 4 (HDAC4) is a class IIa HDACs encoded by a gene located 
on 2q37.2. The amplification of this segment has been associated with oral 
squamous carcinomas (Wolff et al.1998).  Abnormalities in the HDAC4 genomic 
region have been implicated in congenital malformation syndrome in a 12-year-
old girl born with a de novo unbalanced t (2; 22) (q37; q11.2) and later displayed 
signs of neurologic impairment. HDAC4 is expressed in a tissue-specific manner 
mainly in skeletal muscle, brain, leukocyte, colon, small intestine, and ovary but 
not in liver, lung, and placenta.  The predicated molecular weight for HDAC4 is 
119-kD protein although it has been shown that the molecular weight of nuclear 
HDAC4 was higher slightly than cytosolic HDAC4 ( Wilson et al. 2008). HDAC4 
contains 1084 amino acid residues, with a highly homologous conserved catalytic 
domain (HDAC domain) at amino acid 802  in the carboxy terminal region (C-
terminal) which is believed to be responsible for the deacetylate activity and 
similar to the deacetylase domain of the yeast Hda1 (Wang et al.1999). The 
functional analysis of HDAC4 by Grozinger et al.1999 confirmed that HDAC4 has 
deacetylation activity against all 4 core histones in vitro.  Bottomley MJ et al. 
2008 demonstrated that the deacetylase domain of HDAC4 possesses 
intrinsically enzymatic activity toward acetylated lysines in vitro but activity lower 
than class I HDACs. The studies used trifluoroacetamide substrate for HDAC 
activity assay since no biological substrates yet have been identified for class IIa 
HDACs (Bertrand, 2010). In the end of the C-terminal there is nuclear export 
signal (NES) and nuclear localization signal sequences (NLS) is located in the N-
terminal (Figure 13). These signal responsive elements in HDAC4 enable its 
shuttling between the nucleus and cytoplasm. The amino acid terminal (N-
terminal) in HDAC4 has been reported to be involved in transcription repression, 
phosphorylation and nucleocytoplasmic shuttling (Bottomley et al. 2008; Lahm et 
al. 2007).HDAC4 repression activity is regulated by its sub-cellular localization. 
Phosphorylated HDAC4 binds to 14-3-3 proteins prevent HDAC4 nuclear 
localization. Thus, 14-3-3 proteins negatively regulate HDAC4 repression 
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function. 14-3-3 proteins are conserved with seven isoforms that present 
ubiquitously in approximately all the tissues in mammals. These proteins are 
known as cytoplasmic anchors for their binding partners (Sun et al. 2009). 14-3-3 
proteins have the ability to recognise phosphorylated proteins and retain their 
partner protein in the cytoplasm (Muslin and Xing, 2000). It has been reported 
that 14-3-3 proteins have more than 200 binding partners and are involved in 
variety of cellular activity such as protein synthesis, transcription repression, cell 
cycle and metabolic pathway (Nishino et al. 2008). HDAC4 function as a 
repressor when inside the nucleus as it binds and represses the transcriptional 
activity of myocyte enhancer factor 2 (MEF2). Furthermore, it has been reported 
that HDAC4 is enzymatically inactive and the deacetylase activity arises from the 
presence of HDAC3 in the transcriptional corepressor SMRT (silencing mediator 
for retinoid and thyroid receptor) and NCoR (nuclear receptor corepressor) 
complex. The interaction between HDAC4 and the complex HDAC3 and 
SMRT/N-CoR happens inside the nucleus (Emiliani et al.1998). HDAC4 has been 
shown to exhibit functional activity on the NCoR/SMRT complex that did not 
contain HDAC3 using recombinant proteins (Huang et al. 2000). Although, the 
enzymatic activity of class II HDACs is associated with multi-proteins complex 
contains HDAC3 and SMRT/N-CoR. Wang et al. 1999 has reported that both the 
deacetylase domain and the amino acid-terminal domain (208 residues) have the 
potential to repress transcription. HDAC4 has a role in muscle differentiation. It 
interacts specifically with the myogenic MEF2 transcription factor and represses 
its activity. In myoblasts cells, phosphorylated HDAC4 binds to 14-3-3 proteins 
and held in the cytoplasm during myoblast differentiation, however it translocates 
to the nucleus once fusion has occurred.  Nuclear HDAC4 suppresses the 
myogenic programme and MEF2-dependent transcription. Activation of the 
Ca2+/calmodulin signalling pathway by active CaMKIV prevents nuclear entry of 
HDAC4 and HDAC4-mediated inhibition of differentiation (Miska et al. 2001). 
HDAC4 also regulates chondrocyte hypertrophy and skeletogenesis through 
interaction with the chondrocyte hypertrophy transcription factor runt-related 
transcription factor-2 (Runx2) and inhibit its activity to activate the transcription of 
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osteoblast-specific genes. HDAC4-null mice display premature ossification of 
developing bones due to ectopic and early onset chondrocyte hypertrophy and 
over-expressed HDAC4 resulted in inhibition of chondrocyte hypertrophy with 
delayed ossification (Vega et al. 2004).  Moreover, HDAC4 has been revealed to 
have a role in the DNA damage response. Kao GD et al. 2003 showed that 
endogenous HDAC4 is recruited to nuclear foci with kinetics similar to 53BP1, a 
p53 binding protein, following DNA damage meditated by -irradiation in human 
HeLa cells. 53BP1 is phosphorylated in response to DNA damage and then 
translocates to nucleus to form nuclear foci that co-localise with those formed by 
phosphorylated histone H2AX, a double strand break marker (Kao et al. 2003). 
53BP1 also participates in the phosphorylation of p53 in the maintenance of S 
and G2 cell cycle checkpoints after DNA damage (Motoyama N, Naka K 2004). 
HDAC4 has been demonstrated to translate to the nucleus upon DNA damage 
caused by adriamycin treatment in NIH3T3 mouse fibroblasts. HDAC4 nuclear 
recruitment after DNA damage has been reported but was not associated with 
apoptosis (Basile et al. 2006). This could indicate a role of HDAC4 in DNA 
damage response.  The role of HDAC4 in the development of cancer also has 
been reported. Immunohistochemical staining of prostate sections of benign 
tissue and primary and hormone refractory (HR) prostate cancer, as well as of 
the CWR22 mouse xenograft model showed that HDAC4 is recruited to the 
nuclei of HR cancer cells, where it might exhibit inhibitory effect on differentiation 
and contribute to the development of the aggressive phenotype of late stage 
prostate cancer (Halkidou et al. 2004). Thus, HDAC4 may participate in the 




















Figure 13: HDAC4 contains amino acid terminal where nuclear localization signal 
sequences (NLS). This amino terminal region interacts with specific transcription factors 
such as MEF2, RUNX1 and 14-3-3 and possesses transcriptional suppressive activity.  
Carboxy terminal deacetylase region of HDAC4 contains a highly homologous 
conserved catalytic domain (HDAC domain) and nuclear export signal (NES) at the end. 
The signal responsive elements in HDAC4 affect its nucleocytoplamic shuttling. It is 
believed that both the deacetylase domain and the amino acid-terminal domain have the 












Likewise, in HeLa cells, HDAC4 knockdown resulted in cell cycle arrest, 
chromatid segregation defects, and caspase-dependent apoptosis. However, 
HDAC4 knockdown seems to be well tolerated in normal human dermal 
fibroblasts and murine embryonic fibroblasts (MEF) cells (Cadot et al. 2009). This 
might imply that the biological function of HDAC4 is different between normal and 
cancer cells. The extracellular signal-regulated kinases 1 and 2 (ERK1/2) 
mitogen-activated protein kinase (MAPK) pathway is an important signalling 
system that mediates ligand-stimulated signals for the initiation of cell 
proliferation, differentiation, and cell survival.  The ERK1/2 pathway has shown to 
be active in ovarian cancer and might be involved in the pathogenesis of these 
tumours (Steinmetz et al. 2004). It has been reported that ERK1/2 interacts with 
HDAC4 by immunoprecipitation analysis and the activation of ERK1/2 by Ras-
MAPK pathway via expression of oncogenic Ras or active MAPK/ERK kinase 1 
increase the percentage of cells expressing HDAC4 in the nucleus in C2C12 
myoblast cells (Zhou et al. 2000). The role of the interaction between HDAC4 and 
ERK1/2 in the regulation of HDAC4 localization is unclear however; the activated 
Ras seems to act on HDAC4 indirectly by enhancing its nuclear localization. 
Moreover, HDAC4 knockdown increased p21 expression in human cancer cell 
lines; ovarian carcinoma (IGROV-1), glioblastoma (U87-MG), cervical cancer cell 
lines (HeLa), colon cancer (Wilson et al. 2008) and Osteosarcoma cells (Saos-2) 
(Mottet D, et al. 2009).  
 
Thus, HDAC4 is a key transcriptional regulator of p21 expression and a potential 
valuable target for anticancer therapies. Together the data show that HDAC4 not 
only plays a role in transcription repression via interaction with MEF2 and RUNX1 
but also plays role in DNA damage response, cell cycle arrest, chromatid 
segregation, and apoptosis in human cancer cell lines. However, the biological 
activity of HDAC4 seems different between human cancer cells and normal cells. 




1.6 Specific background to the thesis: 
1.6.1 Identification of HDAC4 up-regulated in platinum-resistant 
ovarian cancer by micro-array analysis:  
 
Microarray technology is a powerful and high-throughput technique to compare 
and identify the change in gene expression levels between two different set of 
samples. A number of genes have been identified to be associated with platinum 
resistance by microarray studies either related to cell cycle control, DNA repair, 
apoptosis and proliferation reviewed in Konstantinopoulos et al. 2008. To identify 
the candidate genes responsible for cisplatin-resistance and to understand the 
molecular mechanisms mediating the development of cisplatin resistance in 
ovarian cancer, gene expression micro-array was performed (Stronach E,  et al. 
2011) on three isogenically paired cell lines which were derived from serous 
ovarian cancer patients before the onset of platinum resistance (PEO1, PEA1, 
PEO14) and from the same patients after the  tumours relapse having acquired 
cisplatin resistance in-vivo (PEO4, PEA2 and PEO23).  Molecular profiling from 
these isogenic cell line pairs, carried out previously, showed that 65 genes were 
up-regulated and 128 genes were down- regulated in resistant cells. HDAC4 was 
one of the genes up-regulated in resistant cell lines relative to the sensitive 
derivative (Figure 14). P-values from t-test were significant in both PEO4 (p-value 





















Figure 14: Molecular profiling from the isogenic cell pairs showing HDAC4 expression in 
PEO4, PEA2 and PEO23 resistant cell lines relative to the sensitive parent lines PEO1, 
PEA1 and PEO23 respectively, Y-axis indicates fold change relative to parent line. This 
shows that HDAC4 mRNA expression is higher in the resistant cell lines; PE04 and 















1.6.2 The aims of the study: 
 
The aim of this study is to enable better understanding of the mechanisms 
involved in the development of platinum-resistance in ovarian cancer and the role 
HDAC4 plays in cisplatin- sensitive and resistant ovarian cancer cell lines. The 
hypothesis that will be tested is the reduction of HDAC4, which is up-regulated in 
cisplatin-resistant cell line, will re-sensitize the cells to cisplatin.  
Assess the involvement of HDAC4 in platinum resistance in ovarian cancer.  
 The expression level of HDAC4 will be assessed by western blot and 
quantitative real time PCR (qRT PCR) in isogenic cell pairs to assess the 
expression of HDAC4 in cisplatin-resistant cells.  
 utilize small interfering RNA (siRNA) gene Knock down technique to 
specifically knock down HDAC4 protein expression in cisplatin resistant 
cells followed by cisplatin treatment to determine if there is enhancement 
in platinum sensitivity using apoptosis (caspase3/7) and cell proliferation 
( MTT) assays.  
  Affymetrix RNA microarray after HDAC4 knockdown will be used to 
identify HDAC4-regulated genes and to monitor global changes following 
knockdown of HDAC4. 
Identify the role of other HDAC isoforms and their effect in platinum 
resistance 
 HDAC isoforms classI and II expression will be screened by qRT PCR in 
the isogenic cell pairs to identify which other HDAC isoforms are also 
involved in the cisplatin-resistance.  
 Assess the apoptotic activity after siRNA-mediated knockdown of HDACs 
isoforms that are up-regulated in cisplatin resistant ovarian cells to identify 
if they contribute in changing platinum response. 
 Investigate the mechanism of HDAC4 activity in ovarian cancer cells. 
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 The sub-cellular localization of HDAC4 after cisplatin-induced DNA 
damage will be assessed by immuno-fluorescence microscopy (IF).  
 The interaction between HDAC4 and STAT1 will assessed by immune-
precipitation, western blot and immuno-fluorescence microscopy after 
HDAC 4 knockdown to identify a possible connection between these 
two genes in platinum resistance.  
Evaluate the clinicopathological correlations of HDAC4 altered expression 
in ovarian cancer  
 The clinicopathological correlations of HDAC4 expression in ovarian 
cancer by immunohisto- chemistry IHC from clinical material, including 
paired pre and post chemotherapy sections will be constructed.  
Immunohistochemical data for expression of HDAC4 will be analysed 
for associations between HDAC4 expression and patient response and 
outcome.  
 The pharmacological reproducibility of knock down HDAC4 will be 
evaluated by using inhibitor that selectively inhibits HDAC4 followed by 













































2.1 Cell lines and culture: 
 
Three isogenically paired epithelial cell lines, derived from the ascites of patients 
with ovarian adenocarcinoma before they develop resistance to cisplatin 
treatment (sensitive to cisplatin: PEO1, PEA1, PEO14) and after clinical 
resistance developed to cisplatin (cisplatin resistance PEO4, PEA2 and PEO23 
respectively), were obtained from Dr Simon Langdon (Cancer Research UK, 
Medical Oncology Unit, Edinburgh, UK) and previously described by Langdon et 
al. 1988. SKOV3 cisplatin-resistant ovarian cancer cells obtained Eurpean 
Collection of Animal Cell Culture (ECACC). In addition to established ovarian 
cancer cell lines; A2780 and its matched cisplatin-resistant A2780/CP70 were 
used. A2780/CP70 developed resistance to cisplatin from repeated exposures of 
the parental A2780 cells to doses of cisplatin in vitro  and as a result had 13-fold 
more resistance to cisplatin than A2780 cells with the IC50 is reached at 40µM 
(Parker et al. 1991). SKOV3 ovarian carcinoma cells were obtained from the 
ECACC repository.  Cells were grown under standard condition in RPMI-1640 
medium supplemented with 10% foetal calf serum (FCS; Invitrogen), penicillin 
(100/ml; Invitrogen) L-glutamine (2Mm; Invitrogen) and streptomycin (100 g/ml; 
Invitrogen) at 37°C in 5%CO2 atmosphere Galaxy-S incubator. Regular 
Mycoplasma testing was performed monthly to ensure cells remained free of 
Mycoplasma infection during the course of the experiments.  
 
2.2 Transient transfection of cell lines with siRNAs: 
 
RNA interference (RNAi) is a process in which double-stranded RNA about 25 
nucleotides in length triggers the degradation of a homologous messenger RNA. 
Dharmacon kit was used to knockdown the selected genes in this study. The 
siGENOME SMARTpool (Dharmacon™) tube containing a mixture of four 
SMART pool selection-designed siRNAs targeting one gene maximizing the 
efficiency of gene knock down and the sequence information was provided. The 
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seeding density for each cell line were optimized. Cells Cells were seeded in 6 
well plates at densities for PEO1=7x105, PEO4=1x106, PEA1=2x105, PEA2= 
2.5x105, PEO23 and PEO14= 3x105, SKOV3= 2x105  for 24 hours prior to 
transfection with smartpool siRNAs directed to HDAC1, HDAC3, HDAC4 and 
control siRNAs, LAMIN A/C, non-targeting and siCONTROL-TOX (100nM final 
concentration. In separate tubes, the  appropriate  diluted amount of  siRNA , 1X 
siRNA Buffer, and OptiMEM media for siRNA HDAC4 , siControl and siTOX were 
added and mixed gently by pipetting (tube1) and Transfection reagent 
(DharmaFECT 1) mixed with the OptiMEM medium (tube 2) incubated for 5 
minutes at room temperature. The contents of tube1 and tube2 were mixed by 
pipetting and incubated for 20 minutes at room temperature to be added to the 6 
wells format after removing the complete culture medium  and replaced with  
appropriate transfection medium (2 l per well) plus antibiotic-free medium (198µl 
per well) to each well. The cells were incubated at 37°C in 5% CO2 for 24hrs. 
The efficiency of siRNA-induced gene knockdown is hindered by low transfection 
efficiency. Therefore, siRNA transfection was applied twice. The frist transfection 
was applied after 24 hours from seeding the cells and the scond transfection was 
applied 24 hours after the first transfection. Cells were washed with PBS, 
trypsinised, collected, and seeded in 96 wells format (3x 104 cells/cavity) for 
Caspase Glo 3/7 (apoptosis), and SRB/MTT (Cell viability) assays and seeded in 
6 well format (1x 106 cells/well) for RNA and protein extractions. Total RNA and 
protein lysates were collected as described below. 
 
2.3 Caspase 3/7 assay:  
 
Cells were seeded in 96 wells white plates (opaque plates) at densities of 
PEO1=1x104, PEO4=3x104, PEO23 and PEO14= 1x104, PEA1=1x104, PEA2= 
9x103, SKOV3= 9x103 cells per well in triplicate and allowed to adhere overnight. 
Caspase-glo 3/7 reagent (Promega)  was then added to the cells in culture media 
in a 1:1 ratio and cells were incubated at room temperature on a shaking platform 
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for an hour. Caspase-Glo 3/7 works by measuring the cleaved caspase3 and 
caspase7 activity. These caspases play key effectors roles in apoptosis and are 
considered as members of the systeine aspartic acid-specific protease (caspase) 
family.  Caspase-Glo 3/7 contained a DEVD-aminolucerfin substrate and a 
thermostable luciferase. Once Caspase-Glo 3/7 is added to the cells, cell lysis 
releases caspase that cleaves the substrate and thereby releasing free 
aminoluciferin that is consumed by the luciferase, generating a luminescent 
signal that is relative to caspase-3/7 activity. The relative Luminescence signal 
was determined by using a computer-interfaced, 96-well mictrotiter plate 
luminometer (BMG Labtech PheraSTAR), that was directly comparative to the 
amount of caspase3/7 activity exist in each well. All the caspase 3/7 values were 
normalized to SRB or MTT.  
 
 2.4 Sul-forhodamine B (SRB) cell viability assay:  
 
Sulphorhodamine B is a water-soluble dye that binds to the basic amino acids of 
the cellular proteins of viable cells. Thus, colorimetric measurement of the bound 
dye provides an estimate of the total protein mass that is related to the cell 
number. Cells were seeded in 96 well microtitre plates at densities of 
PEO1=1x104, PEO4=3x104, PEO23 and PEO14= 1x104, PEA1=1x104, PEA2= 
9x103, SKOV3= 9x103 in triplicates for each condition and allowed to adhere 24 
hours (Three wells left without cells to serve as a control for the minimum 
absorbance).  Cells were then fixed with 10 % trichloroacetic acid final 
concentration for one hour at 4°C  after which plates were washed with tap water 
5 times, air-dried and  stained for 30 minutes with 0.4% sulphorhodamine B (SRB) 
(Sigma) dissolved in 1% acetic acid. Unbound dye was removed by four washes 
with 1% acetic acid, air dired, and protein-bound dye solubilised with 10 mM 
unbuffered Tris base [tris (hydroxymethyl) aminomethane] (Sigma) for 
determination of optical density in Anthos 2001 microplate reader at 492nm 
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Absorbance. Three replicate values were averaged and expressed relative to 
untreated samples.  
2.5 MTT Proliferation assay: 
 
The MTT assay was used to deterime the cytotoxicity  and as a correction for 
caspase  3/7 assay. Cells were seeded in a 96 well clear plate (three wells left 
without cells to serve as a control for the minimum absorbance). Plate was 
incubated overnight at 37°C in a humidified incubator, 5% CO2. After 24 hours, 
cisplatin treatment ±25 M cddp MTT reagent (Sigma) was added at a final 
concentration of 0.5mg/ml (i.e. 10 l of 3 mg/ml MTT stock per well of the 96 well 
plate). The plate was incubated at 37°C for 2 hours. Then equal volume (60 l) of 
stop solution (40 l 10% SDS/0.01% HCl;Fisher Scientific, plus 20 l RPMI - non-
sterile) was added and left on shaker overnight at RT in the dark. This will allow 
time for the formazan precipitate to dissolve. Absorbance was measured next 
day at 570 nm with the Anthos plate reader. 
2.6 Preparation and quantification of protein lysates: 
 
Cells were washed twice with ice-cold PBS (Sigma)  then freshly made protein 
lysis buffer (0.5M TrisCl pH 6.8. 2% SDS, 10% glycerol; Sigma)  25X Protease 
Inhibitor  (Roche) and 100X Phosphatase Inhibitor  (Calbiochem)  were added at 
1X to the protein lysis buffer which was applied on the cells and proteins 
collected using a scraper for the adherent cell. The lysate were syringed by 27G 
needle to reduce the viscosity and were stored at -20°C. Protein concentrations 
of samples were quantified using MicroBCA assay Kit (Pierce).  The assay relies 
on the formation of a Cu2+-protein complex under alkaline conditions followed by 
reduction of Cu2+ to Cu1+. The amount of product formed is dependent upon the 
amount of protein in the sample. Bovine serum standards were prepared 
according to the manufacturer's instruction, ranging from 0.02 g/mL to 
2.0mg/mL (MicroBCA Protein Assay Kit, Pierce). Protein lysates were diluted to 
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1:250, 1:500 and 1:1000 concentrations from stock.150μl of each standard and 
each protein sample (at the 3 dilutions above) were pipetted in triplicate into 
individual wells of a 96-well microplate.150 l of working reagent (25:24:1v/v of 
Reagent MA, MB, MC) was added to each well and the microplate was incubated 
at 37°C for 30 mintues then absorbance at 570nm was measured for each lysate 
using an Anthos plate reader.  R2 value > 0.99 required for the standard curve to 
consider reliable to determinate the concentration of samples. Protein lysate 
samples for western blots were prepared accordingly to a final concentration of 
2mg/ml. 
2.7 Western blotting: 
 
Following quantification by BCA, 40 g of each lysates was prepared to final 
concentration 2M DTT(sigma), 1X sample Buffer( Laemmli sample buffer:0.125M 
TrisCl,4% SDS,20% Glycerol, 0.02% Bromophenol Blue, protease inhibitor 
cocktail; Sigma) boiled  at 95°C for 5 minutes then loaded onto an 8-12% 
acrylamide gel (Water, Sucrose (50% stock), Acrylamide (30% stock), Tris (1.5M 
pH 8.8 stock), SDS (10% stock) APS (10% stock), TEMED; Sigma). After 
electrophoresis at 20mA, proteins on the gel were transferred to a 0.22 M 
nitrocellulose membrane (Bio-Rad) by electroblotted at 200mA per gel at 4°C for 
2 hours. The membrane was then blocked in an appropriate solution (see table 3) 
for one hour at room temperature and then incubated with a primary antibody 
overnight at 4°C. The primary antibody was removed and the membrane washed 
for 3 times at room temperature for 10 minutes and 10ml of an appropriate 
secondary antibody ( see table 4) was added for 1 hour and then washed for 3 
times for 15 minutes. Antibodies dilutions described in table 4.  
2. 8 RNA preparation:  
 
Total RNA from the ovarian cancer cell lines were isolated using Stratagene 
absolutely RNA kit briefly, Media was removed and 4.2 l B-mercaptothanol with 
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600ul lysis buffer was added per wells. Cells were collected and transferd to pre-
filter spin cup. The tube then spun for 5 minutes and spin cup was removed.  An 
equal volume of 70% ethanol was added to the filtrate tube and vortexed the tube 
for 5 seconds to mix thoroughly. The mixture was transfered to RNA binding spin 
cup and spun at maximum speed for 60 seconds. The filtrate was discarded and 
the spin cup was kept to add 600 l of 1xLow Salt wash Buffer and spun at max 
60 seconds. The filtrate was discarded and the spin cup was kept to add DNase 
solution of 50 μl of DNase Digestion Buffer with 5 l of RNase-Free DNaseI to 
each tube. The tubes were incubated at 37°C for 15 minutes. After that, the tubes 
were washed with 600 l of 1xHigh Salt wash Buffer and 600 l of 1xLow Salt 
wash Buffer.   The spin cup was transferred to 1.5ml tube and 20 μl of the Elution 
buffer was added to each tube and incubated at 37°C for 2 minutes. The tubes 
were spun at maximum speed for 1 minute and the concentration of RNA was 
quantified by nonodrop (ND-1000)-nucleic acid-RNA, A260/A280 ratio between 
1.9-2.1. 
2.8.1 Quantitative Real time PCR (qRT-PCR):  
 
Cells were grown to 80% confluency according to standard culture conditions. 
Total RNA was isolated using Absolutely RNA (Strategene) Kit according to the 
manufacturer's instructions.  cDNA was synthesised from total RNA using 1 g of 
total RNA per sample, incubated at 65°C for 5 minutes, then 37°C for 2 minutes 
then 1XMMLV buffer, 0.4mM dNTP, 0.5ug/mL Oligo dT (15), and 0.015U MMLV 
(Promega) reverse transcriptase to final volume of 20 L, the tubes were 
incubated at 37°C for 1hour and 95°C for 5 minutes. The cDNA quality was 
checked using lamin A/C primers. The master mix for qRT PCR was made from 
0.04umol of forward and reverse primers, 1 x SYBR Green 1x Rox reference Dye, 
(ABI)  2 L of 1:50 cDNA  and dH2O in total volume of 10 L in microAmp Optical 
96well plate. Cycling conditions comprised denaturation 15 sec at 95°C, 
amplification 40 cycles at 95°C for 3 sec and 56°C for 20 sec and extension 95°C 




















119 1:1000, 5% Milk/PBS-T 




119 1:1000, 5% Milk/PBS-T 
Goat Anti- Goat Ig/HRP 
1:2000 5%Milk/TBS-T 
HDAC3 (Cell Signalling) 49 1:1000, 5% Milk/PBS-T 
Goat Anti-Mouse Ig/HRP 
1:2000 5%Milk/TBS-T 
HDAC1 (Cell Signalling) 62 1:1000, 5% Milk/PBS-T 
Goat Anti-Rabbit Ig/HRP 
1:2000 5%Milk/TBS-T 
-tubulin(Santa Cruz) 54 1:1000, 5% Milk/PBS-T 
Goat Anti-Rabbit Ig/HRP 
1:2000 5%Milk/TBS-T 
pH2A.X( S139) (abcam) 15 1:500, 5% Milk/PBS-T 
Goat Anti-Rabbit Ig/HRP 
1:2000 5%Milk/TBS-T 
Lamin A/C (Upstate) 65/74 1:2000, 5% Milk/PBS-T 
Goat Anti- Mouse Ig/HRP 
1:5000 5%Milk/TBS-T 
p21(Fisher) 21 1:1000, 5% Milk/PBS-T 




91 1:200 5% Milk/PBS-T 
Goat Anti-Mouse Ig/HRP 
1:5000 5%Milk/PBS-T 
β-actin (Upstate) 42 1:40 000 5% Milk/PBS-T 




11 1:2000 5% Milk/PBS-T 
Goat Anti-Mouse Ig/HRP 
1:5000 5%Milk/PBS-T 
p-STAT-1(abcam) 91 1:800, 5% BSA/TBS-T 
Goat Anti-Rabbit Ig/HRP 
1:2000 5%Milk/TBS-T 
UCHL1 (abcam) 24 1:800, 5% BSA/TBS-T 
Goat Anti- Mouse Ig/HRP 
1:2000 5%Milk/TBS-T 
 
Table  3: The antibodies used for western blotting, protein band size Kda, primary and 
secondary dilution conditions. PBS-T = phosphate buffered saline with 0.1% Tween-20, 
TBS-T = 10 mM Tris buffered saline with 0.1% Tween-20, BSA = bovine serum albumin, 
Ig/HRP = immunoglobulin conjugated with horseradish peroxidise. 
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SYBR green ( Invitrogen) double strand DNA binding dye was used to detect 
PCR product as they accumulate during PCR cycle and the dissociation curve 
was used to detect non-specific product formation which help in optimizing the 
primers condition. Furthermore, to check that the correct fragment was amplified, 
the machine was programmed to measure the change in the melting temperature 
and in fluorescence. The two strands of DNA will separate and the fluorescence 
speedily decreases at the melting point. The software plots the peak at the 
melting temperature (Tm) and the melting curves.  All PCR products for a specific 
primer pair should have the same melting temperature if there is no 
contamination, mispriming or primer-dimer.  Each assay included (in triplicate): a 
standard curve of six serial dilution points of pooled cDNA and no-template 
control. PCR reactions were taken forward for analysis only if efficiency was 
calculated to by 95% or greater (Applied Biosystems). Results were imported into 
Microsoft excel for analysis. The median coefficient of variation (based on 
calculated quantities) of triplicate samples was measured.  Although, RT-PCR is 
a useful tool for measuring mRNA expression in different cell lines, using the 
genes that considered as housekeeping genes individually for qRT-PCR 
normalization gave considerable difference in gene expression which results in 
variable errors into the analysis. Thus, the choice of adequate controls is critical 
to normalize the results. For that reason, the GeNorm algorithm was used  
(Vandesompele, De Preter et al. 2002) to determine the most stable internal 
housekeeping genes from a set of tested candidate reference genes in a given 
sample panel to generate reproducible data. The GeNorm algorithm is a freely 
available tool that was developed to identify the optimal qRT-PCR normalisation 
genes among candidates for a given RNA sample set by calculating then ranking 
the reference (house-keeping) genes in order of stability/reproducibility of 
expression in the samples. GeNorm analysis was performed, measuring the 
expression of nine references genes (-act, -tub,  GAPDH, HPRT1, RPL19, 
SDHA, TBP, 18S and PPIA; Invitrogen, Table 4 for primer sequences) in a panel 
of ovarian cancer cell lines. Analysis of the  expression values for these 
reference genes in GeNorm software (http://medgen.ugent.be/geNorm/) 
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produces a constancy plot highlighting the most suitable reference  genes (figure 
15). In this particular analysis peptidylprolyl isomerase A (PPIA) and alpha-
tubulin 1b (-tub) emerged as the most robust genes for normalisation of qRT-
PCR data (Figure 15). Therefore, PPIA and -tub have been selected for qRT-
PCR normalisation in the ovarian cancer cell lines used in this study.    
2.9 PCR Primer design:  
 
Gene sequences were selected using Entrez at NCBI: Nucleotide: sequence 
database http://www.ncbi.nlm.nih.gov/. Primers were designed to amplify the 
selected region on the genes (table2) using freely available Primer3 software 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) and their specificity was 
verified by Blast analysis on References sequences (refseq_rna) 
(http://www.ncbi.nlm.nih.gov/BLAST/). Primer3 software basically allows manual 
selection of primers, which could be of interest in case of targeting specific region 
and looking for precise product size.  
2.10 Pharmacological inhibition of HDAC4 
 
PEO4 and SKOV3 cells were seeded at a density of 3x104 and 9x103 
respectively cells/well in 96 well dishes in a volume of 50 l. After 24hrs, media 
was removed and cells were either treated with 40 l of fresh culture media 
(untreated control) or 40 l of media containing HDAC inhibitor APHA4a at final 
concentration, calculated for 50 l final volume, of 5 M or 10μM. After one hour, 
cells were treated by adding 10μl of cisplatin in media to a final concentration of 
25 M in 50 l; 10 l of fresh culture media was added to control cells. Apoptotic 
activity was measured by caspase 3/7 activity assay and cell viability by MTT 











Figure 15: The geNorm expression stability plot shows the mean expression 
reproducibility across the isogenic ovarian cancer cell lines. The mean expression value 
shows the least stable genes and the most stable genes using cut-off value of 0.5  to 
select  the suitable genes for normalisation among nine housekeeping genes; βact βeta 
Actin; tbp TATA binding protein; rps18 ribosomal protein 18s; sdha succinate 
dehydrogenase complex, subunit A; hrptI hypoxanthine-guanine 
phosphoribosyltransferase; gapdh glyceraldehyde-3-phosphate dehydrogenase; rpl19 
ribosomal protein L19; αtub α-tubulin; ppia peptidylprolyl isomerase A. αtub and ppia are 















Forward Primer  Reverse Primer  gene name  
167 GCGGAAGGGTACAGCCAAT  GCAGCCGGCGCAAA  RPL19 ribosomal protein L19, mRNA  
145 
CACGCCAGTACAAGATCCCA  CAGTCGCTCCAGGTCTTCAC  Ribosomal protein S18 (RPS18), mRNA.  
182 GCCAAGCGTGCCTTTGTTC  CACACCAACCTCCTCATAATCC  tubulin, alpha 1b (TUBA1B), mRNA  
149 GCAGACTTTGCTTTCCTTGGT
C  CTGGCTTATATCCAACACTTCGTG  
HPRTI hypoxanthine phosphoribosyltransferase 1 
(HPRT1), mRNA  
180 
CTGCACTGCCAAGACTGA  GCCATTCCTGGACCCAAA  PPIA peptidylprolyl isomerase A , mRNA  
132 TGCACAGGAGCCAAGAGTGA
A  CACATCACAGCTCCCCACC  
TBP TAF1 RNA polymerase II, TATA box binding 
protein, mRNA  
183 
TGGGAACAAGAGGGCATCTG  CCACCACTGCATCAAATTCATG   
SDHA succinate dehydrogenase complex, 
subunit A, (SDHA), mRNA  
195 GCATGGAGTCCTGTGGCATC
CACG  GGTGTAACGCAACTAAGTCATAG  actin, beta (ACTB), mRNA  
156 TCATTTCCTGGTATGACAACG
A  TCTACATGGCAACTGTGAGG  
glyceraldehyde-3-phosphate 
dehydrogenase(GAPDH), mRNA  
168 TGGAAATCTATCGCCCTCAC  AACAGGCCATCGAATACTGG  HDAC1, mRNA  
276 GGTGCTGGAAAAGGCAAATA  ACGGATTGTTAGCCACCTC  HDAC2, mRNA  
219 ACGTGGGCAACTTCCACTAC  GACTCTTGGTGAAGCCTTGC  HDAC3, mRNA  
168 CCACCAGCTGAGGAACTACC  CTTCAGCATCAGCGTGTCAT  HDAC4, mRNA  
109 AGTGACACCGTGTGGAATGA  TCATTGTAGAACGCCTGCTG  HDAC5, mRNA  
118 AAGTAGGCAGAACCCCCAGT  GTGCTTCAGCCTCAAGGTTC  HDAC6, mRNA  
269 AGCCAAGAGGTCCCATATTC
C  TCAGTGCCCAGTGGTAGA  HDAC7, mRNA  
270 GGTGACGTGTCTGATGTTGG  AGCTCCCAGCTGTAAGACCA  HDAC8, mRNA  
165 CCTTCGAAAAACTGCCTCTG  GACCAGAGCCTGGAGAACTG  HDAC9, mRNA  
182 GCACTTGGGAAGCTCCTGTA  GAGGCTGGAGTGGCTGCTAT  HDAC10, mRNA  
164 CAATGGGCATGAGGGAGC  TGTGGCGGTTGTAGACATCC  HDAC11, mRNA  
 
Table 4: The primers sequences for the housekeeping genes used to identfy the best 
internal control genes for qRT-PCR normalisation as well as  the primer sequences for 












2.11 Gene expression microarray:  
 
Total RNA from PEO4 untreated and transfected with siRNA and HDAC4, Lamin 
A/C cells were isolated using Stratagene absolutely RNA kit as pervuoisly 
described in section 2.8. The quality of RNA was assessed on an Agilent 
Bioanalyser™. clear  18S and 28S ribosomal RNA peaks was observed in the 
electropherogram of total RNA samples with RNA integrity (RIN) score above ~9 
to ensure the good quality of total RNA. Affymetrix U133 plus 2.0 microarrys 
hybridisation was performed at Professor Mike Bierrer’s laboratory ( Harverd 
medical school, USA) to identify transcriptional targets of HDAC4 by single gene 
and pathway level analysis. The analysis was carried out using Genechip 
Operating System (GCOS) with P-Value cut off of 0.01. For a Two-sample, 
univariate t-test analysis, a random variance model was used (Wright and Simon, 
2003).  In a small sample sizes; the variances for the genes are not close to each 
other which makes accurate estimation of genes variability difficult because 
variance estimates made on a gene by gene basis. The random variance model 
used to overcome this problem and give accurate analysis. This model will allow 
the information from the entire set of genes to be used to influence the variance 
estimate of a single gene (Wright and Simon, 2003). To identify differentially 
expressed genes after HDAC4 knockdown, the comparison included the common 
up regulated and down-regulated genes between HDAC4 knockdown / 
untransfected (UN) and HDAC4 knockdown / lamin knockdown. These candidate 
genes were chosen for further analysis (Figure 16).   
2.12 Immunofluorescence:  
 
Glass coverslips (BDH) were treated with 1M HCl (Fisher Scientific) for improved 
cell attachment for 30 minutes then with 50%, 70% and 100% Ethanol ( Sigma ) 
for 30 minutes each.  Cells were seeded onto coverslips and incubated for 24hrs 







Figure 16: The flow chart shows the steps that have been taken to identify the 
differentially expressed genes after knock down HDAC4, RNA from three independent 
experiments after HDAC4 knockdown in PEO4 cells was collected, assessed for their 
quality then sent for microarray.  The analysis included only the common differentially 
expressed genes between HDAC4 knockdown vs untransfected and HDAC4 knockdown 
vs lamin knockdown (shown in green). The final step is validating the data and interprets 









After appropriate treatment, cells were washed with PBS followed by fixation and 
permeabilisation at 37°C for 30 minutes with 4% paraformaldehyde/1.8% (BDH) 
Triton X-100 in PBS (Sigma). Coverslips were blocked in 10% goat serum/2% 
BSA/PBS, at RT for 30 minutes. Coverslips were washed with PBS and 
incubated with antibodies(anti-HDAC41:100, anti-Pstat1 1:50 dilution) overnight 
at 4°C. Coverslips were washed in PBS and incubated with 1:500 dilutions of 
fluorochrome conjugated secondary antibodies (FITC anti-goat IgG, FITC anti-
rabbit IgG, Alexa Fluor 555 anti-mouse IgG and Alexa Fluor 488 goat anti-rabbit 
IgG)  in blocking buffer at RT for 1hour. Cells were rinsed three times in PBS for 
5 minutes and mounted onto glass slides using Vectashield mounting media 
containing 4',6- diamidino-2-phenylindole (DAPI) (Vector Laboratories, Canada). 
Slides were visualised on an inverted confocal microscopy system (Axiovert 
200M, Zeiss, US and TCS SP5, Leica, Germany). 
2.13 Immunoprecipitation (IP): 
 
Immunopreciptitation is used to identify protein-protein interactions. This method 
is designed to immunopreciptitate protein from total cell lysates using HDAC4, 
pan acetyl and STAT1 antibodies. Proteins that bind to HDAC4 antibody are then 
bound to sepharose beads via protein G and separated from un-bound proteins 
by centrifugation. Analysis of protein complexes was done by western blot. Cells 
were seeded in 6 wells plates at densities of PEO1=7x105, PEO4=1x106, 
PEA1=2x105, PEA2= 2.5x105, SKOV3= 2x105 per well. Then harvested and 
lysed with protein lysis buffer (IP lysis buffer: 1% Triton-X, 150mM NaCl, 50mM 
Tris-HCl, 0.2mM Na3VO4, 50mM NaF, 2mM EDTA, 1mM PMSF, 25 g/mL 
Aprotinin, 25 g/mL Leupeptin; Sigma). 100 l protein G sepharose (PGS; Sigma) 
beads were washed twice in PBS and once with IP lysis buffer. 1mg each sample 
lysate was incubated with 30 l PGS rotating at 4°C for 1 hour. Pre-cleared 
lysates were incubated overnight at 4°C with 2 g primary antibody. An antibody 
only control was also included. Thirty microlitres of PGS were added to each 
sample, including a whole cell extract control, and incubated with rotation at 4°C 
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prior to centrifugation at 10000rpm for 2 mintues. Collected beads were washed 
three times with IP lysis buffer then dissolved in 50 l of 2x sample buffer (1% 
Triton-X, 150mM NaCl, 50mM Tris-HCl, 0.2MmM, EDTA, 1mM PMSF; Sigma) by 
heating to 95°C for 10 minutes. Equal volumes of the IP sample, extract only and 
controls were separated and visualized by western blot. 
2.14 Immunostaining:  
 
The immunostaining was done in Doctor Roberto Dina’s lab, Hammersmith 
Hospital and Imperial College London. Briefly, after inactivation of endogenous 
peroxidase with 0.3% hydrogen peroxide in methanol, blocking of nonspecific 
background staining with normal rabbit serum and antigen retrieval by 20 minutes 
microwave in 0.1mM citrate buffer, sections were incubated with mouse 
monoclonal to HDAC4 (sc-46672, Santa Cruz Biotechnology) at 1/500. Sections 
were rinsed with PBS/Tween and 100μl Super Enhancer (Biogenex) added for 20 
minutes at room temperature. 100 μl poly-HRP (Biogenex) was applied at RT for 
30 minutes. Sections were covered with DAB in substrate buffer for 5 minutes 
after which slides were counterstained in Coles Haematoxylin for 2 minutes, 
rinsed in tap water, acid alcohol, again in water, then blued in Scotts tap water 
and mounted by hand with Pertex mounting medium. Positive and negative 
controls were used in each run. Immuno-histochemistry was separately scored 
by two pathologists. The score criteria based on the intensity of staining and the 
percentage cells stained. 
 
2.15 Quick-ChIP on fixed chromatin:  
 
This method was adapted from Dahl JA and Collas P, Stem Cells, 2007; 
25:1037-1046. The protocol has been developed to allow ChIP experiments with 
fewer cells, compared to conventional ChIP. It uses magnetic beads, instead of 
sepharose, in order to reduce the amount of chromatin needed per IP. PEO4  
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cells were seeded at 1x106 density, harvested after 24 hours, washed with PBS. 
Formaldehyde (BDH)  was added to 1% final concentration and incubated for 10 
minutes at 37°C for crosslinking. Crosslinking was stopped by adding glycine 
(VWR) to 0.125M final concentration, incubated for 10 at RT. Cells washed with 
in PBS x3 times. 10 l of beads were washed with 100 l of chilled sonication 
buffer (x2) using a magnet and resuspended in 1 volume of sonication buffer (50 
mM Hepes, 140 mM NaCl, 1 mM EDTA, 1% Triton, 0.1% Na-deoxycholate, 0.1% 
SDS (Sigma) and protease inhibitor ( Roche) freshly was added before use). 
Then for each IP, 10 l  of washed beads were combined and 2 l pan acetyl 
lysine antibody. Sonication buffer was added to 100ul and sample incubated on a 
rotator for at least 2h at 4°C. Cell were respsuspend in 1.5ml of swelling 
buffer( 25 mM Hepes pH7.9, 1.5 mM MgCl2, 10 mM KCl, 0.1% NP-40 (Sigma) 
and protease inhibitor freshly was added before use), incubated on ice for 10 
minutes and homogenised with a dounce homogeniser 50 strokes. Nuclei were 
pelleted by centrifugation at 3000g and resuspend in sonication buffer to 2.5-
3x107 cells/ml.  200l aliquots in 1.5ml tubes were sonicated for 1x10min cycle 
(30’sec on – 30’sec off, high power) as a starting point using a Bioruptor 
sonicator.  Chromatin fragments were checked on a 2% agarose gel (Fisher 
Scientific) Optimal fragments sizes are between 500-1000bp. The chromatin 
fragments were spun down at 10’000g for 10’ to recover the supernatant. The 
chromatin concentration was measured by using a nanodrop. 100ug of 
chromatin/IP were Used and a portion of the chromatin was kept to normalize the 
sample with. The antibody-beads complex was placed on a magnet and the 
supernatant removed. Then the chromatin was incubated on a rotator overnight 
at 4°C. 100 l of chilled buffers (1x sonication buffer, 1x wash buffer A (As 
sonication buffer but with 500mM NaCl), 1x wash buffer B(20 mM Tris pH 8.0, 1 
mM EDTA, 250 mM LiCl, and 0.5% NP-40 and 0.5% Na-deoxycholate, 1x TE; 
Sigma) were used for the washes. The magnet was used to capture the beads at 
each step. Each wash step was incubated for 5 minutes on a rotator at 4°C. The 
beads were resuspend in 100ul of TE, transferred to a new tube, placed on a 
magnet and the buffer was removed.  To reverse the chromatin crosslinking in 
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the samples and in the  INPUT chromatin,  the beads were resuspend in 150ul of 
elution buffer (50 mM Tris pH8.0, 50 mM NaCl, 1 mM EDTA, 1% SDS, and  
DNase-free RNase), incubated on a thermomixer at 68°C max speed for at least 
4hours, placed on a magnet and the supernatant was recovered. This step was 
repeated and supernatants were pooled. Proteinase K (was used for the 
digestion of proteins and the purification of ChIP DNA fragments) was added to 
200ug/ml final concentration and incubated for 2 hours. QIAGEN kit was used to 
purify the DNA. DNA was resuspend in 40l of TE and concentration was 
measured Nanodrop.  
 
Primer Z (http://genepipe.ngc.sinica.edu.tw/primerz/beginDesign.do) was used to 
design primers for UCHL1 (to identify if there is change in the acetylation level in 
UCHL1 gene after HDAC4 knockdown) and PPIA (was used as control to check 
if HDAC4 knockdown effect other genes) promoter regions. Quantitative RT-PCR 
analysis was performed using the immunoprecipitated fraction samples and 
normalized to the value of the input material to determine the amount of relative 
enrichment of DNA fragments at UCHL1 promoter region after HDAC4 
knockdown.   
 
 








2.16 Quantification of CpG methylation levels in UCHL1 
by pyrosequencing: 
 
Pyrosequencing was used to quantify methylation of UCHL1  that has been 
methylated obtained from the CpG array data via collaboration with Professor 
Reverse Primer Forward Primer gene name 
TAATCCACCTTGGTCGGAAG AAGCGGAAATGTGAAAATGG PPIA-CHIP 
AAAGGCATTCGTCCATCAAG GTCCCCTGAAGACAGAGGAA UCHL1-CHIP 
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Brown, Chair in Translational Oncology in the Department of Surgery and 
Oncology at Imperial College. The array has been perfomed on the isogenic 
ovarian cancer cell lines using two CpG for a number of genes. UCHL1 was 
among the genes tetsed and  was found to be methylated at (Position 40953551) 
in PEO1 and PEO4 cells.   This position contains CpG islands and was shown to 
be methylated in the DNA methylation arrays. Genomic DNA was collected after 
HDAC4 knockdown in PEO1 and PEO4 cell lines (untransfected, lamin 
transfected and HDAC4 transfected) and extracted according to the 
manufacturer's instructions using Qiagen DNA Mini-kit 
2.16 .1 Bisulphite Conversion of DNA: 
 
DNA was bisulfite treated using the EpiTect Bisulfite Kit (Qiagen) according to 
manufacturer's instructions. Briefly, 1 μg of PEO1, PEO4 cell lines and control 
DNA (unmethylated and in vitro  methylated DNA) genomic DNA was diluted in 
water to a final volume of 20 μl was combined with 85 μl of Bisulfite mix and 35 μl 
of DNA protect buffer. The bisulfite DNA conversion was performed using the 
following conditions; denaturation for 5 minutes at 99°C, incubation for 25 
minutes at 60°C, denaturation for 5 minutes at 99°C, incubation for 85 min at 
60°C, denaturation for 5 minutes at 99°C, incubation for 175 minutes at 60°C, 
final hold at 20°C. The bisulfite converted DNA was purified following 
manufacturer's instructions the DNA Purification kit (Qiagen). In brief, the bisulfite 
reaction was mixed with 560 μl of Buffer BL, applied to the spin column and 
centrifuged at 12,000 rpm for 1 minute. The flow through was discarded and the 
column was washed with 500 μl of Buffer BW. 500 μl of Buffer BD was applied to 
the column and incubated at room temperature for 15 minutes. The column was 
centrifuged to get rid of Buffer BD and then washed twice with 500 μl of Buffer 
BW. Residual BW buffer was removed by an additional spin at 12,000 rpm for 1 
minutes. 20 μl of Buffer EB was added to the column to elute the DNA. The DNA 
concentration was determined using a Nano-drop spectrophotometer. 
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2.16 .2 Pyrosequencing: 
 
All biotinylated primers were designed using Pyromark Assay Design version 
2.0.1.15 (Qiagen), are HPLC-purified. PCR was carried out in a 25 μl volume 
containing 1 µl of all the bisulfite treated DNA samples (control in vitro  
methylated DNA, normal DNA, PEO4 and PEO1 cell lines after transfection with 
HDAC4 and lamin), 1µg/µl of pyrosequencing primers, 0.5 μl of 10 mM dNTP mix, 
2.5 μl of 10 x PCR buffer, 7 μl of 50 mM MgCl2, 0.2 μl of fastTaq DNA 
polymerase and sterile H2O up to a final volume of 25 μl.  Amplification was 
performed for cycling were 95°C for 5 minutes, followed by 45 cycles of 95°C for 
15 sec, 55°C for 30 sec and 72°C for 15 sec, then extension step at 72°C for 5 
minutes.  The specificity of the primers was checked on 1% agarose gel stained 
with ethidium bromide in order to see the precise bands.  the Biotin-labelled PCR 
product were immobilized on Streptavidin-coated Sepharose beads by mixing 15 
µl of a PCR product with 6 µl Streptavidin Sepharose suspension, 10 µl water 
and 40 µl Binding Buffer (26; 10 mmol/L Tris-HCl, 1 mmol/L EDTA, 2 mol/L NaCl, 
1 mL/L Tween 20, pH 7.6) in a PSQ 96-well reaction plate followed by shaking at 
room temperature for 5 minutes for preparation to single-stranded DNA template 
to act as a template in a pyrosequencing reaction. The Pyrosequencing Vacuum 
Prep Workstation that consists of a hand-held Vacuum Prep Tool with 96-filter 
probes was used to transfer the biotinylated PCR products onto the filter probes 
after applying the vacuum and then washed with 70% ethanol for 15 sec, 
denaturation solution (0.2 M NaOH) for 15 sec and washing buffer (10mM Tris-
acetate pH 7.6) for 15 sec. The vacuum was removed to release beads from the 
filter and biotinylated ssDNA templates were resuspended in 12 mL annealing 
buffer (20 mmol/LTris-acetate, 2 mmol/L Mg Ac2) containing 0.3 mM sequencing 
primer in the wells of a PSQ-HS 96 plate (Biotage). The mixture was heated at 
90°C for 2 minutes and then cooled to room temperature to allow the annealing 
of the Pyrosequencing primers to the templates. The plate was analyzed using 
PyroMark MD Pyrosequencer (Biotage), after which methylation values were 
quantified using by the Pyro Q-CpG Software v1.0.9 (Biotage). 
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Figure 17: The pyrosequencing assay starts with bisulfite treatment to the DNA samples 
that converts nonmethylated cytosines to uracils, whereas methylated cytosines are 
resistant for the conversion. PCR amplification will follow using biotinylated primer. The 
tagged biotinylated primer incorporated into the amplicon sequence and anneal to the 
complementary sequence which will result in labelled amplicons with biotin. The biotin-
labelled amplicons will capture by binding to streptavidin-coated Sepharose beads. Then 
the DNA will be denaturing to produce single strand DNA template. The sequencing 
primer incorporates with the single strand DNA making the sequence of the template 
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DNA.  Finally, the pyro-sequencing apparatus will detect every nucleotide in the template 
DNA in order as they will be distinguished with different lights seen as a peak in the 
pyrosequencing program. This will quantify C for methylated and T for unmethylated and 




GGGGGAGTAGGGGTAGAATTA Sequencing 1 
CCACAACCACCAAATTATCTC Sequencing 2 
GGAGTAGGGGTAGAATTAA Forward  
GTTAGATGGGTAAGAATTT Biotylated reverse  
 
 
Table 6: Pyrosequencing primers for UCHL1; forward, biotin-labelled reverse and two 
sequencing for UCHL1 gene; Probe cg24715245 and Position 40953551. In CpG islands 
that are densely populated by CpG sites, it is difficult to quantify consecutive CpG sites 
with one sequencing primer. Therefore, 2 sequencing primers were design to quantify all 
the CpG sites in the region.  
 
2.17 Statistical analysis: 
 
In this project all experiments were performed at least in triplicate unless 
indicated and the results of caspase3/7, SRB, MTT and qRT-PCR were 
expressed as mean +/- SEM (standard error of mean) unless indicated. 
Comparison between two groups was analyzed by two-sided Student’s t tests 
with Microsoft office excel 2003 and P value was calculated.  P value of less than 




















































3.1 HDAC4 expression is up-regulated in resistant 
ovarian cancer:   
 
Molecular profiling was used to identify the gene expression changes between 
cisplatin-resistant  and paired cisplatin-sensitive ovarian cancer cell lines using a  
1.5 fold expression difference cutoff and t-test p-value p<0.05, including a 
Benjamini and Hochberg false discovery rate correction. 91 genes were up-
regulated and 126 genes down-regulated between cisplatin-sensitive and 
resistant cell lines. HDAC4 was one of the genes regulated in cisplatin-resistant 
cell lines relative to the paired sensitive. In PEO4 cells, there was a 1.7 fold 
increase in HDAC4 levels compared to PEO1 cells; and for PEA2 there was a 1.9 
fold increase relative to PEA1. However, HDAC4 was down-regulated in PEO23 
cisplatin-resistant cell line relative to the paired sensitive PEO14. The up-
regulation of HDAC4 was observed in all the resistant cell lines by real-time 
quantitative PCR (Figure 18 A) and western blot (Figure 18 B).  It is worth noting 
that every microarray platform is prone to errors and it is not sensitive as qRT-
PCR. This might be attributed to the way probes are associated with genes and 
which probes are detectable, as genes have different splice variants. Thus, if the 
microarray probe detects one splice variant and qRT-PCR primers detect another 
for the same gene, it is unlikely that the two assays will show the same results. 















Figure 18: (A) real-time PCR of HDAC4 mRNA expression normalised to PPIA and -
tubulin genes, fold changes between the sensitive and the resistant cell lines was 
indicated above in red (B) Western blot showing higher HDAC4 expression in the 
resistant cells PEO4, PEO6, PEA2 and PEO23 relative to their platinum sensitive 
counterpart.  
 100 
3.2 siRNA-mediated knock down of HDAC4 enhanced platinum 
mediated apoptotic activity in cisplatin-resistant ovarian cancer cells:  
 
The functional significance of HDAC4 in cisplatin resistant ovarian cancer cell 
lines was investigated using small interfering RNA (siRNA) meditated gene knock 
down. Dharmacon SMARTpool siRNA, which is comprised of 4 individual siRNA 
duplexes, were used to knock down target genes. Cells were either untransfected 
or transfected with 100 nM siRNA targeting HDAC4, Lamin siRNA or non-
targetting2 (NT2) siRNA (as control for transfection). After 24 hours incubation, 
cells were treated with 25µM of cisplatin. Based on the IC50 values for cisplatin 
(11.6 µM, 9.5 µM, and 8.2µM for PEO4, PEA2, and PEO23, respectively), the 
concentration of 25µM cisplatin was chosen to induce apoptosis in shorter period 
of time (24hours) compared with cell survival assay (72 hours). Cell viability was 
measured by SRB or MTT assays and cell death was detected by Caspase Glo 
3/7 assay, which was then normalised by SRB or MTT assays for the same 
treatment to account for changes in cell number. Protein lysates were collected to 
confirm the knockdown of HDAC4 by western blot. HDAC4 expression 
knockdown sensitized resistant cell lines PEO4 (Figure 19), PEA2 (Figure 20), 
PEO23 (Figure 21) and SKOV3 (Figure 22) to cisplatin. Significant p-values were 
detected from t-test analysis in PEO4 (p = 0.0004), PEA2 (p = 0.0001) and 
PEO23 (p = 0.0006) when comparing the increased apoptotic activity following 
24 hours treatment with 25µM of cisplatin treatment between untransfected cells 














Figure 19: cells were either untransfected or transfected with 100 nM siRNA targeting 
HDAC4, (100 nM Lamin siRNA control). HDAC4 siRNA knockdown followed by 25µM of 
cisplatin treatment enhanced apoptotic induction compared to control cells. Caspase3/7 
data are normalised to SRB for the same treatment to account for changes in cell 
number. Data are represented as means ±SEM of 4 replicate experiments. Data was 
analysed by t-test for significant difference in cisplatin induced caspase 3/7 induction 
between test gene siRNA transfected cells and siRNA controls in PEO4 with P-value 
0.0004. HDAC4 siRNA knockdown was confirmed by western blot. Bands were 














Figure 20: Cells were either untransfected or transfected with 100 nM siRNA targeting 
HDAC4, (100 nM NT2 siRNA control). HDAC4 siRNA knockdown followed by cisplatin 
treatment enhanced apoptotic induction compared to control cells. Caspase3/7 data are 
normalised to MTT data for the same treatment to account for changes in cell number. 
Data are represented as means ±SEM of 4 replicate experiments. Data was analysed by 
t-test for significant difference in cisplatin induced caspase 3/7 induction between test 
gene siRNA transfected cells and siRNA controls in PEA2 with P-value 0.0001. HDAC4 
siRNA knockdown was confirmed by western blot. Bands were observed at the predicted 















Figure  21: cells were either untransfected or transfected with 100 nM siRNA targeting 
HDAC4, (100 nM NT2 siRNA control). HDAC4 siRNA knockdown followed by cisplatin 
treatment enhanced apoptotic induction compared to control cells. Caspase3/7 data are 
normalised to MTT data for the same treatment to account for changes in cell number. 
Data are represented as means ±SEM of 4 replicate experiments. Data was analysed by 
t-test for significant difference in cisplatin induced caspase 3/7 induction between test 
gene siRNA transfected cells and siRNA controls in PEO23 with P-value 0.0006. HDAC4 
siRNA knockdown was confirmed by western blot. Bands were observed at the predicted 













Figure 22: cells were either untransfected or transfected with 100 nM siRNA targeting 
HDAC4, (100 nM NT2 siRNA control). HDAC4 siRNA knockdown followed by cisplatin 
treatment enhanced apoptotic induction compared to control cells. Caspase3/7 data are 
normalised to MTT data for the same treatment to account for changes in cell number. 
Data are represented as means ±SEM of 4 replicate experiments. Data was analysed by 
t-test for significant difference in cisplatin induced caspase 3/7 induction between test 
gene siRNA transfected cells and siRNA controls in SKOV3 with P-value 0.0004. 
HDAC4 siRNA knockdown was confirmed by western blot. Bands were observed at the 





3.2.1 HDAC4 Knockdown using deconvoluted siRNA’s in cisplatin-
resistant ovarian cancer cell lines: 
 
To determine the likelihood that restoration of platinum sensitivity in PEO4 was 
due to knockdown of HDAC4, the individual deconvoluted oligos comprising the 
HDAC4 SMARTpool siRNA oligos were further evaluated. Protein lysates were 
collected to check the efficacy of siRNA knockdown at protein level. Three out of 
four of HDAC4 siRNAs HDAC4-b, HDAC4-c and HDAC4-d induce comparably 
high caspase 3/7 activity to that exhibited by the HDAC4 SMARTpool siRNA. 
HDAC4-a shows more modest induction in caspase 3/7 activity. Nonetheless, its 
effect is still above control treatments (Figure 23). All four of HDAC4 siRNAs 
targeted HDAC4, showing knockdown at protein level compared to controls. This 
confirms that HDAC4 knockdown enhances sensitivity to platinum in PEO4 cells. 
However, HDAC4-a showed knockdown on HDAC4 at protein level but exhibited 
less resensitisation to platinum in PEO4 cells unlike the three deconvoluted 
oligos which might be an off target effect of HDAC4-a.  
 
3.2.2 HDAC4 knockdown in cisplatin-sensitive ovarian cancer: 
 
Reduction in the high level of HDAC4 in acquired platinum resistance restores 
the platinum sensitivity. Therefore, the effect of HDAC4 knockdown was 
assessed on PEO1, cisplatin-sensitive ovarian cancer cell lines to determine 
whether the reduction in the low amount of HDAC4 in these cells will increase 
cisplatin sensitivity. The results showed no increase in caspase 3/7 activity 
following platinum treatment (Figure 24). Although, PEO1 and PEO4 cells 
derived from the same patient before and after the development of cisplatin-
resistance, however, HDAC4 level is much lower in PEO1 compared with PEO4. 
It suggests that the level of HDAC4 in PEO1 is below the cellular threshold to 
exhibit any effect towards platinum. The same result was observed on the other 
isogenic cisplatin-sensitive ovarian cancer cell lines (PEA1 and PEO14). This 
means HDAC4 knockdown in the sensitive ovarian cancer cell lines did not 
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enhance the sensitivity and suggests increased HDAC4 expression enhances the 
platinum resistance mechanism in resistant cell lines.  
 
3.2.3 Validation of early caspase 3/7 induction at later time points 
using MTT assay.  
 
The MTT assay was used to determine if the early caspase 3/7 induction 
observed at 24hrs results in reduced cell numbers at later time points. Cisplatin- 
sensitive and resistant cell lines were transfected with 100 nM siRNA targeting 
HDAC4, 100 nM lamin siRNA and Non-targetting2 controls. Another batch was 
left untreated as control. Following a 24 hour incubation period, cells were 
seeded in 96-well microtiter plates and left to adhere overnight. The media was 
then replaced with cisplatin-containing media at concentrations of 0.1, 0.39, 0.78, 
1.56, 3.525, 6.25, 12.5, 25, 50µM. Cell viability was measured by adding MTT at 
a final concentration of 0.5mg/ml to the culture medium for 2 hours.  
 
The percentage of growth inhibition was determined by the MTT assay after 
exposing the cells to the different concentrations of cisplatin over 72 hours. The 
longer-term effect of siRNA knockdown in PEO4 showed reduction in HDAC4 
expression following 72hr exposure to cisplatin (Figure 25). This finding 
demonstrates that 24hr apoptotic response is representative of longer term 
effects in cisplatin resistant ovarian cancer cells and validates the results 
obtained by caspase 3/7 and MTT assays following 24hr exposure to cisplatin. 
HDAC4 silencing in PEO4 reduces cell viability. On the other hand, HDAC4 
knockdown in cisplatin-sensitive PEO1 cells did not enhance platinum response. 
The change in the IC50 values was measured comparing the untransfected 
control with HDAC4 knockdown in PEO1 and gave an insignificant P-value 0.4. 
This confirms that HDAC4 knockdown does not enhance response to cisplatin.  
 
In PEA2 cells, NT2 knockdown, used as control, appears to have undesirable 
toxicity as the growth curve of NT2 is nearer to HDAC4 knockdown compared to 
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untransfected cells. However, HDAC4 knockdown elicits a modest decrease in 
cell proliferation compared to untransfected cells (Figure 26). The P-values were 
0.2 and 0.05 for PEA1 and PEA2 respectively. In PEO23 knockdown of HDAC4 
suppresses cell growth (Figure 27). The P-values for PEO14 and PEO23 were 
0.9 and 0.04 f respectively. This indicates that the change in the IC50 in PEO14 
is not significant.  
3.3 HDAC4 is over-expressed in clinical cases of 
acquired platinum resistance: 
 
HDAC4 levels were examined by immuno-histochemistry in 16 clinically platinum 
sensitive ovarian cancer patients matched to second biopsies from the same 
patients following development of platinum resistance, in order to validate the 
observed increase in HDAC4 in platinum resistant cells. Sections cut from FFPE 
ovarian tumour blocks before and after acquisition of platinum resistance were 
stained for HDAC4 expression (Santa Cruz sc-44672). HDAC4 staining was 
detected in the tumour cells but not the adjacent normal stroma which is a good 
control for the specificity of the antibody. Intensity and frequency (the proportion 
of cells positive for HDAC4 staining) of HDAC4 staining was scored by two 
pathologists and the change in score on platinum resistance was analysed. 
Intensity of staining was scored on a 0 to 3 scale and the percentage of cells 
stained scored on a 0 to 4 (1<10%, 2 = 11-50%, 3 = 51-90%, 4>90%) scale. The 
product score ((intensity of staining) x (percentage cells stained)) was used for 
further statistical analysis. 
 
An example for strong HDAC4 staining with two different magnifications in the 
resistant biopsies compared with its matched sensitive is shown in Figure 28 with 
scores for 16 paired sections. In the paired pre- and post- acquired platinum-
resistant relapsed patients, cytoplasmic HDAC4 levels significantly increased in 
biopsies from patients who acquired platinum resistance compared with their 
matched platinum sensitive biopsies as detected by the Wilcoxon Matched-Pairs 
Signed-Ranks Test (p= 0.039). 
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Figure 23: Caspase 3/7assay to determine if the deconvoluted siRNA comprising the 
HDAC4 SMARTpool siRNA can be used individually to inhibit HDAC4 expression and 
restore the sensitivity to cisplatin in PEO4. Three siRNA b, c, and d restored cisplatin 
sensitivity however, all four deconvoluted siRNA’s showed knockdown at protein levels. 
Data are represented as means standard deviation of single experiment in triplicate. 










Figure 24: The effect of HDAC4 knockdown on PEO1, PEA1 and PEO14 ovarian cancer 
platinum-sensitive cells. Cells were either untransfected or transfected with 100 nM 
siRNA targeting HDAC4, (100 nM Lamin siRNA control). HDAC4 siRNA knockdown 
followed by cisplatin treatment did not enhance apoptotic induction compared to control 
cells. Caspase3/7 data are normalised to MTT data for the same treatment to account 












Figure 25: The effect of HDAC4 knockdown on cisplatin response was validated by cell 
proliferation MTT assay carried out 72hr post cisplatin exposure (untransfected, Lamin 
and HDAC4) in treated PEO4 and PEO1 cells. HDAC4 knockdown showed significant 
effect on PEO4 cell but no change in cell survival in PEO1. PEO1 and PEO4 are 
showing the HDAC4 knockdown was confirmed by western blot. Bands were observed 
at the predicted sizes for HDAC4 at 119KDa and  tubulin at 54KDa. Data are 
represented as mean ± SEM of 3 replicate experiments, was analysed by t-test for 
significant difference in cell growth between untransfected cells and HDAC4 knockdown 




Figure 26: The effect of HDAC4 knockdown on cisplatin response was validated by cell 
proliferation MTT assay carried out 72hr post cisplatin exposure (untransfected, siNT2 
and siHDAC4) in treated PEA1 and PEA2. HDAC4 knockdown showed significant 
decrease in the cell proliferation compared with untransfected cells in PEA2 but no 
change in cell survival in PEA1. HDAC4 knockdown was confirmed by western blot. 
Bands were observed at the predicted sizes for HDAC4 at 119KDa and  tubulin at 
54KDa. Data are represented as mean ± SEM of 3 replicate experiments for PEA2 and 2 
experiments for PEA1, was analysed by t-test for significant difference in cell growth 
between untransfected cells and HDAC4 knockdown in PEA1 with P-value 0.2 and 
PEA2 P-value 0.05 as indicated in red in the lower graph. 
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Figure 27: The effect of HDAC4 knockdown on cisplatin response was validated by cell 
proliferation MTT assay carried out 72hr post cisplatin exposure of siRNA (untransfected, 
NT2 and HDAC4) in treated PEO14 and PEO23 cells and showed significant effect on 
PEO23 cell survival but not in PEO14. HDAC4 knockdown was confirmed by western 
blot. Bands were observed at the predicted sizes for HDAC4 at 119KDa and  tubulin at 
54KDa. Data are represented as mean ± SEM of 3 replicate experiments, was analysed 
by t-test for significant difference in cell growth between untransfected cells and HDAC4 
knockdown in PEO14 with P-value 0.9 and PEO23 P-value 0.04 as indicated in red in 
the lower graph. 
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Interestingly, the analysis of 14 paired biopsies from patients with platinum 
refractory disease showed no increase in HDAC4 expression between the pre- 
and post- chemotherapy biopsies (data not shown). The samples were primary 
responsive resistant and refractory of different histological subtypes: 
endometrioid, mucinous, serous, mixed serous/endometeiod and mixed clear 
cells/endometeiod. The patients were grade 2 or 3 and received platinum based 
therapy for both 1st and 2nd lines. This indicates that HDAC4 might contribute to 
the development of acquired platinum resistance in ovarian cancer cells but not 
in intrinsic platinum resistance.  
 
3.4 The specificity of HDAC inhibitors: 
 
In view of the siRNA data showing enhancement of cisplatin mediated apoptosis, 
specific HDAC4 inhibitors were assessed to determine the effects of 
pharmacological HDAC4 inhibition on our cell system. A selective HDAC4 
inhibitor has not yet been developed to mimic the siRNA effect in resensitisation. 
However, class II HDAC inhibitors could lead to platinum resensitisation with 
fewer off-target effects. Chemical manipulation of aroyl-pyrrolyl-hydroxyamides 
(APHAs) has generated a new class of HDAC inhibitors (aryloxopropenyl) 
pyrrolyl hydroxamates 2f and 4a (Mai et al. 2005; Mai et al. 2007).  
 
The compounds were tested for their specificity to class I and II HDACs. 2f 
showed no inhibitory activity against HDAC1 but was able to inhibit HDAC4 (at 5 
µM for 2f HDACi, 0% for HDAC1 and 54.9% for HDAC4) which the only HDAC 
isoforms in class II HDACs was tested against the HDACi (2f). 4a HDACi was 
highly effective on HDAC4 (inhibitory activity at 5µM, 50% for HDAC1 and 475% 
for HDAC4) on the human leukaemia U937 cell line (Mai et al. 2005; Mai et al. 
2007).  HDAC inhibitors (2f and 4a) were assessed in ovarian cancer cell lines. 2f 
HDAC inhibitor caused reduction in HDAC4 protein level at 20uM concentration 
and increased the acetylation of histone4 (H4) at 10µM concentration when 
combined with 25µM of cisplatin after 24hrs incubation as detected by Western 
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blot (Figure 29). There was an increase in the acetylation level of H4, as the 
HDAC inhibiting mechanism is expected to enhance acetylation. The reduction in 
HDAC4 levels was not expected as all publications on HDAC inhibitors assess 
the acetylation level not the protein degradation caused by HDACs inhibitors. 4a 
HDAC inhibitor causes reduction in HDAC4 protein levels at 5µM, 10µM and 
20µM concentrations and increase H4 acetylation at all tested concentrations. 
3.4.1 HDAC inhibitors potentiate induction of apoptosis by cisplatin: 
 
APHA4a showed a potent effect on HDAC4 inhibition (Mai, et al. 2005 and 2007) 
and increased H3 and H4 acetylation. Therefore, 4a inhibitor was used for further 
analysis on ovarian cancer cell lines. The effect of APHA4a inhibitor on cisplatin 
resensitisation was determined by caspase 3/7 assay. 4a inhibitor was used to 
determine if the inhibitor has the same effect of siRNA HDAC4 in restoring 
sensitivity to cisplatin in ovarian cancer cells. If the inhibitor showed a significant 
re-sensitization effect, it would be considered for further clinical analysis to 
combat cisplatin resistance in ovarian cancer. PEO4 and SKOV3 cells were 
treated with either 5µM or 10µM concentration of HDAC inhibitors APHA4a (4a-
MC1511) for 2hours then 25µM cisplatin was added. Caspase 3/7 assay and 
MTT assays were performed.  
 
Caspase 3/7 values were normalised to MTT and the results showed that the 
APHA4a Inhibitor enhanced cisplatin cytotoxicity at all concentrations tested in 
both PEO4 and SKOV3 cisplatin-resistant cells with no toxicity observed with a 
single agent (Figure 30). As mentioned earlier APHA4a inhibitor blocks HDAC4 
but to some extent HDAC1 as well. This means that the effect detected here is 
likely to be due to its effect on both enzymes (HDAC1 and HDAC4). Therefore, 
the results of this inhibitor do not mimic the specific effects of HDAC4 knockdown 
by siRNA.                                                             







Figure 28: Photomicrographs indicate increased expression of HDAC4 (brown staining) 
in resistant (right) compared to sensitive (left) biopsies from the same patient in two 
different magnification, x200 (upper) and x600 (lower) in patient x8086 and x8927 (A) as 
an example for the strong staining of HDAC4 in the resistant biopsies. HDAC4 
expression was scored and the change in scores was analysed by Wilcoxon rank sum 
test, p= 0.039. 7 out of 16 paired sections showed strong HDAC4 expression. Although, 
8 paired lines are visible in the blot but the other 8 paired lines produced identical scores 


















Figure 29: cells were treated with indicated concentrations of HDAC inhibitors APHA 2f-
MC1568 and APHA 4a-MC1511 alone and in combination with 25uM cisplatin for 24hrs 
followed by protein collection to check the expression of HDAC4 and the acetyl histone 
H4. 2f inhibitor cause reduction in HDAC4 at 20uM concentration and increase the 
acetylation at 10µM concentration with 25µM of cisplatin. However, 4a inhibitor cause 
reduction in HDAC4 levels at 5, 10 and 20µM concentration and increase H4 acetylation 
at all concentration used. Bands were observed at the predicted sizes for HDAC4 at 
















Figure 30: Treatment of the cisplatin-resistant cells PEO4 or SKOV3 with the HDAC 
inhibitor APHA4a at 5µM or 10µM (2 hours incubation) enhances the apoptotic response 







3.5 HDAC4 expression following cisplatin treatment in 
ovarian cancer cell lines: 
 
 
To determine the effect of cisplatin on HDAC4 expression, PEO1 and PEO4 cells 
were treated with either vehicle (only media) or 25µM cisplatin. Next, protein 
lysates were collected at different time intervals. There was no significant change 
in HDAC4 expression in untreated PEO1 cells throughout the time course used. 
Although, in PEO4 untreated cells, HDAC4 expression decreased at 2hours and 
then increased at 24hours compared with 0hour as shown by Western blot 
analysis (Figure 31 A).  
 
The most striking effect of cisplatin on HDAC4 protein expression in PEO1 was 
the loss of HDAC4 expression at 8hours cisplatin treatment (Figure 31 B). The 
loss of HDAC4 in PEO1 cells might indicate that cells are dying following cisplatin 
treatment. Nonetheless, in PEO4 the expression of HDAC4 was strong and 
maintained, with increased between 12 hours post cisplatin treatment with 
notable loss of HDAC4 at 24 hours post cisplatin treatment. This shows that 
presence of HDAC4 may protect cancer cells from the cytotoxic effects of 
cisplatin and that HDAC4 disappears following response to treatment.  
 
3.5.1 Histone deacetylase 4 and H2AX expression in ovarian cancer 
upon cisplatin exposure: 
 
It has been reported that phosphorylation of histone H2AX on Ser 139 is a 
sensitive reporter of double stranded DNA damage (Huang et al. 2004). 
Therefore, H2AX is a useful marker for interstrand crosslinking agents such as 
cisplatin. Moreover, it has been shown that HDAC4 formed foci that are 
concurrent with the DNA damage response protein 53BP1 (p53 binding protein 1) 
in HeLa cells after being exposed to γ-irradiation (Kao et al. 2003). Accordingly, 
PEO1 and PEO4 were used to determine if there is a correlation between 
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HDAC4 and H2AX and to check the time point at which cisplatin induces the 
formation of H2AX in both cisplatin-resistant and sensitive ovarian cancer cell 
lines. PEO1 and PEO4 lysates treated with cisplatin over a 24 hour time course 
were examined. In both cell lines H2AX was undetectable in the absence of 
cisplatin treatment. Phosphorylation of histone H2AX ( H2AX) in PEO1 
increased from 4hrs and peaked at 24hours post cisplatin treatment whereas in 
the same cell line HDAC4 decreased as H2AX accumulated, indicating an 
inverse correlation (Figure 32). In PEO4, phosphorylation of histone p H2AX 
was not observed until 24 hours post cisplatin treatment. This correlates inversely 
with a decrease seen in HDAC4 levels at 24hours. In both lines, the inverse 
correlation between the accumulation of H2AX and the loss of HDAC4 may be 
functionally related to cisplatin sensitivity. However, the change in HDAC4 protein 
levels and phosphorylation of H2AX were detected at different time points. 
 
3.5.2 Analysis of HDAC4 cytoplasmic/nuclear shuttling after platinum 
induced DNA damage: 
 
The specificity of the HDAC4 antibody was examined by immunofluorescence 
technique (IF) on PEO4 transiently transfected cells with siRNA against HDAC4 
(Figure 33), then untransfected cells.  After 24 hours the HDAC4 antibody (Cell 
Signalling Technology) and Total STAT1 (T-STAT1; BD Biosciences) antibody 
applied. T-STAT1 was used as control because its expression supposes to be 
detected in both untransfected and siRNA against HDAC4 cells. Expression of 
HDAC4 and T-STAT1 were strong in untransfected cells. However, HDAC4 
expression become weaker but T-STAT1 expression was still strong in cells with 
siRNA against HDAC4. This shows that the antibody is specific to HDAC4 and 
can be used in IF. Moreover, the formation of H2AX induced by cisplatin 
treatment was not HDAC4 dependant since the expression of H2AX does not 
change following HDAC4 knockdown.  
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The localization of HDAC4 and H2AX was then tested in untreated, cisplatin-
sensitive PEO1 and cisplatin-resistant PEO4 cells and after 4 and 24 hours of 
25uM cisplatin exposure. In untreated PEO4 cells, endogenous and abundant 
HDAC4 was localized mainly in the cytoplasm, whereas no detection of H2AX 
was evident with the absence of cisplatin. HDAC4 was detected in the nucleus 
after 4 hours of cisplatin treatment with no H2AX phosphorylation. The 
phosphorylated histone H2AX was detected in the nuclei only after 24hours 
cisplatin treatment with HDAC4 accumulation in the nuclei (Figure 34). 
 
 In untreated PEO1 cisplatin-sensitive cells, endogenous and scarce HDAC4 was 
diffused in the cytoplasm, while no detection of H2AX was evident for the 
absence of cisplatin (Figure 35). At 4 hours of cisplatin treatment, cytoplasmic 
HDAC4 translocated to the nucleus with H2AX at 4 hours. This suggests that 
cisplatin caused DNA damage at earlier time points in the sensitive cells than in 
the resistant cells. In agreement with immune-blot analysis of cisplatin time 
course treatment in PEO1 (Figure 32) at 24 hours post-treatment, HDAC4 was 
not detected. However; strong expression of H2AX was observed. In SKOV3 
cisplatin-resistant cells, the cytoplasmic HDAC4 staining was present in 
untreated cells with no detection of H2AX. The translocation of both HDAC4 
and H2AX to the nucleus was observed at 4 hours cisplatin-treatment and the 
co-localization of HDAC4 and H2AX to nuclear foci after double-strand DNA 
damage was detected in 24hours cisplatin-treated cells (Figure 36).  
 
The expression and localization of HDAC4 and H2AX in SKOV3 cells were 
similar to PEO4 cells indicating that in cisplatin-resistant cells, the cytoplasmic 
HDAC4 is translocated to the nucleus after treatment with cisplatin and co-
localises with H2AX in the nucleus 24 hours post-treatment. Cisplatin caused 
DNA damage at 24 hours (late time point) in PEO4 and at 4hours in SKOV3 
resistant cells. In addition, the different time points of phosphorylation H2AX 








Figure 31 A: No significant change in HDAC4 expression level was observed in 
untreated PEO1 the sensitive cell line however, HDAC4 expression was lower at 2hours 
and higher at 24hours compared with 0hour in PEO4 the resistant cell line. Bands were 




Figure 31 B: In PEO1 the sensitive cell line, HDAC4 levels decreased upon cisplatin 
exposure and were undetectable from 8 hours post treatment. In PEO4 the resistant cell 
line HDAC4 protein was strong and up-regulated from 4hrs after cisplatin treatment with 
loss of its expression at 24hours. Bands were observed at the predicted sizes for 

















Figure 32: Western blot analysis showing an inverse correlation between H2AX and 
HDAC4 expression. H2AX level increased gradually starting from 8 hours following 
cisplatin treatment in PEO1 but detected at 24 hours in PEO4 cell line while HDAC4 
expression decreased. Lamin A/C used as loading control. Bands were observed at the 




















Figure 33: The specificity of the HDAC4 antibody was examined using PEO4 cells were 
either untransfected or transiently transfected with siRNA against HDAC4 after 2hours  
incubated with HDAC4 C-terminus (green) and total STAT1(red) antibodies after fixation 
and permeabilisation. The cells were stained with FITC to label HDAC4, Alexa 495 to 
label Total STAT1 and finally counterstained with DAPI to label the nucleus. The top 
panels show strong staining for HDAC4 and Total STAT1 in untransfected cells. In the 
bottom panels, Total STAT1 was detected in HDAC4 knockdown cells, however, weak 




















Figure 34: HDAC4 cytoplasmic/nuclear shuttling after DNA damage (cisplatin). PEO4 
cells were treated with 25uM cisplatin treated 4 and 24hours or without treatment then 
incubated with HDAC4 C-terminus (green) and H2AX (red) antibodies after fixation and 
permeabilisation. The cells were stained with FITC to label HDAC4, Alexa 495 to label 
H2AX and finally counterstained with DAPI to stain the nuclear DNA. The top panels 
show cytoplasmic HDAC4 staining in untreated cells and H2AX was not detected. The 
middle panels show detection of part of HDAC4 with detection of H2AX at 4hours. 
Magnification, x300. The lower panels showing co-localization of HDAC4 and H2A.X in 
nuclear foci after double-strand DNA damage in 24hours cisplatin-treated cells. The 
images in the lower panels were captured in closer magnification than the other panels 













Figure 35: HDAC4 cytoplasmic/nuclear shuttling after DNA damage (cisplatin). PEO1 
cells were treated with 25uM cisplatin treated 24hours or without treatment then 
incubated with HDAC4 C-terminus (green) and H2AX (red) antibodies after fixation and 
permeabilisation. The cells were stained with FITC to label HDAC4, Alexa 495 to label 
H2AX and finally counterstained with DAPI to label the nucleus. The top panels show 
diffused cytoplasmic HDAC4 staining in untreated cells and H2AX was not detected. 
The middle panels showing the recruitment of HDAC4 and H2AX to nuclear foci after 
double-strand DNA damage in 4hours cisplatin-treated cells. Magnification, x150. The 
lower panels show no staining for HDAC4 and the recruitment of H2AX to nucleus 
following 24 hours cisplatin treatment. The images in the lower panels were captured in 
closer magnification than the other panels to view close and clarify the co-localization of 














Figure 36: HDAC4 cytoplasmic/nuclear shuttling after DNA damage (cisplatin). SKOV3 
cells were treated with 25uM cisplatin treated 24hours or without treatment then 
incubated with HDAC4 C-terminus (green) and H2AX (red) antibodies after fixation and 
permeabilisation. The cells were stained FITC to label HDAC4, Alexa 495 to label 
H2AX and finally counterstained with DAPI to label the nucleus. The top panels show 
cytoplasmic HDAC4 staining in untreated cells and H2AX was not detected. The 
middle panels are showing the translocation of both HDAC4 and H2AX to the nucleus 
following 24hr cisplatin treatment. The middle panels showing the co-localization of 
HDAC4 and H2AX to nuclear foci after double-strand DNA damage in 24hours 
cisplatin-treated cells. Magnification, x200.The images in the lower panels were captured 
at higher magnification than the other panels to view close and clarify the co-localization 




3.6 Expression pattern of class I and II HDAC isoforms in 
ovarian cancer cell lines: 
 
The expression of 11 members of the histone deacetylase gene family in the 
isogenic ovarian cancer cell lines were evaluated using qRT-PCR. The 
expression of each gene was measured and normalised to the geometric mean 
of two housekeeping genes (PPIA and Alpha tubulin). Since there are multiple 
HDAC isoforms, determining the precise role of individual HDAC isoforms in 
cisplatin-resistance and progression of ovarian cancer has the potential of 
influencing the use of selective HDAC inhibitors as strategic therapeutic agents 
with fewer undesirable side effects.  
 
This provides evidence that HDAC4, 3 and 1 are expressed at higher levels in 
cisplatin resistant ovarian cancers in comparison to sensitive ovarian cell lines at 
mRNA (Figure 37) and protein levels (Figure 38). However, the other HDAC 
isoforms showed difference in their expression between the resistant and 
sensitive cell lines. HDAC2 and HDAC5 were high in PEO23 compared with its 
parent line PEO14 but not PEO4 and PEA2. HDAC6, 7, 8, 9 10, 11 were high in 
the resistant cell PEA2 and PEO23 but not in PEO4. This shows that these 
isoforms do not follow the same trend of up regulation in all the resistant like 
HDAC4 (Figure 37) and indicates that HDAC isoforms might have different role in 
platinum resistance in ovarian cancer.  
 
3.6.1 Identification of HDAC4 complexes with HDAC1 and HDAC3 by 
immunoprecipitation (IP): 
 
qRT data suggests HDAC1, HDAC3 and HDAC4 have similar regulation. For that 
reason, IP was performed to determine if these HDACs acted and interact 
together. HDAC4 (C-terminus and N-terminus), and HDAC1/3 antibodies were 
used in the immunoprecipitation assay. HDAC4 C and N terminal antibodies were 
used to confirm that the interaction observed by Western blot is not an antibody 
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specific artefact. Moreover, if both HDAC4 antibodies showed interaction with 
HDAC1 and 3, this would mean that the observed interaction is more likely to be 
real. HDAC4 C-terminus antibody was pulled down using PEO4 cells [treated for 
24hours with 25μM of cisplatin (CDDP) or without (UN)], and then Western blot 
analysis was performed and probed with HDAC1 and HDAC3. The HDAC4 
immunoprecipitated material interacted with HDAC1 and HDAC3 (Figure 39). 
HDAC4 was pulled down with N-terminal antibody and immunprecipitates probed 
with HDAC1 and the band in the IP lane was detected and confirmed the 
interaction with HDAC1 antibody.  
 
The interaction between HDAC3 and HDAC4 was previously reported by 
Grozinger CM et al.1999 using Jurkat cells. However, the interaction between 
HDAC1 and HDAC4 has not been previously reported. This might indicate that 
HDAC1, 3 and 4 interact together in ovarian cancer and this interaction might 
contribute in the development of cisplatin-resistance. After confirming the 
interaction between HDAC4 immunoprecipitation complex with HDAC1 and 
HDAC3, reverse IP was performed to confirm the interaction between HDAC4, 
HDAC1 and HDAC3. Protein complexes were pulled down from PEO4 cell 
lysates using HDAC1 and HDAC3 antibodies. Western blot was performed and 
probed with HDAC4 N-terminus antibody. HDAC1 and HDAC3 complexes were 
shown to co-immunoprecipitate HDAC4. The reverse IP was performed to 
confirm the interaction (Figure 40).  
 
3.6.2 The effect of HDAC1 and HDAC3 knockdown compared with 
HDAC4 knockdown in ovarian cancer platinum resistant cell lines:  
 
qRT-PCR showed that HDAC1 and HDAC3 was up-regulated in cisplatin-
resistant (PEO4, PEA1, PEO23 and SKOV3) cells as was observed with HDAC4. 
IP revealed that these 3 HDAC enzymes interact. Therefore, knockdown of 
HDAC1 and HDAC3 was investigated to compare their effect on cisplatin-
sensitivity with HDAC4 knockdown in ovarian cancer cells.  
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The effect of HDAC1 and HDAC3 silencing was assessed using siRNA against 
HDAC1,3 and lamin A/C or NT2 as controls to be compared with siRNA HDAC4 
knockdown in PEO4, PEA2 and PEO23 platinum-resistant cell lines. After 
transfection was performed on the cells, cells were either treated with 25μM 
cisplatin or left without treatment for 24hours. Caspase 3/7 assay was performed 
and normalised to MTT assay. Protein lysates were collected after 24hours to 
confirm the knockdown of HDAC1, 3 and 4 as well as lamin knockdown.  
 
The result showed that silencing HDAC4 has the highest effect on caspase 3/7 
activation following cisplatin treatment compared with HDAC1 and HDAC3 
knockdown that showed an increase in caspase 3/7 activity compared with 
control. Significance levels for HDAC1 were p<0.041107, p<0.045143 for HDAC3 
and p< 0.001578 for HDAC4 in PEO4 cells (Figure 41). Significance levels for 
HDAC1, 3 and HDAC4 were p<0.0394, p<0.0681 and p<0.00013, respectively in 
PEA2 (Figure 42 A). HDAC1, 3 and HDAC4 significance levels were p<0.01474, 
p<0.374365044 and p<0.000317428, respectively in PEO23 (Figure 42 B). This 
suggests that HDAC4 plays an important role in cisplatin-resistance in ovarian 
cancer compared with HDAC1 and HDAC3. 
 
3.6.3 HDAC1 and HDAC3 expression in PEO4 cell line after HDAC4 
knockdown: 
 
Silencing HDAC4 in the resistant cells enhanced sensitivity to cisplatin.  HDAC1, 
HDAC3, and HDAC4 proteins interact and have higher levels in the resistant cells 
compared with their counterpart. However, HDAC1 knockdown had a slight effect 
while HDAC3 knockdown had no effect. The effect of HDAC4 knockdown was 
assessed at mRNA and protein levels in PEO4 cells.  
 
The result of the qRT-PCR data based on siRNA against HDAC4 showed a 
significant reduction in HDAC1 levels while HDAC3 levels showed a slight 
 130 
increase following HDAC4 knockdown. HDAC4 knockdown was confirmed by q-
RT PCR. Using the deconvoluted siRNA against HDAC4 showed a decrease in 
HDAC1 and an increase in HDAC3 at the protein level (Figure 43). Western blot 
showed an increase in HDAC3 following HDAC4 knockdown with a concurrent 
reduction in HDAC1 levels. This might indicate that HDAC4 knockdown regulates 
positively or negatively these proteins. The assessment of the re-sensitization 
effect of the dual knockdown of HDAC1, HDAC3 and HDAC4 was used for 
comparison with HDAC4 silencing in PEO4 cells. The data showed that dual 
knockdown of HDAC1 and HDAC3 had no effect on apoptotic activity. 
Knockdown of HDAC1 and 4 had a higher apoptotic activity than HDAC1 and 3 
knockdowns. Silencing HDAC4 individually had the highest apoptotic effect 
compared with all the dual knockdowns in PEO4.  
 
Interestingly, the dual knockdown of HDAC3+4 did not affect sensitivity to 
cisplatin. This implies that the resensitising effect of HDAC4 knockdown in fact 
requires the presence of HDAC3 in ovarian cancer. Therefore, knocking down 
HDAC3 had a negative effect on resensitisation to cisplatin, consistent with an 


















Figure 37: mRNA expression level of HDACs Class I (HDAC 1, 2, 3 and 8), class II 
(HDAC 5, 6, 7, 9 and 10) and class IV (HDAC11) in the isogenic cell lines. HDAC3 and 1 
have higher expression in cisplatin resistant ovarian cell lines compared to cisplatin 
sensitive at mRNA with difference in expression of other isoforms observed between the 











Figure 38: Western blot analysis of HDAC4, HDAC1 and HDAC3 from the isogenic cell 
lines. The expression of these three HDACs is higher in ovarian cancer resistant cell 
lines compared with the sensitive parent lines with exception of PEO14 and PEO23 
where there is no significant different in HDACs expression. Bands were observed at the 















Figure 39: The immunoprecipitated products from PEO4 cells, treated with 25μM of 
cisplatin (CDDP) or without (UN), were analyzed by western blotting using HDAC1 and 3 
antibodies and showing the interaction between HDAC1/3 and HDAC4. Lanes were 
loaded with whole cell lysates (input) as positive control, pre-cleared whole cell lysates 
with beads without antibody as negative control (Beads), immunoprecipitation complex 
(IP) to detect if there is interaction by showing a band or no interaction if there is no band, 
IP supernatant as positive control (wash) and lysis buffer containing antibody with beads 
as negative control (Ab control). Bands were observed at the predicted sizes for HDAC1 
















Figure 40: The immunoprecipitated products from PEO4 cells were analyzed by western 
blotting using HDAC4 antibody. HDAC1 and HDAC3 interact with HDAC4. Reverse IP 
confirmed the interaction between HDAC4 (N-terminal antibody) and HDAC1 / HDAC3. 
Lanes were loaded with whole cell lysates as positive control (input), pre-cleared whole 
cell lysates with beads without antibody as negative control (Beads), 
immunoprecipitation complex (IP), IP supernatant as positive control (wash) and lysis 
buffer containing antibody with beads as negative control (Ab control). Bands were 















Figure 41: SiRNA-mediated silencing of HDAC1, 3 and 4 on PEO4 cells followed by 
Caspase Glo 3/7 based apoptosis assay. Cells were transfected with 100 nM siRNA 
targeting HDAC1, 3 and 4 100 nM lamin A/C siRNA. Cell viability was measured by MTT 
assay at 24 h. Caspase3/7 data are normalised to MTT data are means ± SEM from 
three separate experiments, each performed in triplicate. P values for HDAC1, 3 and 
HDAC4 are p< 0.041107, p<0.045143 and p< 0.001578 respectively. HDAC4 
knockdown was confirmed by western blot. Bands were observed at the predicted sizes 
for lamin at 65/74, HDAC4 at 119KDa, HDAC1 at 62KDa, HDAC3 at 49KDa and 





Figure 42: SiRNA-mediated silencing of HDAC1, 3 and 4 on PEA2 (A) and PEO23 (B) 
cells using caspase Glo 3/7. Cells were transfected with 100 nM siRNA targeting HDAC1, 
3 and 4 100 nM lamin A/C siRNA. Cell viability was measured by MTT assay at 24 hours. 
Caspase3/7 data are normalised to MTT data are means ± SEM from three separate 
experiments, each performed in triplicate. PEA2, p values for HDAC1, 3 and HDAC4 are 
p< 0.0394, p<0.0681 and p< 0.00013 respectively. PEO23, P values for HDAC1, 3 and 
HDAC4 are p< 0.01474 p< 0.374365044 and p< 0.000317428 respectively. Bands were 
observed at the predicted sizes for lamin at 65/74, HDAC4 at 119KDa, HDAC1 at 62KDa, 








        
 
Figure 43: qRT-PCR analysis HDAC1, HDAC3 and HDAC4 after HDAC4 knockdown 
and p values are indicated in red (A). Western blots analysis of the expression of HDAC1, 
3 and 4 after HDAC4 knockdown using the deconvoluted oligos in PEO4 cells (B). 
Caspase 3/7 activity after the dual knockdown of HDAC1+3, HDAC1+4, HDAC3+4 and 
HDAC4 (C) at 24 hours post cisplatin treatment, cells were transfected with 100 nM 
siRNA targeting HDAC1, 3 and 4 as well as lamin A/C siRNA. Caspase3/7 data are 
normalised to MTT data from single experiment in triplicate. Bands were observed at the 
predicted sizes for HDAC4 at 119KDa, HDAC1 at 62KDa, HDAC3 at 49KDa and 
tubulin at 54KDa. 
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3.7 Immunoprecipitation demonstrated an interaction 
between HDAC4 and STAT1 in platinum sensitive and 
resistant cell lines: 
 
Signal Transducers and Activators of Transcription (STAT1) was one of the up-
regulated genes in the cisplatin-resistant ovarian cancer cell lines compared with 
their counterpart the cisplatin-sensitive cells in the microarray. Knockdown of 
STAT1 by siRNA technique enhanced sensitivity to platinum in cisplatin-resistant 
ovarian cancer cells (Figure 58). Furthermore, it has been reported that HDAC 
inhibitors (valproic acid and trichostatin A) treatment increased the acetylation 
level of STAT1 in melanoma cells (Kramer et al. 2006). Butyrate, trichostatin A, 
and suberoylanilide hydroxamic acid, HDAC inhibitors, prevented STAT1 
phosphorylation, its nuclear translocation, and STAT1-dependent gene activation. 
Moreover, overexpression of HDAC1, HDAC2, and HDAC3 but not HDAC4 
enhanced STAT1-dependent transcriptional activity in colorectal carcinoma cells 
(Klampfer et al. 2004). This might indicate that specific HDAC isoforms have 
different effect depending on cell type. It also shows that STAT1 acetylation 
depends on the balance between STAT1-associated histone deacetylases 
(HDACs) and histone acetyltransferases (HATs).  
 
Thus, the inhibition of HDACs changes this balance and induces STAT1 
acetylation thereby triggering apoptosis via inhibition of nuclear factor-kB (NF-kB; 
Kramer et al. 2006). NF-kB activation has been associated with cell proliferation, 
survival and invasion in cancer (Brown, Cohen et al. 2008). Therefore, the 
interaction between HDAC4 and STAT1 was investigated using HDAC4 antibody 
for pull-down. HDAC4 immunoprecipitated materials were shown to interact with 
STAT1 in PEO1, PEO4, PEA1, PEA2 and SKOV3 cells. This identifies an 
interaction between HDAC4 and STAT1 in both resistant and sensitive ovarian 
cancer cell lines as well as indicating that HDAC4 might play a role in STAT1 
regulation (Figure 44 A, B and C). The inhibition HDAC4 and STAT1 by siRNA 
enhanced sensitivity to cisplatin and their interaction in both cisplatin-sensitive 
and resistant cell lines, suggests that these genes might work in the same 
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pathway to trigger the restoration of cisplatin sensitivity in ovarian cancer cells. 
To determine the effect of cisplatin on HDAC4 and pSTAT1 expression, PEO4 
cells were treated with either vehicle or 25uM cisplatin.  
 
Next, protein lysates were collected at different time intervals. HDAC4 increased 
at 8 hours, peaked at 12 hours and decreased at 48. On the other hand, STAT1 
seemed to peak at 24hrs followed by a reduction at 24 hours as shown by 
Western blot analysis. The expression of pSTAT1 and HDAC4 was different at 
24hrs treatment with cisplatin, when HDAC4 started to decrease and pSTAT1 
reached its highest expression level. It is worth noting that HDAC4 expression 
was present at all time points following cisplatin treatment (Figure 31 B) but the 
western blot (Figure 44 D) was exposed for short time to show the high levels of 
HDAC4 at 12 hours without being saturated. It is possible that deacetylation of 
STAT1 by HDAC4 is required for its phosphorylation. As a result HDAC4 activity 
starts first by removing acetyl groups from STAT1 to enhance the 
phosphorylation of STAT1. Therefore, further experiments were conducted to 
clarify the possible role of HDAC4 in the acetylation and phosphorylation of 
STAT1 (Figure 44 D).  
 
3.7.1 Knockdown HDAC4 increases the acetylation level of STAT1 in 
cisplatin-resistant cells: 
 
Acetyl STAT1 has been reported to be induced following administration of HDAC 
inhibitors (Kramer et al. 2006).Therefore, the acetylation level of STAT1 was 
examined by pull down using a pan acetyl-lysine antibody with either 
untransfected control cells or HDAC4 knockdown cells. Acetylation of STAT1 was 
not detectable by western blot in the cisplatin resistant cell lines that expressed 
high level of HDAC4 relative to their paired cisplatin-sensitive cell lines. Following 
HDAC4 knockdown acetyl-STAT1 was clearly visible in all cisplatin-resistant lines 
tested (SKOV3, PEO4 and PEA2), indicating a direct role for HDAC4 in the 
deacetylation of STAT1. Conversely, in the sensitive cells PEO1 and PEA1, 
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when HDAC4 expression was low, acetyl-STAT1 was detected in both 
untransfected and HDAC4 silenced cells. Thus, when HDAC4 is low in the cells, 
acetyl STAT1 is detected but acetyl STAT1 is not present when HDAC4 is high. 
Furthermore, the inhibition of HDAC4 by siRNA increased the acetylation of 
STAT1 suggesting that HDAC4 deacetylates STAT1. It might also imply that a 
certain threshold level of HDAC4 is necessary to determine the acetylation level 
of STAT1. Therefore, if HDAC4 level is below a certain level in the cells, STAT1 
is acetylated and resists cisplatin-induced activation. When HDAC4 levels are 
abundant in the cells, the acetylation level of STAT1 is more likely to decrease or 
be lost as seen in the cisplatin resistant cells (Figure 45).  
 
3.7.2 HDAC4 inhibition prevents nuclear localization of pSTAT after 
cisplatin treatment in the cisplatin-resistant cells:  
 
It has been mentioned earlier that HDACi prevented STAT1 phosphorylation and 
HDAC1, HDAC2 and HDAC3 might have a role in this process in colon cells 
(Klampfer et al. 2004). Here it seems that HDAC4 levels in ovarian cancer cells 
affect the acetylation level of STAT1. Thus, the phosphorylation of STAT1 might 
also be influenced by HDAC4 levels. The effect of HDAC4 knockdown on STAT1 
was investigated using immunofluorescent microscopy and western blot. 
 
 In SKOV3 cell, the immunofluorescent data show cytoplasmic HDAC4 staining in 
control cells and reduced staining in both siRNA HDAC4 cells and HDAC inhibitor 
APHA4a treated cells (Figure 46). The phosphorylation of pSTAT1-Y701 and 
nuclear translocation following cisplatin-treatment was observed in control cells. 
Reduction in pSTAT1-Y701 staining in both siRNA HDAC4 cells and HDAC 
inhibitor treated cells. This shows that HDAC4 modulate the expression of 
pSTAT1.  Moreover, the co-localization of HDAC4 and pSTAT1-Y701 in the 
nucleus was observed after 24 hours of cisplatin treatment. In siRNA HDAC4 
cells and HDAC inhibitor APHA4a treated cells both treated and untreated with 
cisplatin, there was partial expression of HDAC4. Furthermore, HDAC4 
 141 
knockdown prevents the phosphorylation of STAT1-Y701 following cisplatin 
treatment in PEO4 and SKOV3 cisplatin-resistant cells. The levels of total STAT1 
did not change indicating a direct phosphorylation alteration (Figure 47). 
 
Taken together, the results show that cisplatin induces the phosphorylation and 
nuclear localisation of pSTAT1-Y701 after 24hrs treatment in cisplatin-resistant 
cells and HDAC4 knockdown using siRNA or inhibition using 5µM APHA4a 
prevents accumulation of pSTAT1 compared with control. This suggests that the 
HDAC4 affects both the phosphorylation and the acetylation of STAT1 in ovarian 
cancer cells and that higher expression of HDAC4 causes deacetylation of 
STAT1 and leads to phosphorylation in response to cisplatin treatment leading to 
cisplatin resistance. In contrast, in cisplatin-sensitive cells that have low levels of 
HDAC4 (similar to HDAC4 knockdown cells), STAT1 acetylates but does not 
respond to cisplatin. Western blot in (Figure 47) is also showing increase in 
HDAC3 expression following 24 hours of cisplatin treatment when HDAC4 
expression decreased in SKOV3. This supports qRT PCR and western blot 
(Figure 43) that showed increase HDAC3 level following HDAC4 knockdown in 
PEO4 cells. The mechanism is unknown yet and it needs further study to clarify 















Figure 44: Immunoprecipitates from untreated SKOV3 (A), PEO1/PEO4 (B) and 
PEA1/PEA2 (C) cells were prepared using anti-HDCA4 antibody and probed for the 
presence of STAT1. Lanes were loaded with whole cell (Lysate), pre-cleared whole cell 
lysate with beads without antibody as negative control (Beads), immunoprecipitation 
complex Immunoprecipitates (IP), IP supernatant as positive control (wash) and lysis 
buffer containing antibody with beads as negative control antibody control(-ve). Western 
blot is showing the expression of HDAC4 and pSTAT1 (Y701) in PEO4 (D) cisplatin-
resistant cell line after exposing the cells to 25µM of cisplatin in different time points. 
HDAC4 and pSTAT1expression increased at 8 hours, peaked at 12 and decreased at 48 
hours as shown by Western blot analysis. Experiments are representative of duplicates. 
Bands were observed at the predicted sizes for HDAC4 at 119KDa, STAT1 and pSTAT1 








Figure 45: Western blot showing the expression of total STAT1 in SKOV3, PEO1/PEO4, 
and PEA1/PEA2 cell lines after pull down with the pan acetyl lysine antibody. Cells were 
either untransfected as control or transfected with siRNA against HDAC4. Lanes were 
loaded with whole cell lysate (Lysate), pre-cleared whole cell lysate with beads without 
antibody as negative control (Beads), immunoprecipitation complex using acetyl lysine 
(ac-lysine), IP supernatant as positive control (wash) and lysis buffer containing antibody 
with beads as negative control (-ve). Experiments are representative of triplicates. Bands 












Figure 46: Immunofluorescent microscopy of cisplatin resistant SKOV3 cells, the top 
panels show cytoplasmic HDAC4 staining (green) in control cells, reduced stain in both 
siRNA HDAC4 cells and HDAC inhibitor APHA4a treated cells. The second panels show 
the induction of pSTAT1-Y701 (red) and nuclear location after 25µM of cisplatin-
treatment and reduced levels of pSTAT1-Y701 in both siRNA HDAC4 cells and HDAC 
inhibitor treated cells. The third panels are showing dapi staining the nucleus. The merge 
images in the bottom panels are showing the cytoplasmic HDAC4 in control cells, the co-
localization of HDAC4 with pSTAT1-Y701 in the nucleus following 24hours of 25µM 
cisplatin treatment. Scarce expression of HDAC4 in siRNA HDAC4 both treated and 
untreated with cisplatin. HDAC4 was not detected in HDAC inhibitor APHA4a treated 











Figure 47: Western blot showing the expression of HDAC1, HDAC 3, HDAC 4, STAT1, 
pSTAT1 (Y701) and -tubulin in PEO4 and SKOV3 cisplatin-resistant cell line either 
untreated or cisplatin treated with control and siRNA HDAC1, HDAC 3 (B) and HDAC 4 
transfected cells (A and B). No expression for pSTAT1 after silencing HDAC4 with and 
without cisplatin in both PEO4 and SKOV3 resistant cells. The phosphorylation of STAT1 
decreased slightly following HDAC1 knockdown but the expression of pSTAT1 after 
HDAC3 knockdown was identical to control. Total-STAT1 (T-STAT1) has no change in 
its expression following HDAC4 knockdown and the absence of HDAC1, HDAC 3 and 
HDAC 4 proteins validates the silencing by siRNA. Bands were observed at the 
predicted sizes for HDAC4 at 119KDa, HDAC1 at 62KDa, HDAC3 at 49KDa, STAT1 and 







3.8 Identification of HDAC4-regulated genes by 
microarray: 
 
In order to identify genes that are regulated by HDAC4, RNA from PEO4 
untransfected, lamin A/C siRNA transfected and HDAC4 siRNA transfected cells 
were hybridized to Affymetrix U133 plus 2.0 microarrays (hybridisation carried out 
at Prof Michael Birrer’s group, NIH). Prior to hybridization, mRNA down-
regulation of HDAC4 was validated by qRT-PCR (Figure 43 A). The analysis was 
carried out using Genechip Operating System (cut off at p<0.01). The type of 
univariate test used was two-sample t-test with the random variance model. This 
model was used for its accurate analysis of small sample sizes. The number of 
differentially expressed genes between HDAC4 knockdown versus lamin 
knockdown was 722, HDAC4 knockdown versus untransfected 87 and 
untransfected versus lamin was 187. The analyses were carried out using the 
common differentially expressed genes between HDAC4 knockdown versus 
untransfected control, and HDAC4 knockdown/lamin knockdown. Finally, the 
genes in the untransfected versus lamin knockdown array were used to exclude 
any falsely associated genes. These three different comparison analyses 
identified twenty-four genes. The twenty-four differentially expressed genes were 
common between HDAC4 knockdown versus lamin knockdown array and 
HDAC4 knockdown versus untransfected array but not present in untransfected 
versus lamin knockdown array. Eight out of 23 genes were up-regulated and 15 
were down-regulated (Table 7). The fold change in HDAC4 expression in HDAC4 
knockdown versus untransfected array was (2.6 fold down; p = 0.00046) 
confirming HDAC4 knockdown. HDAC4 knockdown versus lamin knockdown was 
(2.5 fold down; p = 0.0004) with no change in HDAC4 in untransfected versus 
lamin knockdown array. This validates the array data and indicates that the data 
confirm to the expectations. The expression of lamin was decreased in 
untransfected versus lamin knockdown arrays, the fold change was (0.2889099 
fold change; p = 0.0029) confirming lamin knockdown in this array. Nonetheless, 
lamin expression increased in HDAC4 knockdown versus lamin knockdown 
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arrays (2.6971143 fold change; p = 0.0008956). Therefore, the fold change of 
lamin in these two arrays provides evidence that microarray analysis results need 
to be carefully interpreted and validated by other gene expression techniques 
such as qRT-PCR. For example the up-regulation of ITGB2 gene following 
HDAC4 knockdown was confirmed by qRT-PCR (Figure 48). Nevertheless, the 
qRT-PCR data showed insignificant down regulation of ANPEP after silencing 
HDAC4. Furthermore, the high number of differentially expressed genes between 
HDAC4 knockdowns versus lamin knockdown array showing that lamin is not the 
ideal control as it changed the expression of certain genes compared with 
untransfected cells that has low number of differentially expressed genes. 
HDAC4 knockdown versus lamin A/C knockdown, HDAC3 expression was found 
to be significantly up-regulated (fold change: 1.656; p = 0.00431). This result is in 
keeping with up-regulation of HDAC3 at mRNA levels following HDAC4 
knockdown shown in Figure 43 earlier and helps to validate the array data. The 
function of up and down regulated genes is involved in different cellular function 
such as regulation of cellular growth, signal transduction, cell adhesion, migration, 
invasion, and survival pathways that have important roles in cancer development.  
 
UCHL1 is one of the genes up regulated following HDAC4 knockdown. In both 
microarray data analyses the up-regulation was significant (siHDAC4 vs 
untransfected = 2.2 fold up (p = 0.001); siHDAC4 vs siLaminA/C = 2.5 fold up (p 
= 0.0002)). It has been reported that UCHL1 is inactivated in human colorectal, 
pancreatic cancers and ovarian cancers via promoter methylation (Okochi-
Takada et al. 2006; Takai and Narahara 2008). The reversal of DNA methylation 
or histone deacetylation is correlated with re-expression silenced genes. A 
combination of DNA methylation inhibition (hydralazine) and HDAC inhibition 
(valproic acid) has been shown to induce re-expression of silenced genes more 
than using these drugs individually (Li, Chen et al. 2008) suggesting a link 
between methylation and acetylation on gene re-expression in cancer cells. 
Therefore, UCHL1 was investigated further to identify the relationship between 
HDAC4 and UCHL1 in ovarian cancer.   
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Table 7: The 8 up-regulated genes and 16 down-regulated genes identified using the three comparison analysis following HDAC4 knockdown. 
The gene symbol, description of the gene, chromosome location, P-value and the fold change respectively for untransfected versus HDAC4 















Figure 48: qRT-PCR analysis showing the expression of ANPEP (p value: 0.0018; 
fold change: 1.5; B) and ITGB2 (p value: 0.43; fold change: 4.4; A) after HDAC4 
knockdown. The data shown are normalised to PPIA and alpha-tubulin mRNA. Data 
are represented as means ±SEM of 3replicate experiment. ANPEP, HDAC4 
knockdown versus untransfected array was (2.17 fold down; P value: 0.003) and in 
HDAC4 knockdown versus lamin knockdown array was (2.6 fold up; P value: 0.002). 
ITGB2, HDAC4 knockdown versus untransfected array was (2.3 fold up; P value: 












3.9 The methylation status and protein expression of 
UCHL1 in the isogenic ovarian cancer cell lines: 
 
 
DNA methylation has an important role in the epigenetic modification of 
chromatin structure that affects regulation of gene expression. DNA 
methylation mainly occurs at cytosines associated with CpG (p indicates a 
phosphodiester bond connecting C with G). The CpG dense regions are 
known as CpG Islands. In mammals, approximately half the genes contain 
such CpG-rich promoter regions making them prone to methylation. UCHL1 
has been shown to be silenced by promoter methylation in both colon and 
ovarian cancer (Okochi-Takada et al. 2006). UCHL1 was detected in HDAC4 
knockdown microarray to be up-regulated at mRNA level in PEO4 cells. 
Therefore, expression of UCHL1 was assessed at protein level and showed 
that no expression in PEO1 and PEO4 but was present in PEA1, PEA2, 
PEO14, PEO23 cell lines and OSEC2 (Ovarian Surface Epithelia Cell; Figure 
49) although the loading control of PEO4 was very low compared with the 
other cells. Interestingly, the DNA  methylation array data which was obtained 
from Professor Robert Brown, relied on the isogenic cell lines’ baseline 
methylation (PEO1, PEO4, PEA1, PEA2, PEO14 and PEO23) and showed 
that UCHL1 was methylated in PEO1, PEO4 and PEO6 while no methylation 
was observed in PEA1, PEA2, PEO14 and PEO23 (Table 8).  
 
Briefly, the DNA methylation array was performed by extracting and purifying 
the genomic DNA from the isogenic ovarian cell lines using the Qiagen 
QIAamp DNA Kit according to standard instructions. 1 µg genomic DNA was 
bisulphite-modified using the EZ DNA Methylation Kit (Zymo Research, Irvine, 
CA, USA). 200ng of converted DNA was further processed to run BeadArrays 
according to the manufacturer’s instructions. The arrays were imaged using a 
BeadArrayTM Reader. Each gene locus is represented by fluorescent signals 
from two bead types corresponding to the methylated (M) and unmethylated 
(U) alleles, respectively. The raw signals of unmethylated and methylated 
bead types were background corrected and computed into a beta value using 
the BeadStudio software Methylation Module (version 1.0.5; Illumina). Value 
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represents the ratio of the intensity of the methylated bead type to the 
combined locus intensity and reflects the methylation status of a specific CpG 
site. Hence, UCHL1 gene is methylated in PEO4 cells but HDAC4 silencing by 
siRNA lead to its up-regulation. The DNA Methylation array data show the 
presence of two CpG sites in UCHL1 gene. The DNA methylation arrays 
range from 0 to 1. Zero means loci are un-methylated, 1 means they are 
methylated and 0.5 means the loci are hemi-methylated. One of the CpG sites 
tested in UCHL1 has very low methylation levels and is therefore not 
considered a CpG island. However, the CpG site in chromosome 4 at position 
40953551, which is a CpG island, is methylated in PEO1 and PEO4. This 
CpG was used to confirm the methylation in PEO1 and PEO4 cell lines. The 
DNA methylation arrays used Gardiner-Garden criteria (CpG islands are 
usually 500 bp in length) to check the CpG islands and to maintain 
consistency with the genome bioinformatic database (the University of 
California Santa Cruz; UCSC) that will be used to locate the CpG island 
(Gardiner-Garden and Frommer 1987).  
 
The protein expression matches the results from the methylation arrays, 
where low methylation of UCHL1 high expression of protein by Western and 
high methylation of UCHL1 no protein expression. PEO4 cells were used for 
further analysis to confirm the methylation observed in the DNA methylation 
array data. This might indicate HDAC4 siRNA could cause re-expression of a 
methylated gene like UCHL1 and show the link between demethylation and 
acetylation. Therefore, UCHL1 was further investigated in PEO4 cells. UCHL1 
was found to be methylated based on the DNA methylation array data 
obtained in PEO4 cells. However, HDAC4 knockdown microarray data 
showed that UCHL1 expression increased. Thus, HDAC4 might either directly 
or indirectly affect UCHL1 promoter methylation.  
 
3.9.1 Methylation of the CpG islands in UCHL1 gene:  
 
 
HDACi has been reported to affect the methylation and the acetylation of 
some genes in transformed cells, for example, the HDACi TSA suberoylanilide 
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down regulates protein and mRNA levels of DNMT3B, a methyltransferase, in 
human endometrial cancer cells. This decreases the de novo DNA 
methylation caused by DNMT3B (yuning xiong 2005). This shows that the 
inhibition of HDACs could alter the methylation level. Therefore, 
pyrosequencing was used to assess the methylation levels of UCHL1 
promoter in PEO1 and PEO4 after HDAC4 knockdown and Lamin knockdown 
experiments and to check if HDAC4 silencing could change methylation level 
of UCHL1 in these cells. Two control DNA were used (in vitro methylated and 
normal unmethylated DNA) to validate the assay. Ten CpG sites in the 
UHCL1 promoter were examined using two sequencing primers to cover the 
methylated region. The percentage of DNA methylation at CpG islands in 
UCHL1 was measured as a ratio of cytosine to thymine (C to T) for each 
condition in triplicate wells. Each sequencing primer in the PCR reaction 
covers 5 CpG islands. The mean across the islands was used for the 
analyses.  
 
As expected, in both sequencing primers, the unmethylated normal DNA 
samples showed low-methylation ( the ratio of C to T was 10%) at all the CpG 
islands while in vitro methylated control DNA samples showed high 
methylation level with 99% ratio C to T (Figure 50 and 51). This result 
validates the assay. In the DNA samples from PEO1, the ratio of C to T was 
80% compared to control DNA in both untransfected and lamin knockdown 
and was 78% in HDAC4 knockdown. This shows that HDAC4 silencing did not 
change the methylation level of UCHL1 significantly and confirmed the 
methylation detected by the DNA methylation array data of the isogenic 
ovarian cancer baseline. However, in PEO4, the ratio of C to T was about 50% 
in untransfected, Lamin and HDAC4 knockdown in the first sequencing primer 
and about 80% in the second sequencing primer. This indicates that UCHL1 is 
methylated in PEO4 but not all the CpG islands in the region tested are 
heavily methylated. Also, knockdown of HDAC4 did not alter the methylation 
level of the UCHL1 gene. Thus, HDAC4 does not seem to change the 
methylation level of UCHL1 gene in both PEO1 and PEO4.  
 
 153 
3.9.2 Chromatin immunoprecipitation (ChIP) followed by 
quantitative real-time PCR: 
 
If HDAC4 has no effect on the methylation level of UCHL1, this means the 
UCHL1 up-regulation at mRNA level detected by the microarray following 
HDAC4 knockdown might occur through a change in the acetylation level of 
UCHL1 protein. Therefore, HDAC4 effects on the acetylation level of UCHL1 
protein was determined by quantifying the change in lysine acetylation in 
DNA-bound protein at UCHL1 locus using qRT-PCR after ChIP. Pan acetyl 
lysine antibody was used to detect the relative amount of acetylated protein 
associated with UCHL1 promoter and the PCR was utilized to quantify the 
change in UCHL1 promoter region specifically. This was used to determine 
whether HDAC4 inhibition alters the acetylation of UCHL1. Briefly, PEO4 cells 
were transfected with siRNA against HDAC4, siRNA against lamin control and 
untransfected, after which DNA/protein complexes were cross-linked with 
formaldehyde to stabilise their interactions prior to analysis. Genomic DNA 
extracts were lysed, sonicated and optimized to produce average size 
fragments of approximately 400 base pairs (Figure 52 A). Chromatin 
fragments were immunoprecipitated with pan acetyl lysine antibody. Then 
UCHL1 and PPIA genes were amplified by qRT-PCR with primers specific to 
their promoters. PPIA gene was used as a negative control for the experiment 
as the acetylation of PPIA was not expected to be influenced.  
HDAC4 knockdown and the acetylation of PPIA, a housekeeping gene, was 
expected to be consistent. The qRT-PCR analysis was done by normalising 
the amount of immunoprecipitated sample values to the amount of the input 
material to determine the relative enrichment amount of acetyl protein bound 
to UCHL1. This allowed mapping the changes at UCHL1 locus that might be 
regulated by HDAC4. The data showed that HDAC4 knockdown increased the 
relative amount of protein acetylation at the UCHL1 promoter region (Figure 
52 B). No change in protein acetylation was observed in PPIA control gene 
following siHDAC4 treatment. This shows that HDAC4 knockdown results in 
alterations of the level of acetyl lysine at UCHL1 locus, which might be related 










Figure 49: Protein level of UCHL1 in the isogenic ovarian cancer cell lines showing 
no expression of UCHL1 in PEO1 and PEO4 and high expression of UCHL1 with no 
expression of UCHL1 in cisplatin-resistant SKOV3 cells and high expression in 
OSEC2 normal ovarian cells. Bands were observed at the predicted sizes for HDAC4 











Table 8: The DNA methylation array data showing the methylation level of UCHL1 
cross the isogenic ovarian cancer cell lines. CpG position (40953551) in UCHL1, 
average of three replicates of PEO1 and PEO4 methylated status as well as average 
of two replicates of PEO6, PEA1, PEA2, PEO14 and PEO23, and CpG island 
information. Based on Gardiner-Garden criteria, this position is considered a CpG 
island.  UCHL1 has high methylation level in PEO1, PEO4 and PEO6 but very low 









Cell lines PEO1 PEO4 PEO6 PEA1 PEA2 PEO14 PEO23 











Figure 50: The percentage of C to T in UCHL1 prompter region using the mean of 
five CpG islands with the first sequencing primer in N; normal unmethylated DNA, in 
vitro  M; in vitro  methylated DNA, PEO1 and PEO4 DNA (UN; untransfected, 
siLamin; transfected with siRNA against Lamin and siHDAC4 transfected with siRNA 
against ). Data represented as SEM of 2 experiments in triplicate. The methylation 
level of the positive in vitro methylated DNA and the negative normal DNA validate 


















Figure 51:The percentage of C to T in UCHL1 promoter region using the mean of five 
CpG islands with the second sequencing primer in N; normal unmethylated DNA, in 
vitro  M; in vitro  methylated DNA, PEO1 and PEO4 DNA (UN; untransfected, 
siLamin; transfected with siRNA against Lamin and siHDAC4 transfected with siRNA 
against ). Data represented as SEM of 2 experiments in triplicate. The methylation 
level of the positive in vitro methylated DNA and the negative normal DNA validate 
the assay. PEO1, methylation percentage was 80% and PEO4 was 90% which 
confirms the methylation obtained from the DNA methylation array for these two 









Figure 52 A: The genomic DNA extracts from PEO1 and PEO4 cells were lysed and 
sonicated at different minutes as indicated above to determine the suitable time to 
produce average size fragments of 500 base pairs (bp) as showing in 1% ethidium 
bromide-stained agarose gel. 5 minutesx2 was required to obtain 500bp and was 
used as an optimal time for sonication for the genomic DNA. The chromatin 
fragments were then immunoprecipitated with pan acetyl lysine antibody.  
 
Figure 52 B: The qRT- PCR quantitative analysis of the association of the pan acetyl 
lysine to the UHCL1 promoter and PPIA promoter normalized to the amplified 
product from the input DNA in PEO4 cisplatin-resistant cells. Data revealed an 
increase in acetylation at the UCHL1 promoter after HDAC4 knockdown in PEO4 
cisplatin-resistant cell line p value 0.0015; t-test. No change in the level of acetylation 
in PPIA promoter after HDAC4 knockdown. Data are represented as mean ± SEM of 







3.10 HDAC4 knockdown up-regulates levels of p21 in 
cddp-sensitive and down-regulates p21 levels cddp-
resistant cells 
 
The cyclin dependent kinase (CDK) inhibitor p21WAF1 (p21) is well known as a 
biomarker of HDAC inhibitor activity. Also, HDAC inhibitors have been shown 
to induce p21 expression in human hepatocellular carcinoma, human 
leukaemia, lung cancer, cervical cancer, melanoma, ovarian cancer and 
breast cancer lines (Blagosklonny et al. 2002; Burgess et al. 2001; Hirsch et al. 
2010; Zopf et al. 2007). On the contrary, the microarray data showed that 
expression of p21 was down-regulated following HDAC4 knockdown versus 
lamin knockdown array in PEO4 cisplatin-resistant cells. This indicates that 
HDAC4 inhibition in cisplatin-resistant cells decreases p21 expression, which 
contradicts with what has been published relating to the effect of HDAC 
inhibitor on p21 expression. Therefore, p21 expression was assessed after 
HDAC4 knockdown to validate the microarray data in PEO4 cells. The down-
regulation of p21 was confirmed by qRT-PCR following HDAC4 knockdown in 
PEO4 cells suggesting that HDAC4 modulates p21 (Figure 53).  
 
Subsequently, the baseline of p21 in all the isogenic cells at both mRNA and 
protein levels was examined. The p21 expression was higher in the cisplatin-
resistant cells compared with their counterparts using both Western blot and 
qRT-PCR analysis (Figure 54). This indicates a consistent up regulation of 
p21 in the paired cell lines and shows that higher expression of p21 mimics 
HDAC4 up-regulation in cisplatin-resistant ovarian cancer cells.  
Next, the level of p21 protein was examined after HDAC4 knockdown in 
ovarian cancer cell lines to confirm the down-regulation in PEO4 cells and 
correlate expression with cisplatin-sensitive cells. Western blot showed 
increased p21 expression in PEO1 and PEA1 cisplatin-sensitive cells (Figure 
56 B). However, the level of p21 declined following HDAC4 knockdown in 
PEO4, PEA2 and SKOV3 cisplatin-resistant cells (Figure 56 A). This indicates 
that p21 expression in the cisplatin-sensitive cells was low at basal level which 
increased following HDAC4 knockdown. In contrast, the expression of p21 
was high in cisplatin-resistant cells at basal level and decreased following 
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knockdown, suggesting HDAC4 might regulate p21 differently based on the 
level of both HDAC4 and p21 in these cells.  
 
However, the expression of HDAC4 protein in the sensitive ovarian cancer cell 
line, A2780, and its parental line in the in vitro resistant cells A2780/CP70 was 
assessed. There was no increase in HDAC4 protein level in resistant cells 
(Figure 56 A and B). The combined results indicate that HDAC4 might have a 
role in clinical platinum resistance in ovarian cancer cells but not in cells 
acquiring resistance to cisplatin in vitro. It also points to a difference in the 
genetic modification between cisplatin-resistant cells and in vitro cisplatin-






Figure 53: qRT PCR showing the down-regulation of p21 following HDAC4 






Figure 54: qRT PCR and western blot showing the higher expression of p21 in 
cisplatin-resistant cells relative to cisplatin sensitive ovarian cancer cells. This shows 
that p21 follows the pattern of up regulation as HDAC4 in the cisplatin-resistant 
ovarian cancer cells. Bands were detected on the predicted size, HDAC4 on 119KDa, 















Figure 55: (A) SiRNA-mediated silencing of HDAC 4 on A2780/CP70 cells using 
caspase Glo 3/7. Cells were transfected with 100 nM siRNA lamin and HDAC4. Cell 
viability was measured by MTT assay at 24 h. Caspase3/7 data are normalised to 
MTT data are means ± SEM from two separate experiments, each performed in 
triplicate. (B) Western blot showing the expression of HDAC4 in the sensitive ovarian 
cancer cells A2780 and its parental line the in vitro resistant cells A2780/CP70. No 
increase of HDAC4 in the resistance cells although the loading control was higher 
compared with the sensitive cells. Bands were detected on the predicted size, 







Figure 56: Western blot showing (A) decrease p21 level in PEO4 and SKOV3 
cisplatin-resistant cell lines (B), increased p21 expression in PEO1, PEA1 cisplatin-
sensitive and (C) A2780/CP70 in vitro cisplatin-resistant cells following HDAC4 
knockdown. Bands were detected on the predicted size, HDAC4 on 119KDa, p21 























































4.1 The role of HDAC4 in the cisplatin resistance of 
ovarian cancer: 
 
 4.1.1 The up-regulation of HDAC4 in cells with acquired cisplatin 
resistance 
 
Aberrant HDAC activity has been detected in several human tumours 
including colorectal cancer, breast cancer (Zhang et al. 2004), prostate cancer 
(Wilson et al. 2008), and ovarian cancer (Hayashi et al. 2010). It is well known 
that chromatin activity is controlled by histone acetylation and deacetylation. 
Acetylation activates and deacetylation deactivates the transcription of the 
genes involved in a diversity of cellular functions. High level of HDACs is 
usually associated with gene silencing. The over expression of class I HDACs 
has been reported in ovarian cancer. Khabele et al. 2007 have demonstrated 
that class I HDACs are expressed at significantly higher levels in ovarian 
carcinomas than in normal tissue and silencing HDAC1 and HDAC3 with 
small-interfering RNAs (siRNAs) reduces ovarian cancer cell growth (Khabele 
et al. 2007). Using a tissue microarray Weichert 2009 revealed that ovarian 
carcinomas showed higher class I HDAC protein expression than normal 
tissues. Expression levels were significantly different in specific tumour 
subtypes with mucinous carcinomas showing the highest positivity rates 
(71%); followed by high-grade serous (64%), clear cell (54%) and 
endometrioid subtypes (36%). However, the previous author did not examine 
the expression of HDAC4. Hayashi A et al. 2010 showed increased 
expression of HDAC1, HDAC2 and HDAC3 in epithelial ovarian malignant 
tumours compared with benign and borderline tumours using tissues obtained 
from 115 cases of ovarian tumours, illustrating the important role of class I 
HDACs in ovarian tumours. Nonetheless, all these studies compared the 
expression of HDACs between benign and malignant tumours but not 
sensitive and resistant to platinum cases. The development of acquired 
platinum resistance limits the successful platinum-based chemotherapy of 
human cancers (Markman, 1994; Sabbatini, 2009). Therefore, it is very 
important to identify the genes involved in this process.  
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The present study has identified a novel role for HDAC4 gene in cisplatin 
resistant ovarian cancer. Three clinically derived isogenic cell line models of 
acquired platinum resistance were used in order to understand the molecular 
changes that drive acquired platinum resistance in ovarian cancer patients. 
The up-regulation of HDAC4 was observed using microarray, in the following 
cell lines that have acquired cisplatin resistance: PEO4, PEO6, PEA2 but not 
PEO23 (Figure 14). Moreover, up-regulation of HDAC4 by both real-time 
quantitative PCR and western blot was detected in all of these four cell lines 
(Figure 18). IHC analysis (Figure 28) from samples obtained before and after 
cisplatin treatment showed a significant expression of HDAC4 in acquired 
cisplatin resistance (7 out of 16 paired sections) with a p-value 0.039. In 
addition, the analysis of 14 paired sections from patients with platinum 
refractory ovarian cancer showed no increase in HDAC4 expression between 
the pre and post chemotherapy biopsies and supports the findings that high 
HDAC4 expression is linked with acquired cisplatin resistance in ovarian 
cancer and not with intrinsic resistance.  
 4.1.2 Knockdown of HDAC4 expression induced apoptosis in 
cisplatin-resistant ovarian cancer 
 
The functional study knockdown of HDAC4 resensitised PEO4, PEA2, PEO23 
and SKOV3 (Figures 19, 20, 21 and 22) to cisplatin-induced apoptosis, 
highlighting the significant role of HDAC4 in cisplatin-sensitivity in ovarian 
cancer. HDAC4 knockdown appears to have partially or fully restored the 
sensitivity of ovarian cancer cells towards cisplatin as evident in (Table 9). In 
patient 1, knockdown of HDAC4 has partially restored sensitivity while in 
patient 2 the restoration of cisplatin sensitivity was almost complete. Patient 3 
on the other hand, not only had cisplatin sensitivity restored but it was 
improved upon the knockdown of HDAC4. One possible reason for this is the 
smaller difference in cell line sensitivity and resistance levels of this patient 
compared with patients 1and 2. A smaller difference between the sensitivity 
and resistance to cisplatin level in the cells of a particular patient could serve 
















Table 9: Showing the sensitivity of each cell line towards cisplatin treatment alone 
and after silencing HDAC4 with siRNA. HDAC4 knockdown had partially restored the 





















The siRNA results were confirmed by using deconvoluted oligonucleotide 
siRNA comprising the HDAC4 SMARTpool siRNA to exclude possible ‘‘off-
target’’ effects and to determine the inhibition efficiency of each individual 
oligonucleotide and their effect in restoring the sensitivity to cisplatin in PEO4 
cells (Figure 23). Three out of four oligos had restored platinum sensitivity 
indicating HDAC4 knockdown certainly restores in cisplatin sensitivity and 
contribute in cisplatin resistance in ovarian cancer.  
 
Likewise, the cell proliferation assay (MTT) after 72 hours of cisplatin 
treatment (as a long term measurement for the effect of HDAC4) was used to 
validate the caspase 3/7 data (which has been performed after 24hours 
following HDAC4 knockdown). The MTT assay data showed a reduction in 
cell survival after HDAC4 knockdown and cisplatin treatment in all the 
cisplatin-resistant ovarian cancer cell lines; PEO4, PEA2 and PEO23 (Figures 
25, 26 and 27) as well as with cisplatin-sensitive PEO14. This confirms 
caspase 3/7 data that a reduction in the high level of HDAC4 sensitises the 
cells to cisplatin. However, a reduction in the low level of HDAC4 in the 
cisplatin sensitive cell; PEO1 and PEA1, did not enhance the sensitivity to 
cisplatin. This suggests that certain level of HDAC4 is required to develop 
resistance to cisplatin. Therefore, reduction in high HDAC4 level by siRNA 
restores cisplatin sensitivity. So far no study has functionally implicated the 
down-regulation of HDAC4 in ovarian cancer with re-sensitisation to platinum. 
However, the effect of silencing HDAC4 has been reported in cancer cells 
without using cisplatin treatment. For example, silencing HDAC4 without 
platinum treatment caused cell cycle arrest and apoptosis in cervical cancer 
(Cadot et al. 2009). Moreover, HDAC4 knockdown has been shown to inhibit 
the proliferation in ovarian, glioblastoma, cervical and osteosarcoma cells 
compared with HDAC1 which did not affect these cells (Mottet et al. 2009). 
This indicates the important role of HDAC4 in cell proliferation and apoptosis. 
The current study correlates silencing HDAC4 with restoration of platinum 
sensitivity in platinum-resistant ovarian cancer cell lines. Thus, HDAC4 could 
be a useful selective target to inhibit in cancer therapy.                                            
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4.1.3 Knockdown of HDAC4 in cisplatin-sensitive ovarian cancer: 
 
Having established the role for HDAC4 in cisplatin resistant cells, the role of 
HDAC4 was investigated in cisplatin sensitive cell line. The reduction in the 
low level of HDAC4 in the cisplatin sensitive cells did not increase the 
sensitivity to cisplatin (Figures 24 and 27). However, the MTT data showed 
that silencing relatively high HDAC4 decrease the cell proliferation in PEO14 
since the expression of HDAC4 is higher in PEO14 compared with PEO1 and 
PEA1. This suggests that PEO14 is relatively sensitive to platinum because of 
higher amount of HDAC4 which when depleted the cells become more 
sensitive to platinum. Therefore, this is evidence confirming the link between 
high expressions of HDAC4 in ovarian cancer cells and acquired platinum 
resistance. In addition, this finding might explain why HDAC inhibitors spare 
toxicity to normal tissues but inhibit proliferation and increasing apoptosis in 
malignant cells. It has been shown that HDAC inhibitors are relatively specific 
for malignant cells, HDAC inhibitor induced proliferation arrest and apoptosis 
in acute myeloid leukaemia (AML) cells, but not in CD34+ human normal 
myeloid progenitors cells (Nebbioso et al. 2005). Phenylbutyrate, a HDAC 
inhibitor have been reported to selectively radiosensitise tumour cells via 
suppressing DNA repair factors (DNA-PK and Ku70), nevertheless they 
protect normal cells from radio-therapy (RT) damage by keeping the DNA 
repair activity (Brown et al. 2008). Another study has shown that 
phenylbutyrate maintains the normal DNA repair activity in normal cells and 
promoting survival after radiation-induced DNA damage (Chung et al. 2009). It 
seems that HDAC inhibitors act selectively on gene expression and alter the 
expression of the genes expressed in tumour cells compared with normal cells. 
It has been reported that the induction of key proapoptotic genes (TRAIL, DR5 
and Fas) by HDAC inhibitors happens only in tumour cells and HDAC 
inhibitors do not sensitise normal cells to TRAIL-mediated apoptosis 
(Nebbioso et al. 2005; Papeleu et al. 2005). It is well known that there is a 
balance in the activity between HDACs and HATS in the normal cells. This 
might keep the level of HDACs in normal cells lower than in malignant cells. 
As a result, HDAC inhibitors selectively target the malignant cells and the 
differential effects of HDAC inhibitors on tumour and normal cell suggest the 
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use of HDACi as a novel anticancer agent to protect normal tissues from 
death and enhance the killing effect of tumours cells only.  
 
4.1.4 HDAC4 as a potential biomarker for acquired platinum 
resistance. 
 
Platinum compounds are considered the most active chemotherapy regimens 
used in patients with ovarian cancer. Therefore, it is important to find potential 
predictive markers for the effectiveness of platinum based therapy. In this 
study the hypothesis that tumours with strong HDAC4 expression will have 
poorer response on average to cisplatin treatment than those with negative or 
weak HDAC4 expression was tested. In addition, the present work set out to 
validate the high expression of HDAC4 observed in clinically acquired cisplatin 
resistant cell lines compared with their sensitive counterparts. Immuno-
histochemistry analysis for HDAC4 expression level in a clinical series of 32 
samples obtained from 16 patients before and after the development 
platinum-resistance (Figure 28) confirmed the findings observed in platinum-
resistant ovarian cancer cell lines and showed that HDAC4 levels significantly 
increased platinum resistance in ovarian cancer patients. This result indicates 
that HDAC4 can be used as a predicative biomarker in acquired platinum 
resistance of ovarian cancer patients. It would have been interesting to 
analyse more clinical biopsies from ovarian cancer patients but samples from 
clinically matched platinum sensitive and resistant ovarian cancer are difficult 
to obtain. Interestingly, an insignificant increase in the HDAC4 expression was 
found in the analysis of 14 clinically paired (pre and post chemotherapy 
biopsies) platinum refractory ovarian cancer patients suggesting that HDAC4 
expression is specifically associated with acquired platinum resistance in 
ovarian cancer but not in intrinsic platinum resistance. The identification of 
specific platinum resistance cancer-related isoforms of HDAC has therapeutic 
interest in ovarian cancer as it might lead to the development of subtype 
specific HDAC inhibitors that might have more benefits for ovarian cancer 
patients than the pan HDAC inhibitors. Other studies have attempted to 
investigate genes that could be used as biomarkers for platinum resistance in 
ovarian cancer.  
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 4.1.5 The role of HDAC inhibitors in enhancing the cytotoxicity of 
cisplatin in ovarian cancer cell lines 
 
As the knockdown of HDAC4 expression in platinum-resistant ovarian cancer 
cell lines restored platinum-sensitivity, the next step is to search for a selective 
HDAC inhibitor that targets HDAC4 in ovarian cancer cells and can be used 
as a potential adjuvant drug with platinum in ovarian cancer patients. The 
structure of SAHA, an efficient HDACs inhibitor, has been used to synthesize 
new HDAC inhibitors. Novel hydroxamate compounds, called aroyl-pyrrolyl-
hydroxyamides (APHAs) has been reported to act as HDAC inhibitors in the 
range of low micromolar-submicromolar concentrations (Mai et al. 2003). The 
Chemical manipulations performed on APHAs led to two HDAC inhibitors; 
APHA4a-MC1511 and APHA 2f-MC1568. These compounds have been 
tested for their specificity for class I and II HDACs using HDAC1 and HDAC4 
respectively. APHA4a-MC1511 has been reported to be highly effective 
against HDAC4 (75% inhibitory activity against HDAC4 at 5 µM) and 
reasonably effective against HDAC1 (50% inhibitory activity against HDAC1 at 
5 µM) on the human leukaemia U937 cell line. The other inhibitor APHA 2f-
MC1568 has been shown to inhibit HDAC4 (54.9%inhibitory activity against 
HDAC4 at 5 µM) but was not effective against HDAC1, using leukaemia cells 
(Mai et al. 2005; Mai et al. 2007). Although, APHA 2f-MC1568 was reported in 
that study to be selective HDAC4 inhibitor, its inhibitory activity was not tested 
against other members of class II and only against one member of class I 
HDACs which was HDAC1. The acetylation and HDAC4 expression levels 
were examined by western blot analysis after HDACi treatment and in 
combination with cisplatin. HDAC inhibition has been demonstrated to induce 
histones acetylation (a pharmaco-dynamic marker for the biological activity of 
HDAC inhibitors) in tumours tissues (Stimson and La Thangue, 2009). 
APHA4a-MC1511 HDAC inhibitor causes a reduction in HDAC4 protein levels 
at 5µM, 10µM and 20µM concentrations and an increase H4 acetylation at all 
concentration used. However, APHA 2f-MC1568 that was claimed to be a 
class II HDACs specific inhibitor had weak activity in enhancing the 
acetylation level of histone 4 as single agent and reduced HDAC4 protein 
level at high concentration (20uM) (Figure 29) suggesting that APHA 2f-
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MC1568 is not effective as an HDAC inhibitor. In parallel to acetylation 
assessment, apoptosis assay was used to determine the effect of HDAC 
inhibitor on cisplatin sensitivity. APHA4a-MC1511 was effective in reversing 
the resistant phenotype following cisplatin treatment at low micro-molar 
concentrations (Figure 30). The efficacy of APHA4a-MC1511 may be related 
to its selectivity against HDAC4 and partially against HDAC1 isoforms as the 
dual knockdown of HDAC1 and HDAC4 induce apoptosis following cisplatin 
treatment. However, HDAC4 knockdown alone has the highest apoptotic 
activity after cisplatin exposure in PEO4 cells compared with HDAC1 and 
HDAC3 knockdown. It seems that the inhibition of HDAC4 by APHA4a-
MC1511 is effective as a chemotherapeutic enhancement strategy and 4a-
MC1511 HDAC inhibitor should be further assessed and potentially 
considered for subsequent drug development studies in combination with 
platinum in the treatment of platinum resistant ovarian cancer. The inhibition 
of HDAC4 expression using HDACi cannot mimic that produced by 
knockdown of HDAC4 using siRNA. The reason is attributed to the specific 
isoform inhibition of HDAC4 by siRNA compared with more general inhibition 
of HDAC4 and other HDAC isoforms by HDAC inhibitors.  
 4.1.6 HDAC4 expression following cisplatin treatment in ovarian 
cancer:  
 
The expression of HDAC4 has been reported to be altered after DNA damage 
(Kao et al. 2006). The latter study associated HDAC4 presence with double-
stranded DNA repair mechanisms suggesting that HDAC4 is one of the 
proteins that form foci at the site of double strand DNA breaks. Moreover, 
HDAC4 foci were shown to overlap with foci of the DNA repair proteins Rad51 
and 53BP1 in HeLa cells following exposure to γ-irradiation (Kao et al. 2003) 
proposing that these proteins may recognize and repair double-stranded DNA 
breaks caused by ionizing radiation in human non–small cell lung cancer. 
Here, HDAC4 expression was assessed following time course of cisplatin 
treatment. HDAC4 expression was lost 8 hours post cisplatin treatment, in 
cisplatin sensitive PEO1 cells suggesting that these cells lose HDAC4 
expression and dye after cisplatin treatment. However, in cisplatin resistant 
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cell PEO4, the expression of HDAC4 was strong and increased 12 hours after 
cisplatin treatment with accompanying significant loss of HDAC4 at 24 hours 
post treatment. This may show that HDAC4 play a role in DNA damage repair 
during cisplatin treatment and the loss of HDAC4 meant that the cells are not 
able to repair the DNA damage therefore, dying from cisplatin exposure. 
Moreover, inhibition of HDAC4 via siRNA sensitises the cells to radiotherapy 
in HeLa cells illustrating that HDAC4 is required for double-stranded DNA 
breaks repair. HDAC4 nuclear translocation has been shown to be required 
for double-stranded DNA breaks suggesting that HDAC4 may play a role in 
the regulation of genes that are involved in DNA repair (Basile et al. 2006; 
Geng et al. 2006). In PEO1, phosphorylation of histone H2AX increased at 
4hours post cisplatin when HDAC4 disappeared. However, in PEO4, H2AX 
phosphorylated at 24hours when HDAC4 expression decreased following 
cisplatin treatment. This shows that there is an inverse correlation between 
HDAC4 and H2AX; also it suggests that HDAC4 expression may be linked to 
the DNA damage response pathway which HDAC4 perhaps acts as a pro-
survival factor by promoting DNA damage repair in cisplatin-resistant ovarian 
cancer. Microarray study was used to identify the HDAC4 signature which 
may correlate to DNA damage response, either through repression of pro-
apoptotic gene expression or through the activation of anti-apoptotic genes. In 
addition, immunofluorescence confirmed western blot data as the cytoplasmic 
HDAC4 was abundant in cisplatin resistant cells and scarce in cisplatin 
sensitive cells when these cells were untreated with cisplatin. Following 
cisplatin treatment, the co-localization of HDAC4 with H2AX in cisplatin 
resistant cells was detected at 24hours. These results show that cisplatin 
induces the translocation of HDAC4 from the cytoplasm to the nucleus in both 
platinum-resistant and platinum sensitive cells (Figures 34, 35 and 36). This is 
in broad agreement with previously reported results by Kao et al. 2003 that 
DNA damage caused by ionizing radiation induces HDAC4 foci formation in 
the nucleus and suggesting that HDAC4 mediate the response to DNA 
damage. Moreover, it has been reported that HDAC4 is able to translocate 
from the cytoplasm to nucleus and interact with HDAC3 to repress target gene 
expression and the association of Class II HDACs with 14-3-3 protein results 
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in the sequestration of HDACs proteins in the cytoplasm (Grozinger and 
Schreiber, 2000). This implies that cellular localization may be essential for 
transcriptional regulation by HDAC4 and suggests that nuclear accumulation 
of HDAC4 could lead to transcriptional silencing of the genes that are 
responsible for the resistance phenotype. Furthermore, it has been 
demonstrated that some of non-histone proteins are also subject to 
acetylation by HDACs in the nucleus and cytoplasm (Chen et al. 2008). 
Therefore, HDAC4 is likely to change the acetylation of certain non-histones 
proteins that are involved in cisplatin resistance. Other possibilities cannot be 
excluded such as that nuclear HDAC4 may promote DNA repair, prevent DNA 
damage or enhance cell growth in cisplatin-resistant ovarian cancer. In 
addition, HDAC4 is one of the proteins that have been shown to form nuclear 
foci upon exposure to double-strand DNA damage (Kao et al. 2003). Knowing 
that increased DNA adduct repair by DNA repair systems is one of the 
cisplatin-resistance mechanisms that limit the effectiveness of cisplatin 
suggests that HDAC4 may contribute to DNA damage response/DNA repair 
system. However, HDAC4 molecular function in double-stranded DNA breaks 
repair remains to be fully clarified.  
4.2 The role of HDAC1 and HDAC3 in cisplatin 
resistance: 
 
  4.2.1 HDAC1 and HDAC3 are up-regulated in cisplatin resistant 
cells: 
 
HDACs class I, are well-known transcriptional co-repressors especially 
HDAC1 and HDAC3 which were reported to be expressed in ovarian cancer in 
comparison with normal ovarian tissues (Khabele et al. 2007). HDAC1 and 
HDAC3 have shown to be over-expressed in serous, mucinous and 
endometrioid ovarian cancer tissues normal tissues indicating the important 
role of these enzymes in ovarian carcinogenesis (Jin et al. 2008). Further 
studies showed that knocking down of HDAC1 suppresses ovarian cancer cell 
proliferation and silencing HDAC3 reduces the cell migration (Hayashi et al. 
2010). This points to the role HDAC1 and HDAC3 may have in regulating the 
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genes responsible for cell proliferation in cancer. Therefore, baseline 
expressions of all class I and II HDAC enzymes were screened at the mRNA 
levels using qRT PCR in the ovarian cancer isogenic cell lines. HDAC1 and 
HDAC3 follow the same pattern of up-regulation as HDAC4 in the cisplatin-
resistant cell lines (Figures 37 and 38). These results indicate class I HDACs, 
HDAC1 and HDAC3 might be expressed during the early stages of tumour 
formation and as tumours get established and resistance to cisplatin treatment 
is developed, HDAC4 is then expressed. This highlights the different biological 
roles each HDAC isoforms play in human tumours. HDAC4 expression is 
associated with cisplatin resistance and HDAC1 and HDAC3 may be 
associated with ovarian cancer progression. Thus, HDAC 1 and HDAC3 over- 
expression may be used as a predictive marker for ovarian cancer 
development.  
  
  4.2 .2 the interaction of HDAC1 and HDAC3 with HDAC4 and its 
effects on cisplatin resistance:  
 
Class II HDACs including HDAC4 has been suggested to regulate 
transcription when associated with NCoR/SMRT-HDAC3 complex and they 
become enzymatically inactive when disassociated from this complex (Fischle 
et al. 2002). The interaction between HDAC4 and HDAC3 has been 
previously reported (Grozinger and Schreiber, 2000). Therefore, the IP 
interaction between HDAC1/HDAC3 and HDAC4 was examined because both 
HDAC1 and HDAC3 were found to be up-regulated in the cisplatin resistant 
cell lines in a similar way to HDAC4 (Figures 39 and 40). HDAC4 was found to 
interact with HDAC3 as well as with HDAC1 indicating that these interactions 
may contribute to HDAC4 nuclear activity as a transcriptional suppressor. 
Furthermore, these interactions were observed in both cisplatin treated (where 
nuclear HDAC4 is more than cytoplasmic HDAC4) and untreated (where 
cytoplasmic HDAC4 is more than nuclear HDAC4) cells. This suggests that 
HDAC4 might possess a high deacetylase activity which is associated with the 
complex during cisplatin treatment as this treatment induces the translocation 
of HDAC4 to the nucleus. However, it is possible that cytoplasmic HDAC4 
possess a different activity that is not associated with this complex as it has 
 175 
been demonstrated that Class II HDACs possess a measurable intrinsic 
deacetylase activities in vitro  (Lahm et al. 2007). Owing to the up-regulation 
of HDAC1/HDAC3 in cisplatin resistant cells and interaction with HDAC4, it is 
likely that these two enzymes have a role in cisplatin re-sensitisation as well 
as HDAC4. HDAC4 knockdown was most effective in enhancing the 
sensitivity to cisplatin in resistant cell lines compared with HDAC1 and HDAC3 
knockdown individually or the dual knockdown of HDAC1+3, HDAC1+4 and 
HDAC3+4. Silencing HDAC1 alone was more effective in restoring cisplatin- 
sensitivity than HDAC3 (Figures 41, 42 and 43) and there was no 
considerable increase of apoptotic activity beyond cisplatin treatment after 
dual knockdown of HDAC3+HDAC4. This may suggest that HDAC3 is 
essential in cisplatin-sensitivity restoration caused by silencing HDAC4. As the 
increase of HDAC3 after HDAC4 knockdown also supports this suggestion. In 
addition, HDAC4 knockdown seems to decrease HDAC1 level significantly. 
HDAC4 exists in a complex with other proteins such as HDAC1 and HDAC3, 
the loss of HDAC4 might affect these other proteins in the complex making it 
possible to observe a decrease in the level of HDAC1. However, the up-
regulation in HDAC3 after HDAC4 knockdown may be due to wider 
association with other of HDACs class II. This might point to the role of 
HDAC4 in the regulation of HDAC1 and HDAC3 in ovarian cancer. Together 
these data indicate that HDAC4 has a main role in cisplatin-resistance in 
ovarian cancer and the interaction with HDAC1 and HDAC3 might suggest a 
further function associated with this interaction in the resistant cells.  
4.3 HDAC4 and STAT1 modulate the resistance in 
ovarian cancer cell lines: 
  4.3.1 HDAC4 interacts with STAT1 in ovarian cancer cells: 
 
(STAT1) The Signal Transducer and Activator of Transcription 1, was one of 
the genes that was over-expressed in ovarian cancer cisplatin resistant cells 
compared with the cisplatin sensitive cell lines as shown in the microarray. 
STAT1 is a member of the STATs family of transcription factors that contain 
seven cytoplasmic proteins and have roles as signal messengers and 
transcription factors that participate in cellular responses to cytokines and 
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growth factors (Levy and Darnell, 2002; Schindler et al. 2007). STAT1 is a 
latent cytoplasmic transcription factor until activated by extracellular stimuli. 
Following activation, STAT1 translocates into the nucleus where it binds to 
specific sites to enhance gene transcription (Gupta et al.1996). 
Phosphorylation of STAT1 on Tyrosine 701 is essential for its functional 
activity and works as a molecular switch between dormant cytoplasmic STAT1 
and active nuclear STAT1 (Shuai et al.1994). In the nucleus, the 
phosphorylation sites of STAT1 itself can be targeted by Suppressors of 
Cytokine Signalling (SOCS) that inhibit STAT1 phosphorylation by binding and 
inhibiting JAKs enhancing STAT1 nuclear export (Krebs and Hilton, 2001). 
STAT1 has been shown to be negatively regulated by Protein Inhibitors of 
Activated STATs (PIAS). PIAS inhibits transcriptional activation by STAT1 
through binding and blocking access to the DNA sequences that STAT1 
recognises in the nucleus (Shuai, 2006). STAT1 can associate with co-
activators like histone acetyl transferases (HATs) or co-repressors like histone 
deacetylases (HDACs) to modulate the transcriptional accessibility of the 
chromatin. STAT1 activation can induce both synergistic activation and 
inhibition of gene transcription (Kouzarides, 2007). It has been estimated, that 
several hundred genes are under the transcriptional control of STAT1; 
including genes involved in cell cycle regulation such as p21 and c-myc. 
Knockout studies have provided evidence that STAT proteins are also 
involved in the development and function of the immune system and play a 
role in maintaining immune tolerance and tumour surveillance (Durbin et 
al.1996; Meraz et al.1996). Moreover, the expression of STAT1 was shown to 
be associated with cisplatin resistance in ovarian cancer. cDNA microarray 
was used to evaluate the expression of approximately 4000 genes in a panel 
of 14 unrelated human ovarian cancer cell lines derived from patients who 
were either untreated or treated with platinum-based chemotherapy. The 
correlation analysis of the microarray data with respect to drug sensitivity and 
resistance revealed an association of STAT1 expression with decreased 
sensitivity to cisplatin (Roberts et al. 2005). Moreover, HDACs also appear to 
have a role in STAT1 acetylation. HDAC inhibitor VPA, a selective inhibitor for 
the class I HDACs was reported to induce STAT1 acetylation. Moreover, co-IP 
experiments showed that STAT1 forms complexes with HDAC1 and HDAC3. 
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Knockdown of HDAC3 promoted STAT1 acetylation. Thus, HDAC1 and 
HDAC3 are the likely STAT1 deacetylases (Kramer et al. 2006). Therefore, 
the influence of HDAC4 on STAT1 gene was investigated to explore the 
involvement of HDAC4 in this process. The interaction between HDAC4 and 
STAT1 was identified by immunoprecipitation in both resistant and sensitive 
ovarian cancer cell lines indicating that HDAC4 might play a role in STAT1 
regulation (Figure 43).  
 
 4.3.2 The expression of HDAC4 and pSTAT-1 upon cisplatin 
exposure: 
 
Interferon-g (IFN-g), a potent anti-proliferative cytokine has been shown to 
modulate STAT-regulated transcription by affecting STAT phosphorylation 
and consequently mediating changes in gene transcription (Nguyen et al. 
2001; Zhao et al. 2005). In this study, cisplatin induced the phosphoraylation 
of STAT1 in cisplatin resistant cell lines. The IP analysis has showed that 
HDAC4 and STAT1 interact in ovarian cancer cells.  Therefore, the 
expression of HDAC4 and STAT1 was examined by western blot. The pattern 
of expression of these two genes following cisplatin exposure was different. 
HDAC4 expression increases at 2 and 4 hours and peaked at 12 hours. 
While, the expression of pSTAT1 seems to peak at 24hrs then decrease at 48 
hours (Figure 44), the expression of pSTAT1 and HDAC4 was different at 
24hrs following treatment with cisplatin, when HDAC4 started to decrease and 
pSTAT1 reached its highest expression. STAT1 have been reported to 
translocate to the nucleus to mediate gene transcription activity and apoptosis 
(Townsend et al. 2004). It is possible to speculate that deacetylation of STAT1 
by HDAC4 activity is required for STAT1 phosphorylation to occur. HDAC4 
activity initiate the process by removing acetyl groups from STAT1 permitting 
the phosphorylation of STAT1 in ovarian cancer cells. It has also been shown 
that HDAC3 deacetylates STAT1 allowing phosphorylation which this is 
reversed by dynamic acetylation to switch STAT1 between different functional 
modes in (HeLa cell) cervical cancer (Kramer and Heinzel, 2010; Kramer et al. 
2009). This shows that HDAC4 have a role in STAT1 phosphorylation and 
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deacetylation. The interaction between STAT1 and HDAC1/HDAC3 was not 
investigated in the present work. Therefore, it could be that HDAC4 form a 
complex with HDAC3 and probably HDAC1 in ovarian cancer cells and these 
three enzymes involved in STAT1 deacetylation and phosphorylation. All of 
this suggests that HDAC activity might be an essential factor for STAT1-
dependent gene expression. 
 
 4.3.3 Increased STAT1 acetylation in cisplatin-resistant cells 
following HDAC4 knockdown 
 
There is increasing evidence that HDACs deacetylate not only histones but 
also non-histone proteins as well. Acetyl STAT1 was not detected in cisplatin 
resistant cells expressing high levels of HDAC4. However, reduction in 
HDAC4 enhances acetyl-STAT1 in these cells compared with untransfected 
cells. On the other hand, in the cisplatin sensitive cells, acetyl-STAT1 was 
detected in both untransfected and HDAC4 siRNA transfected cells (Figure 
45). This proposes that the acetylation level of STAT1 is controlled by the 
level of HDAC4 in the cells. In cisplatin-resistant cells, loss of HDAC4 caused 
increasing STAT1acetylation and high HDAC4 levels decreased STAT1 
acetylation indicating a direct role for HDAC4 in the deacetylation of STAT1. 
These observations prove that HDAC4 modulates the deacetylation status of 
STAT1 and show that HDAC4 level in the cells could be used as a predicator 
for STAT1 acetylation level in both cisplatin-resistant and sensitive ovarian 
cancer cells. It has been reported that some of HDAC isoforms affect the 
deacetylation level of non-histone proteins. For example, HDAC6 has been 
reported to interact with tubulin in the cytoplasm (Hubbert et al. 2002; 
Matsuyama et al. 2002). HDAC6 has been shown to deacetylate tubulin and 
Hsp90, thus affecting cell morphology, adhesion and migration (Kekatpure et 
al. 2009; Valenzuela-Fernandez et al. 2008). A significant increase in tubulin 
and Hsp90 acetylation was found in HDAC6-deficient mice despite this, 
however, the mice were viable. Thus, HDAC6 can modulate the acetylation of 
tubulin and Hsp90.  Moreover, it has been reported that the acetylation status 
of STAT1 is determined by the balance of STAT1-associated histone 
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deacetylases (HDACs) and histone acetylates (HATS) and this might be 
another molecular switch reducing anti-apoptotic signalling via binding of 
STAT1 to nuclear factor kappa B (NF-κB) binding in melanoma cells. 
Increased acetylation of STAT1 was shown following HDAC inhibition (Kramer 
et al. 2006). These authors showed that class I HDACs, HDAC1 and HDCA3, 
co-immunoprecipitated with STAT1 however the class II HDACs, which 
includes HDAC4, were not analysed in their study. In ovarian cancer cells, 
acetylation and phosphoraylation level of STAT1 appears to be dependent on 
the level of HDAC4 in the cells. Reduction of HDAC4 enhanced the 
acetylation and the phosphoraylation of STAT1 in the resistant cells. 
Therefore, HDAC4 may control the balance of acetyl-STAT1 and p-STAT1.  
 
 4.3.4 HDAC4 inhibition via siRNA or HDACi treatment averts 
pSTAT nuclear localization subsequent to cisplatin treatment in 
the cisplatin-resistant cells 
 
It has been shown that phosphorylated STAT1 complexes translocate to the 
nucleus, where they specifically bind to the promoters of certain gene 
controlled by STAT1 such as IFN-stimulated genes to exert growth inhibition 
of cultured cells (Bromberg et al.1996). STAT1 phosphorylation has been 
reported to be prevented by HDACi highlighting the role of HDAC in STAT1 
phosphorylation in colon cells (Klampfer et al. 2004). The co-localization of 
HDAC4 and pSTAT1-Y701 in the nucleus after 24hours of cisplatin treatment 
was observed (Figure 46). HDAC4 inhibition via siRNA or by using APHA4a 
prevented the phosphorylation of STAT1 at Y701 following cisplatin treatment 
in cisplatin-resistant cells. A dynamic regulation of STAT1 phospho-acetyl 
levels is controlled by HDAC4 activity. STAT1 is activated, phosphorylated 
and translocated to nucleus following cisplatin treatment in ovarian cancer 
cells with acquired clinical platinum resistance but not platinum sensitive cells 
indicating that the over-expression of HDAC4 promotes de-acetylation of 
STAT1 and this permit STAT1 phosphorylation at Y701 and its subsequent 
nuclear translocation. STAT1 knockdown in resistant ovarian cancer cells 













Figure 57: SiRNA-mediated silencing of lamin and STAT1 on PEO4 cells followed by 
Caspase Glo 3/7 based apoptosis assay. Cells were transfected with 100 nM siRNA 
targeting lamin and STAT1. Cell viability was measured by MTT assay at 24 h. 
Caspase3/7 data are normalized to MTT data are means ± SEM from three separate 
experiments, each performed in triplicate. P-value: 0.0002. This experiment was 










In contrast, isogenically matched cisplatin sensitive cells have low HDAC4 
level therefore; acetyl-STAT1 is present which might explain the inability of 
cisplatin treatment to induce phospho-STAT1 Y701 in these cells. 
Furthermore, the reduction of HDAC4 in platinum resistant cells by increasing 
the acetylation level of STAT1 which later induce apoptosis following cisplatin 
treatment is similar to low level of HDAC4 in cisplatin sensitive cells. These 
data show that the level of HDAC4 expression differentiate between the 
response of STAT1 in clinical platinum sensitivity and acquired platinum 
resistance and identify a novel mechanism involving HDAC4 and STAT1 
interaction to alter the apoptotic response to platinum in ovarian cancer cells 
with acquired resistance (Figure 47). 
 
 Here, the pharmacological modulation of HDAC4 using the HDAC inhibitors 
resulted in inhibitory effects on both the STAT1 and HDAC4. Furthermore The 
inhibition of histone deacetylase (HDAC) activity by butyrate, trichostatin A, 
and suberoylanilide hydroxamic acid has been shown to prevent STAT1 
phosphorylation, its nuclear translocation, as well as STAT1-dependent gene 
activation (Klampfer et al. 2004). Together these data show that HDAC4 
inhibition changes the phosphorylation of STAT1 and nuclear translocation in 
resistant ovarian cancer cells following cisplatin treatment. In addition, STAT1 
acetylation depends on the balance between STAT1-associated HDACs and 
HATs and inhibition of HDAC4 changes this balance and induces STAT1 
acetylation. The exact mechanism that causes the resensitisation to cisplatin 
via HDAC4/STAT1 is unknown. However, the data show evidence that the 
acquisition of resistance can be reversed by HDAC inhibitors in ovarian 
cancer. 
 
4.4 Identification of HDAC4-regulated genes by 
microarray: 
 
The data presented in the current work showed that HDAC4 knockdown in 
platinum-resistant ovarian cancer cells restores the sensitivity to cisplatin by 
modulating the acetylation and gene expression of genes such as STAT1. 
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Therefore, in order to identify HDAC4 signature which may correlate HDAC4 
to DNA damage response, either through repression of pro-apoptotic gene 
expression or activation of anti-apoptotic genes, microarray analyses were 
carried out using RNA from PEO4 cells transfected with siRNA against 
HDAC4, Lamin A/C (as control) and untransfected PEO4 cells. Differentially 
expressed genes were compared between untransfected versus HDAC4 
knockdown, untransfected versus Lamin A/C knockdown and HDAC4 
knockdown versus Lamin A/C knockdown generated using Genechip 
Operating System (GCOS) using random variance analysis with a P-value cut 
off of 0.01. A random variance model for the detection of differential gene 
expression was used as it is recommended for small microarray experiments 
to generate more accurate and robust variance estimation (Wright and Simon, 
2003). Subsequently, the overlapped genes between untransfected versus 
HDAC4 knockdown and HDAC4 knockdown versus Lamin A/C knockdown 
were selected for further investigation. This provides strict criteria for selecting 
differentially expressed genes but the assumption is that those overlapped 
genes are the ones which are most significant and are most likely to be of 
biological interest.  
 
Microarray has been used to generate transcriptional profiles to determine the 
functional consequence of HDAC inhibition on gene expression (Chambers et 
al. 2003; Peart et al. 2005). These studies have reported that about 8-10% of 
genes were altered by pan HDAC inhibitors; trichostatin A, SAHA, 
depsipeptide suggesting that certain genes are regulated by HDACs. Here the 
analyses identified twenty-four genes that appear to be regulated by HDAC4. 
The twenty-four differentially expressed genes were those overlapped 
between HDAC4-knockdown versus Lamin-knockdown array and HDAC4-
knockdown versus untransfected array but not present in untransfected 
versus Lamin-knockdown array. Eight out of the 23 genes were up-regulated 
and 15 were down-regulated in PEO4 cisplatin resistant cells following 
HDAC4 knockdown by siRNA compared with controls (untransfected and 
lamin knockdown). The analysis confirmed HDAC4 knockdown in the array 
(Table 7).  
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4.5 HDAC4 regulates the expression of UCHL1: 
 
   4.5.1 UCHL1 methylation status correlates with its protein 
expression in the isogenic ovarian cancer cell lines:  
 
UCHL1 (Ubiquitin carboxy-terminal hydrolase L1), also called PGP9.5, is a 
protein of 223 amino acids (Wilkinson et al.1989). The gene of this protein is 
up-regulated after HDAC4 knockdown in PEO4 cells. UCHL1 gene is probably 
involved in modulating cellular protein degradation through the ubiquitin 
proteasome to eliminate unwanted proteins. UCHL1 is a member of the 
ubiquitin carboxy-terminal hydrolase family of deubiquitinating enzymes 
(Wilkinson et al.1989) and mutations in UCHL1 was implicated in Parkinson 
disease, a human neurodegenerative disorders (Xue and Jia, 2006). This 
enzyme is found in nerve cells throughout the brain and immunohistochemical 
experiments demonstrated that it is exclusively localized in neurons, forming 
about 5-10% of cytoplasmic proteins (Wilson et al.1990). UCHL1 is also 
involved in controlling the intracellular proteolysis, protein turnover and 
regulatory processes, which are important in maintaining normal cellular 
homeostasis (Day and Thompson, 2010).  
 
There is conflicting evidence about the role of UCHL1 in cancer varying from 
anti-tumour to pro-tumour properties depending on the tumour type examined. 
Immuno-histochemistry analysis has shown high expression of UHCL1 in 
esophageal squamous cell carcinoma as well as in gastric cancers samples 
suggesting that this protein can be a potential cancer marker in these tumours 
(Takase et al. 2003). The level of UCHL1 expression was assessed by 
Western blot analyses and Immuno-histochemistry and was found to be 
associated with the metastatic phenotype of renal cell carcinoma when 
compared with primary renal cell carcinoma lesions as a result UCHL1 was 
suggested to be a potential biomarker for the diagnosis and prognosis of renal 
cell carcinoma patients (Seliger et al. 2007).  
 
On the other hand, the methylation of UCHL1 was proposed to disturb cellular 
ubiquitin levels of DNA methylation at CpG dinucleotides within the promoter 
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region of UCHL1 gene and this is a common event in the pathogenesis of 
tumours including ovarian cancers. UCHL1 methylation has been reported in 
metastatic colorectal cancer (Fukutomi et al. 2007; Mizukami et al. 2008) and 
ovarian cancers (Okochi-Takada et al. 2006). In addition, UCHL1 was found 
to be frequently methylated in pancreatic (Sato et al. 2003), gastric, colon 
(Kagara et al. 2008), ovarian and head neck squamous cell cancers 
(Tokumaru et al. 2004). This might indicate different function for UCHL1 in 
different cancer types. The methylation of UCHL1 that was detected by the 
DNA methylation arrays in PEO1 and PEO4 but not in PEA1, PEA2, PEO14 
and PEO23 cell lines suggesting that the role of UHCL1 in ovarian cancer is 
cell type specific (Table 8 ). 
 
The assessment of UCHL1 protein level showed that there is correlation 
between the DNA methylation arrays results and the protein expression of 
these cell lines. High expression of UCHL1 protein level in PEA1, PEA2, 
PEO14 and PEO23 cell lines and no expression in PEO1, PEO4 (Figure 49). 
The absence of UCHL1 protein expression in PEO1 and PEO4 cell lines could 
indicate that UCHL1 is methylated and the presence of UCHL1 in PEA1, 
PEA2, PEO14 and PEO23 cell lines indicate that UCHL1 is unmethylated. 
Interestingly, no protein expression of UCHL1 was found in SKOV3 cell line 
but it is expressed in OSAC2 (normal ovarian cell line) suggesting that UCHL1 
may act as a tumour suppresser gene and therefore, the expression of 
UCHL1 is absent in cisplatin-resistant cell line but present in normal ovarian 
cells. Furthermore, UCHL1 has been proposed to function as a regulator of 
apoptosis in neural cells (Harada et al. 2004). It has been shown that the 
functional loss of UCHL1 in gracile axonal dystrophy (gad) mice with an exon 
deletion for UCHL1 lead to significantly high expression levels of anti-
apoptotic (Bcl-2 and XIAP) and pro-survival (brain-derived neurotrophic factor) 
after stress stimuli suggesting that loss of UCHL1 may decrease cytochrome c 
release from mitochondria and later caspase inactivation in gad mice leading 
to survival (Harada et al. 2004). Thus, it is possible that the presence of 
UCHL1 in ovarian cell enhances the suppression of Bcl-2 which leads in turn 
to altered mitochondrial membrane permeability resulting in the release of 
cytochrome c into the cytosol. The release of cytochrome c could activate 
 185 
caspase leading to apoptosis in response to chemotherapy. Conversely, the 
loss or silencing of UCHL1 in ovarian cancer enhances the survival of cells 
during the chemotherapy treatment leading to resistance. The exact 
mechanism by which UCHL1 regulates apoptosis during chemotherapy 
treatment remains unclear. However, the interaction between HDAC4 and 
UHCL1 in both cisplatin sensitive and resistant cancer cells was not reported 
before and indicate that HDAC4 may directly regulate the expression of 
UCHL1.  
 
 4.5.2 No change in UCHL1 methylation level following HDAC4 
knockdown. 
 
The role of HDAC4 in regulating UCHL1 was further investigated as the up-
regulation of UCHL1 mRNA after HDAC4 knockdown shows that HDAC4 
might be involved in changing the methylation of UCHL1 and leading to an 
increase in its mRNA level in PEO4 cells. However, pyrosequencing analysis 
on PEO1 and PEO4 comparing untransfected, lamin knockdown and HDAC4 
knockdown using two primers covering different regions to quantify the 
methylation status of UCHL1 detected insignificant change in UCHL1 
methylation level in both PEO1 and PEO4 cells but validate the methylation 
status of UCHL1 observed in the DNA methylation arrays. This is in broad 
agreement with the previously reported promoter methylation of UCHL1 in 
ovarian cancer cell lines and primary ovarian cancers (Okochi-Takada et al. 
2006). Moreover, the methylation status of UCHL1 in PEO1 cells was identical 
at about 80% when both primers were used (highly methylated). Nevertheless, 
the primers gave different methylation levels in PEO4 which were 50% 
(partially methylated) and 90 %( highly methylated) indicating different degree 
in UCHL1 methylation in these cell lines (Figures 50 and 51). This suggested 
that different sites of UCHL1 have different methylation levels and could 
possibly distinguish between the cisplatin-resistant and sensitive cells. Here, 
the hypothesis that HDAC4 inhibition by siRNA could change the level of 
methylated UCHL1 in ovarian cancer seems invalid based on the 
pyrosequencing data but it is possible that HDAC4 inhibition may involve 
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different mechanism to enhance the mRNA expression of UCHL1 in PEO4 
following HDAC4 silencing.  
4.5.3 Silencing HDAC4 changes the acetylation level of UCHL1 
 
The up-regulation of UCHL1 observed in HDAC4 knockdown array could be 
associated with HDAC4 influencing the acetylation at the UCHL1 locus.  
Chromatin-immunoprecipitated analysis showed HDAC4 knockdown 
increased the amount of ChIP-enriched DNA at UCHL1 promoter region 
compared with control lamin knockdown. Nevertheless, no change was 
observed in PPIA control gene as quantified by qRT-PCR (Figure 52). For this 
reason, UCHL1 could act as a tumour suppressor gene in PEO1 and PEO4 
ovarian cancer cells since silencing UCHL1 is considered as a common event 
in tumour cells. Reduction of HDAC4 enhances the expression of UCHL1 as 
seen in PEO4 cells and identifying the important role of HDAC4 in regulation 
of UCHL1 gene in ovarian cancer. HDAC inhibitors have been demonstrated 
to up-regulate genes that have been epigenetically silenced in cancers. 
UCHL1 expression was found to be increased after 5Aza-dC and SAHA 
treatment in pancreatic cancer PANC-1 cells (Kumagai et al. 2009). However, 
since SAHA inhibits both class I and class II HDACs, it becomes difficult to 
conclude which particular HDAC is responsible for this observation. This study 
specifies that HDAC4 is the key protein that alters the acetylation level of 
UCHL1 in ovarian cancer cells.  
 
Similarly, it has been reported that silencing tumour suppressor genes might 
occur by epigenetic alterations including aberrant hypermethylation of the 
promoter region and chromatin modification accompanied by histone 
deacetylation. For example, the acetylation and methylation of chromatin 
associated with ras homologue member I (ARHI) promoter was suggested to 
result in the loss of its expression.  ARHI  is a tumour suppressor in the ras 
super family that was found to be  down regulated or lost in about 70% of 
ovarian and breast cancers. Knockdown of HDAC1, HDAC3 and HDAC 11 in 
breast cancer cells increased the expression of ARHI at mRNA level and  
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HDACi  activate  its expression (Feng, Lu et al. 2007; Lu, Luo et al. 2006; 
Wang, Hoque et al. 2003; Rosen, Wang et al. 2004). 
 
4.6 The effect of HDAC4 on p21 / WAF1 in ovarian 
cancer cells: 
 
4.6.1 P21 up-regulated in cisplatin resistant cells: 
 
P21 gene was one of the down-regulated genes after HDAC4 knockdown in 
PEO4 cisplatin-resistant ovarian cancer cells as detected by lamin knockdown 
versus HDAC4 knockdown arrays. However, p21 is one of the best known 
targets for HDAC inhibitors and its induction has been previously reported as 
due to the selective inhibition of Class I HDACs (Hecker et al. 2010; Mai et al. 
2005; Romanov et al. 2010). Therefore, p21 was investigated further in this 
study to clarify the role of HDAC4 in its regulation in ovarian cancer. The basal 
expression was assessed in the isogenic cells and the data showed that in all 
ovarian cancer cisplatin resistant cells (PEO4, PEO6, PEA2 and PEO23) the 
expression of p21 was significantly higher than cisplatin-sensitive counterparts 
at both mRNA and protein levels (Figure 54). The expression pattern of p21 
was similar to HDAC4 and both were up-regulated in the resistant cells. The 
expression of these genes, p21 and HDAC4, was not previously associated 
with cisplatin-resistance in ovarian cancer. The basal expression of p21 
appears an important factor in relation to cell sensitivity to cisplatin in ovarian 
cancer cells.  
 
P21 is known as cyclin-dependent kinase inhibitor 1 or CDK-interacting 
protein 1 (el-Deiry et al.1993). It is considered as a potent cyclin-dependent 
kinase inhibitor (CKI) that binds to and inhibits the activity of cyclin-CDK2 or 
cyclin-CDK4 complexes, and as a result functions as a monitor of cell cycle 
progression at G1. The expression of p21 is controlled by the tumour 
suppressor protein p53, which mediates the p53-dependent cell cycle G1 
phase arrest in response to a variety of stress stimuli (Bendjennat et al. 2003). 
It has been shown that p21 knockout mice are impaired in their ability to 
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undergo G1 arrest following DNA damage whereas this knockout had no 
effect on p53-dependent apoptosis following irradiation (Brugarolas et al.1995; 
Deng et al.1995). Therefore, p21 may not depend on p53 for all its activities. 
Furthermore, no correlation was found between p21 and p53 in ovarian 
cancer cells (Schmider et al. 2000). Additionally, the ovarian cancer cell lines 
used in this study are p53 mutants and nonetheless, p21 protein and mRNA 
were detected in all the isogenic cells indicating that the expression of p21 is 
not dependent on p53 status in the cells. P21 was considered to be a tumour-
suppressor and it was identified as a key mediator of p53-dependent cell cycle 
arrest. Reviewed in (Gartel, 2009).  
 
On the other hand, it has been suggested that p21 may also act as an 
oncogene because it was also found to inhibit apoptosis in mouse models (De 
la Cueva et al. 2006) and in human cancer (Shah et al. 2005).  Thus, p21 
appears to play a role as a tumour suppressor, but it also behaves as an 
oncogene in certain cell types at the same time. Reviewed in (Abbas and 
Dutta, 2009). The expression of p21 was associated with early stage in FIGO 
classification and showed a better overall survival for cases with strong p21 
expression (79 months versus 40 months for weak expression). Normal levels 
of p21 RNA was detected in 4 out of 7 (57%) cancers with wild-type p53 
(Elbendary et al. 1996). Furthermore, the role for p21 in ovarian cancer in 
response to cisplatin treatment has been reported by Poulain et al.1998, 
showing an accumulation of p53 in cisplatin sensitive IGROV1 cells in 
response to cisplatin and, in parallel, induction of p21 expression at a nuclear 
level. However, p53 remained over-expressed during the 4 weeks after 
cisplatin treatment; unlike, the p21 expression which went down during the 
same period of time (Smith and Fornace, 1996). This might suggest that the 
low of level of p21 that was observed in cisplatin sensitive cells may increase 
in response to cisplatin leading to cell cycle arrest and apoptosis (Zamble et 
al.1998). 
 
However, it is possible that p21 could follow different pathway in responding to 
platinum in acquired cisplatin resistant cells as the level is higher compared 
with the sensitive cells. Additionally, it is possible that cisplatin resistant cells 
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may restore the oncogenic function of p21 to inhibit apoptosis or p21 might 
undergo different modification depending on the level of HDACs in the cells. 
Since the level of both HDAC4 and p21 are up-regulated in the resistant cells, 
it is likely that HDAC4 regulate the expression of p21 in ovarian cancer cells. 
Therefore, p21 expresses differentially between the resistant and the sensitive 
cells by elevating the level in cisplatin resistant cells where HDAC4 level is 
high to allow the cells to overcome the cell cycle checkpoints and to escape 
apoptosis. Moreover, the loss of p21 has been shown to increase the 
sensitivity to ionizing radiation in ataxia telangiectasia mutated (ATM) deficient 
mice (Wang et al.1997) suggesting that this mechanism may operate in 
cisplatin sensitive cells where p21 level was low. In addition, it has been 
reported that acquired platinum resistance can be mediated by secondary 
mutations in BRCA1/2 that restore the wild-type BRCA1/2 reading frame. 
Restoring BRCA1/2 function generates resistance to cisplatin therapy (Sakai 
et al. 2009) and proposes that genetically heterogeneous clones may exist 
within the tumour mass before treatment and populations with advantageous 
mutations are selected for survival subsequent to clearance of the sensitive 
clone (dominant clone) by chemotherapy. Otherwise, cisplatin resistance 
could develop by mutation under the selective pressure of chemotherapy 
(Agarwal and Kaye, 2003). Genetic heterogeneity before treatment and strong 
selective effects by chemotherapy has been shown in studies of acute 
lymphoblastic leukaemia, in which relapsed disease has different copy 
number aberrations and p53 mutations than at presentation (Mullighan et al. 
2008; Zhu et al.1999). This indicates that acquired platinum resistant cell lines 
are genetically different from their counterpart sensitive cell lines. Therefore, it 
could be possible that p21 function in different pathways depends on the 
genetic background and signals operating in the cells. 
 
 4.6.2 Silencing HDAC4 induces p21 expression in cisplatin-
sensitive and down-regulates the expression of p21 cisplatin-
resistant cells: 
 
Cooke et al. 2010 have shown that acquired platinum resistant cell lines are 
different genetically from the sensitive parent lines. Therefore, p21 is likely to 
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have different activity since its level is higher in acquired cisplatin resistant 
cells compared with cisplatin sensitive cells. The data have demonstrated that 
siRNA knockdown of HDAC4 decreases the expression of p21 at both mRNA 
and protein levels in PEO4 resistant cells (Figures 53 and 54). This 
observation was also applicable with SKOV3 cisplatin resistant cells where 
the level of p21 protein was not detectable following HDAC4 knockdown. 
However, silencing HDAC4 by siRNA in the sensitive cells (PEO1 and PEA1) 
(Figure 56) enhances the expression of p21. This indicates that HDAC4 
regulates p21 in different ways depending on the cells sensitivity to platinum. 
Enhanced expression of p21 in the sensitive cells following HDAC4 
knockdown did not induced apoptosis but the decrease in p21 expression in 
the resistant cells induced apoptosis in ovarian cancer cells. Down-regulation 
of HDAC4 by siRNA induced growth inhibition and apoptosis as well as 
increased the expression of p21 in colon cancer cells suggesting that HDAC4 
function in regulating transcriptional repression of p21 (Wilson et al. 2008). 
Moreover, it has been shown that knockdown of HDAC4 but not HDAC1, 
HDAC2, HDAC3, HDAC5 and HDAC7 increased p21 expression in both 
mRNA and protein level and inhibited the proliferation in cancer tumour such 
as ovarian, glioblastoma, cervical and Osteosarcoma cells (Mottet et al. 
2009). Enhanced expression of p21 following HDAC4 knockdown was 
observed in the present study in the sensitive cells but not the resistant cells 
highlighting the controversial role of p21 in acting as both positive and 
negative regulator of cell proliferation in ovarian cancer. The over-expression 
of HDAC4 has been shown to repress p21 promoter activity (Wilson et al. 
2008).  
 
However, the over-expression of HDAC4 and p21 in ovarian cancer resistant 
cells suggests that p21 is a possible target of HDAC4. HDAC4 down-
regulation increased p21 expression in the platinum sensitive cells and 
decrease p21 in the resistance cells. The up-regulation of p21 following 
HDAC4 knockdown has been shown in ovarian cancer cells with low 
expression of p21 (Mottet et al. 2009). Moreover, p21 expression has been 
reported to increase upon HDAC1 knockdown in U2OS cells (a human 
osteosarcoma cell line) but not in MCF7 cells (a breast cancer cell line; 
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Senese et al. 2007). This would suggest that different cell lines might have 
different signalling which may depend on the level of HDACs in the cells. 
HDAC inhibitors have been used to stop cancer cell proliferation in vitro and 
have proven effective against haematological cancers (Hamilton et al.  2010). 
It is been reported that HDAC inhibitors inhibit proliferation through 
transcriptional reactivation of the p21 gene in tumour cells (Romanov et al. 
2010). In addition, histone hyper-acetylation was associated with the 
activation of p21 transcription (Simboeck et al. 2010). It has also been 
reported that the HDAC inhibitor FK228 (among the most potent inhibitors of 
both Class I and Class II HDACs) activate p21 in ovarian cancer cells (Son et 
al.  2010).  
 
In this study, knockdown of HDAC4 increases p21 in cisplatin-sensitive and 
decreases its expression in cisplatin-resistant ovarian cancer cells suggesting 
a role for HDAC4 in the regulation of p21. Interestingly, A2780/CP70, in vitro 
platinum-resistant cells (cells originally developed their resistance to cisplatin 
from repeated exposures of the parental A2780 cells to doses of cisplatin) did 
not follow the same pattern because HDAC4 knockdown in these cells did not 
restore platinum sensitivity and up-regulated p21 protein expression (Figure 
55). This behaviour is dissimilar to the clinical cisplatin-resistant ovarian 
cancer cells where knockdown of HDAC4 down-regulates p21 protein 
expression. Taking all of these observations together, it appears that the high 
expression of p21 in platinum-resistant ovarian cells may protect the cells 
from apoptosis induced by cisplatin. Therefore, the reduction of p21 by 
HDAC4 knockdown enhances the sensitivity to cisplatin. In addition, increase 
p21 expression after HDAC4 silencing in platinum-sensitive cells did not 
enhance cell death following cisplatin treatment. A number of studies have 
supported the protective role of p21 against apoptosis in cancer cells such as 
colorectal carcinoma, melanoma and colon cancer cells (Gorospe et al.1997; 
Polyak et al.1996; Waldman et al.1996). This protective role might be 
associated with the ability of p21 to enhance DNA repair (McDonald et 
al.1996). Therefore, p21 role in regulating cell cycle progression in ovarian 
cancer needs further investigation.  
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4.7 Possible mechanism by which HDAC4 re-
sensitises cells towards platinum: 
 
The following is a proposed model for platinum resistance in ovarian cancer 
cells based on the findings of this study. In basal state, no expression of 
acetylated histone H4 and high expression of HDAC4 and STAT1 were shown 
by western blot indicating that the high level of HDAC4 is likely to be 
controlling the level of acetyl STAT1 in the resistant cells. For this reason the 
acetylation level of STAT1 was not detected in platinum resistant cells. 
However, high level of acetyl STAT1 (Figure 58 A) was found in the sensitive 
cells where HDAC4 expression is low.  Following cisplatin exposure, HDAC4 
interacts with STAT1 and mediate the acetylation of STAT1, which enhances 
the phosphorylation and nuclear localisation of STAT1 in platinum resistance. 
Part of HDAC4 also translocate into the nucleus as shown by IF where it 
represses the expression of certain genes (Table 7) that are likely be to 
implicated in platinum resistance in ovarian cancer cells (Figure 58 B). The 
inhibition of HDAC4 via siRNA or HDACi in platinum-resistant cells enhance 
the apoptotic activity towards cisplatin treatment and restores platinum 
sensitivity by increasing the acetylation and decreasing the phosphorylation of 
STAT1 leading to platinum resensitisation (Figure 58 C). However, other 
genes might also be involved in HDAC4-mediated platinum re-sensitisation in 
ovarian cancer. The down regulation of p21 which is involved in survival and 
the up-regulation of UCHL1 which is considered as a tumour suppressor gene 
require further investigations to reveal the relationship of these genes with 


























Figure 58: In the basal state of ovarian cancer cisplatin resistant cells, the high 
expression of HDAC4 modulates the level of acetyl STAT1 by reducing the 
acetylation of STAT1 (A). HDAC4 interacts with STAT1 and mediates the acetylation 
of STAT1; accordingly it enhances the phosphorylation and nuclear localisation of 
STAT1 in response to cisplatin resulting in platinum resistance in ovarian cancer cells 
(B). Silencing HDAC4 by siRNA increased the acetylation and decreased the 


















The gene expression profiling of clinically derived, isogenically matched cell 
line models of platinum resistance identified the over-expression of HDAC4 in 
cisplatin-resistance in ovarian cancer cell lines. The over-expressed HDAC4 is 
validated in platinum resistant tumour biopsies. Hence, elevated HDAC4 
expression was associated with cisplatin-resistance in ovarian cancer, and 
inhibition of HDAC4 by siRNA reversed this acquired cisplatin resistance and 
restore cisplatin sensitivity. Consequently, HDAC4 is a potential therapeutic 
target in ovarian cancer with acquired resistance to cisplatin-based 
chemotherapy. The HDAC inhibitor 4a-MC1511 showed a promising effect by 
enhancing cisplatin mediated apoptosis. This observation suggests that it may 
be worthy to pursue strategies to block HDAC4 function using drugs 
developed around 4a-MC1511 in combination with platinum based treatments 
to overcome cisplatin resistance in ovarian cancer. Analysis of the expression 
profiles of all Class I and Class II HDACs across the isogenic cell lines 
revealed that HDAC1 and HDAC3 followed the same pattern of up-regulation 
in cisplatin-resistant cell lines as HDAC4. The interaction between HDAC1 
and HDAC3 with HDAC4 was confirmed by immunoprecipitation. Yet HDAC4 
knockdown showed higher apoptotic activity following cisplatin treatment 
compared with HDAC1 and HDAC3 knockdown and suggesting that HDAC4 
plays an essential role in acquired-cisplatin resistance in ovarian cancer.  
 
The acetylation status of STAT1 is altered by HDAC4 over-expression in 
acquired platinum resistance. This change in STAT1 acetylation alters 
platinum induced phosphorylation and sub-cellular location of STAT1 which 
can be considered a novel mechanism of platinum resistance in ovarian 
cancer. The identification of non-histone protein STAT1 acetyl control 
mechanisms affecting platinum resistance in ovarian cancer provide a 
foundation for targeted treatment with inhibitors for HDAC4 or STAT1 to 
overcome platinum resistance in ovarian cancer. Microarray analysis of 
platinum resistant cells identified differentially regulated genes following 
HDAC4 knockdown.  
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The UCHL1 is methylated in both (PEO1) cisplatin sensitive and (PEO4) 
resistant paired cells. HDAC4 knockdown in PEO4 resistant cells up regulates 
UCHL1. ChIP analysis revealed an increase in acetylation at the UCHL1 
promoter and pyrosequencing analysis showed no significant change in 
UCHL1 methylation level after HDAC4 knockdown suggesting that silencing 
HDAC4 affect the acetylation level but not the methylation level of UCHL1. On 
the other hand, p21 is down-regulated by HDAC4 knockdown in resistant 
PEO4 cells in contrast to reports of p21 over-expression as a biomarker of 
HDAC inhibition. Strikingly, however, p21 is up-regulated after HDAC4 
knockdown in cisplatin-sensitive, paired PEO1 cells showing a fundamental 
change in its expression control on acquisition of platinum resistance.  
 
In summary, this study provides evidence that HDAC4 is required for platinum 
mediated STAT1 activation; a phenomenon associated with clinical platinum 
resistance, and identifies frequent HDAC4 over-expression in platinum 
resistant tumour biopsies. Pharmacological modulation of this pathway is 
shown to restore sensitivity to cisplatin. Microarray analysis revealed HDAC4 
regulated a number of target genes. These studies identify new, clinically 
relevant insights into platinum resistance, which may lead to improved 
















6. Future Work:  
 
The over-expression of HDAC4 was observed in both platinum-resistant 
ovarian cancer cells and in tumour biopsies and the inhibition of HDAC4 by 
siRNA or HDAC inhibitor sensitises the platinum-resistant ovarian cancer cells 
to cisplatin. This highlights the importance of HDAC4 as a useful target for 
new anti-cancer therapies. The results are encouraging and it may be worthy 
to pursue strategies to block HDAC4 function using future compounds 
developed around 4a-MC1511 in combination with platinum based treatments 
to overcome cisplatin resistance in ovarian cancer. The pharmacological 
modulation of this pathway can restore sensitivity to platinum based therapy 
on a selective inhibition of HDAC4. Thus, identifying HDACs profile in cisplatin 
resistant ovarian cancer patients can be very useful in the clinical 
management and could identify suitable patients who will benefits from HDAC 
inhibitors to enhance the sensitivity to chemotherapy. Furthermore, 
identification of the interaction between HDAC4 and STAT1 as well as the 
involvement of HDAC4 in the regulation of STAT1 acetylation and 
phosphorylation level in ovarian cancer could have a significant impact on the 
treatment of platinum resistant ovarian cancer.  
 
Given that the pharmacological modulation of HDAC4 via HDAC inhibitors 
lead to inhibition of both the STAT1 and HDAC4 effects and re-sensitised cells 
to cisplatin treatment which may lead to improved therapeutic options in 
ovarian cancer, further studies are required to identify the role of 
HDAC4/STAT1 in other resistant cancer tumours such as breast and colon 
cancers to be able to generalize the effect of HDAC4 inhibition in the 
treatment of cisplatin-resistant patients. In addition, the assessment of 
STAT1/HDAC4 response to other chemotherapeutics agents will determine 
whether the HDAC4/STAT1 phenomenon is restricted to cisplatin or not. 
Moreover, microarray analysis is required to identify the transcriptional 
signature following STAT1 activation that leads to cell survival in ovarian 
cancer resistant cells. Questions such as; what are the acetylation sites on 
STAT1 that are deacetylated by HDAC4? Are these sites similar to interferon 
mediates STAT1 mechanisms? Does HDAC4/STAT1 inhibition help to reduce 
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tumours size in vivo ovarian cancer mouse models? Is HDAC4 inhibition alone 
sufficient to enhance the sensitivity and decrease the tumours size? It will be 
important to investigate. Moreover, silencing HDAC4 in sensitive cell had no 
effect on platinum sensitivity because of the low level of HDAC4 in these cells, 
the introduction of HDAC4 in these cells will be an essential experiment to 
evaluate in order to understand the correlation between HDAC4 and platinum 
sensitivity.  
 
The pyrosequencing can be performed to determine the effect of HDACi such 
as SAHA on the methylated UCHL1 on PEO4 cells. Moreover, the expression 
of UCHL1 was undetectable in SKOV3 platinum-resistant ovarian cancer cells 
at the protein level compared with OSAC2 which are the normal ovarian cells 
with high level of UCHL1 protein. Nonetheless, HDAC4 was expressed in 
SKOV3 cells but not in OSAC2 cells. This might indicate that UCHL1 is likely 
to be silenced via a mechanism related to HDAC4 deacetylation effect in the 
cisplatin-resistant cells SKOV3. However, the methylation status of UCHL1 in 
these two cell lines was not tested. Therefore, the methylation status 
(pyrosequencing) and knockdown of HDAC4 are required to determine the 
correlation between HDAC4 and UCHL1 using SKOV3 and OSAC2 as they 
provide a good model for the expression of UCHL1 and HDAC4. Regarding 
the change on the acetylation in promoter of UCHL1, different acetyl histone 
should be used in CHIP analysis to determine which specific acetyl lysine is 
involved in the acetylation of UCHL1 either after HDAC4 knockdown or HDACi. 
P21 expression was found to be higher in platinum-resistant cells compared 
with sensitive ovarian cancer cells. Knockdown of HDAC4 up-regulates p21 in 
platinum sensitive cells and down regulates p21 in platinum-resistant ovarian 
cancer cells. Is the decrease of p21 following HDAC4 knockdown caused by 
proteasomal degradation or does it result from a decrease in the level of 
HDAC4 in the resistant cells? Actinomycin D that blocks mRNA transcription 
could be used to examine p21 mRNA levels and to understand the underlying 
molecular mechanisms of platinum resistance. P21 expression could be 
assessed by IHC analysis using matched pre- and post platinum samples to 
validate the up-regulation of p21 observed in the cisplatin-resistant ovarian 
cancer cell lines.  
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8. Appendix:  
 
 
 Untreated  siLamin  siHDAC4 
cell 
lines average SEM average SEM average SEM 
PEO1 5.3  1.8  5.3  1.3  3 0.5  
PEO4 16.6  2.4  16 2.5  7.6  1.4  
PEA1 17 0.4  17 0 12 0.4  
PEA2 30 0 26.6  3.3  16.6  3.3  
PEO14 5 1 5 1 1.3  0.3  
PEO23 39.3  5.6  33.6  5.3  12.3  0.8  

















Identifier Stage Grade Histology Regimen 1 PFS1 Plat Res 1st line Regimen 2 PFS2 Plat Res 2nd line OS 
1 3A 3 ENDOMETRIOID CRB/TXL 468 NO  Carboplatin 179 YES 1764 
2 3C 2 ENDOMETRIOID CISPLATIN 445 NO  Carboplatin then 
Paclitaxel then 
ET-743 which 
was given post 
surgery 
0 REFRACTORY 958 
3 3C 2 ENDOMETRIOID CARBOPLATIN 301 NO Carboplatin 153 YES 1037 
4 3C 2 MUCINOUS CARBOPLATIN 980 NO  Carboplatin 118 YES 1460 
5 3 (pre FIGO) 3 SEROUS PAP CARBOPLATIN 236 NO Carboplatin 0 REFRACTORY 877 
6 2C 3 SEROUS PAP CISPLATIN 1366 NO Carboplatin 158 YES 2675 
7 3C 3 SEROUS PAP CRB/TXL 1881 NO Cap/Oxaliplatin 
(originally 
thought to be 
new CRC) 
27 YES 2792 
8 2A 3 SEROUS PAP CARBOPLATIN 1135 NO Carboplatin 127 YES 2175 
9 3C 3 SEROUS PAP CRB/TXL 200 NO Carboplatin 13 REFRACTORY 401 
10 3C 3 MIXED 
SEROUS/ENDO 
CARBOPLATIN 560 NO Carboplatin 119 YES 2142 
11 4 2 SEROUS PAP CRB/TXL 206 NO Carboplatin 74 REFRACTORY 678 
12 3 unknown ENDOMETRIOID CISPLATIN 314 NO Carboplatin 112 YES 1075 
13 3C 3 SEROUS PAP CARBOPLATIN 415 NO Carboplatin 182 YES 1952 
14 3C 3 SEROUS PAP CRB/TXL 265 NO Carboplatin 146 YES 1194 
15 3C 3 ENDOMETRIOID CISPLATIN 928 NO Cisplatin 140 YES  2074 




 Primary resistant/refractory  
Identifier Stage Grade Histology Regimen 1 PFS1 Plat Res 1st line Regimen 2 PFS2 Plat Res 2nd line OS 
17 2A 3 CLEAR CELL CARBOPLATIN 147 YES None - XRT n/a n/a 761 
18 3 3 ENDOMETRIOID CISPLATIN 105 YES Paclitaxel 34 n/a 626 
19 3C 3 ENDOMETRIOID CSP/TPT 87 REFRACTORY Paclitaxel 52 n/a 1145 
20 4 3 MIXED 
ENDOMETRIOID/ 
CLEAR CELL 
CARBOPLATIN 41 REFRACTORY None n/a n/a 282 
21 4 3 ENDOMETRIOID CARBOPLATIN 153 YES None n/a n/a 564 
22 4 3 MIXED 
ENDOMETRIOID/ 
CLEAR CELL 
CRB/TXL 135 YES Carboplatin 19 REFRACTORY 368 
23 3C 2 SEROUS PAP CARBOPLATIN 63 REFRACTORY Carboplatin 18 REFRACTORY 430 
24 3 3 UNDIFFERENTIATED 
CARCINOMA 
CSP/TPT 53 YES Carboplatin then 
Paclitaxel post 
surgery 
43 Unknown 589 
25 2B 3 ENDOMETRIOID CRB/TXL 22 REFRACTORY None n/a n/a 278 
26 3C 3 ENDOMETRIOID CSP/TPT 53 REFRACTORY None n/a n/a 236 
27 3C 3 SEROUS PAP CRB/TXL 63 YES Caelyx 36 n/a 510 
28 3C 2 MUCINOUS CISPLATIN 161 YES 5FU/FA (pre 
surgery) 
51 n/a 642 
29 2C 3 SEROUS PAP CARBOPLATIN 0 YES None-cured by 2nd 
surg & XRT 
n/a n/a 3816 
30 4 3 SEROUS PAP CISPLATIN 112 YES Cisplatin pre-











Identifier Arbitrary numerical identifier for individual patient 
Stage FIGO Stage (where no letter is listed, is prior to new staging system - eg 'Stage 3' 
Grade Grade of histological differentiation 
Histology Histological subtype 
Regimen 1 Chemotherapy Regimen on 1st line 
PFS 1 Progression-free survival from date of last chemotherapy infusion to date of progression/relapse; should be <182.5 for plat resistant, 91 for refractory 
Plat Res 1st 
line 
Was the disease platinum resistant following 1st line chemo? 
Regimen 2 Chemotherapy Regimen on 2nd line 
PFS 2 Progression free survival from 2nd surgery; date of last chemotherapy infusion post surgery 2 to date of 2nd relapse - should be <182.5 for plat resistant, 91 
for refractory 
Plat Res 2nd 
line 
Was the disease platinum resistant following 2nd line chemo? 
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HDAC4-Regulated STAT1 Activation Mediates Platinum
Resistance in Ovarian Cancer
Euan A. Stronach1, Albandri Alfraidi1, Nona Rama1, Christoph Datler1, James B. Studd1, Roshan Agarwal1,
Tankut G. Guney1, Charlie Gourley3, Bryan T. Hennessy4, Gordon B. Mills4, Antonello Mai5,
Robert Brown1, Roberto Dina2, and Hani Gabra1
Abstract
Ovarian cancer frequently acquires resistance to platinum chemotherapy, representing a major challenge for
improving patient survival. Recent work suggests that resistant clones exist within a larger drug-sensitive cell
population prior to chemotherapy, implying that resistance is selected for rather than generated by treatment.
We sought to compare clinically derived, intrapatient paired models of initial platinum response and subsequent
resistant relapse to define molecular determinants of evolved resistance. Transcriptional analysis of a matched
cell line series from three patients with high-grade serous ovarian cancer before and after development of clinical
platinum resistance (PEO1/PEO4/PEO6, PEA1/PEA2, PEO14/PEO23) identified 91 up- and 126 downregulated
genes common to acquired resistance. Significantly enhanced apoptotic response to platinum treatment in
resistant cells was observed following knockdown of histone deacetylase (HDAC) 4, FOLR2, PIK3R1, or STAT1
(P < 0.05). Interestingly, HDAC4 and STAT1 were found to physically interact. Acetyl-STAT1 was detected in
platinum-sensitive cells but not in HDAC4 overexpressing platinum-resistant cells from the same patient. In
resistant cells, STAT1 phosphorylation/nuclear translocation was seen following platinum exposure, whereas
silencing of HDAC4 increased acetyl-STAT1 levels, prevented platinum-induced STAT1 activation, and restored
cisplatin sensitivity. Conversely, matched sensitive cells were refractory to STAT1 phosphorylation on platinum
treatment. Analysis of 16 paired tumor biopsies taken before and after development of clinical platinum
resistance showed significantly increased HDAC4 expression in resistant tumors [n ¼ 7 of 16 (44%); P ¼ 0.04].
Therefore, clinical selection of HDAC4-overexpressing tumor cells upon exposure to chemotherapy promotes
STAT1 deacetylation and cancer cell survival. Together, our findings identify HDAC4 as a novel, therapeutically
tractable target to counter platinum resistance in ovarian cancer. Cancer Res; 71(13); 4412–22. 2011 AACR.
Introduction
One of the greatest areas of unmet need compromising the
successful treatment of ovarian cancer is the acquisition of
clinical resistance to platinum chemotherapy. Platinum-based
compounds are standard first-line agents for ovarian cancer
and initial response rates are high (1). However, subsequent
relapse with acquired platinum resistance is frequent and
closely linked to the poor survival associated with this cancer.
Multiple mechanisms for platinum resistance have been
described and are reviewed elsewhere (2–4).
A recent genomic analysis of a cell line series derived from 3
cases of serous ovarian cancer both before and after acquisi-
tion of clinical platinum resistance revealed that in addition to
shared genomic features, sensitive and resistant tumor cells
from the same patient also exhibit mutually exclusive genomic
characteristics, indicating that rather than a direct linear
evolution of resistance from sensitive disease in response
to platinum challenge, platinum-resistant clones are present
from the outset at low abundance within the sensitive pre-
senting tumor (5). In this model, the minor resistant clone
persists despite effective killing of the dominant sensitive
population and subsequently expands causing relapse. This
is in contrast to alternative hypotheses of acquired resistance
whereby mutations are proposed to arise in sensitive cells in
response to treatment with chemotherapy. In vitro derivation
of acquired resistance by treatment of a sensitive cancer cell
line with platinum agents is likely to mimic this alternative
hypothesis producing adaptive linear responses, which may
not accurately reflect clinical resistance. As such, we focused
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our analysis here on clinically derived models of resistance.
Henceforth, for brevity, we refer to this selection hypothesis as
acquired platinum resistance, as it describes the known
clinical entity of relapse within 6 months of last platinum
therapy after previous remission/response.
Here, we report the first linked gene expression profiling
and functional analysis of intrapatient paired pre- and post-
clinically acquired platinum resistance in ovarian cancer. Our
analysis used ovarian cancer cell line series described pre-
viously (5, 6), identifying several novel modulators of platinum
response and focuses on a previously unreported functional
mechanism that behaves in a fundamentally different manner
between clinically platinum-sensitive and -resistant cells from
the same patients. In addition, we noted that this mechanism
operates to produce resistance independently of pre-existing
established changes in platinum response caused by func-
tional reversion of a germ line BRCA2 truncating mutation (7).
This work identifies therapeutic targets with implications for
the management of ovarian cancer.
Materials and Methods
Cell lines and reagents
The paired high-grade serous ovarian carcinoma cell lines
PEO1 versus PEO4/PEO6, PEA1 versus PEA2, and PEO14
versus PEO23 were obtained from Dr. Simon Langdon (Edin-
burgh, UK) and have been described elsewhere (5–7). Cell line
verification was by Identifyler kit (Applied Biosystems). In the
matched pairs, the first set of cell lines (PEO1, PEA1, PEO14)
were derived prior to and the second set (PEO4/PEO6, PEA2,
PEO23), following the onset of acquired clinical platinum
resistance. SKOV3 cells were obtained from European Collec-
tion of Animal Cell Cultures (ECACC). Cisplatin response was
measured by sulforhodamine B (SRB) assay as described (8).
All cell lines have confirmed TP53 mutations (5). BRCA1/2
sequencing was done as described (ref. 9; see also Supple-
mentary Methods). All lines were maintained in RPMI 1640
media with 10% fetal calf serum (FCS), penicillin, streptomy-
cin, glutamine at 37C/5% CO2. Antibodies used were FOLR2
(Abcam); STAT1 (BD Biosciences); HDAC4, pSTAT1Y701,
Acetyl-Lys (Cell Signaling Technology); FAK, PIK3R1, Lamin
A/C (Upstate); b-tubulin and HDAC4 (for immunohistochem-
istry; Santa Cruz Biotechnology).
Microarray hybridization and data analysis
RNAwas prepared using TriReagent (Sigma) and hybridized
to Sanger Hver1.2.1 10K cDNA microarrays as described else-
where (ref. 10; see also Supplementary Methods), and data
analyzed using the Genespring GX Software Package (Aglient)
following lowess normalization and averaging of quadruplicate
hybridizations. Genes were filtered on the basis of expression
change between sensitive and resistant cells after which
Student's t tests were conducted with Benjamini–Hochberg
false discovery rate correction (see also Supplementary Fig. S2).
siRNA transfection and apoptosis assay
Cells were grown to 60% confluence in 6-well plates prior
to transfection with smartpool siRNAs directed to FAK,
FOLR2, HDAC4, HSXIAPAF1, ITGB2, LAMA4, MYC, PIK3R1,
PRKCBP1, STAT1, TAP1, VEGFA and control siRNAs,
LAMIN A/C, nontargeting and siCONTROL-TOX (100
nmol/L final concentration; Dharmacon). Cells were
retransfected after 48 hours. The siRNAs in 1 siRNA buffer
were mixed with 2 mL transfection reagent #1 (Dharmacon)
per transfection in a total volume of 400 mL with OptiMEM
media. Following 30 minutes incubation, siRNAs were
added to 1,600 mL antibiotic-free RPMI 1640/10% FCS on
cells. Twenty-four hours after second transfection, cells
were reseeded. Cells reseeded in 6-well trays were incubated
for 48 hours and protein and RNA samples prepared. RNA
extraction was by RNeasy Mini Kit (Qiagen). Cells reseeded
into clear and opaque 96-well trays were treated identically:
for each transfection condition, 24 hours after seeding, 3
replicate wells were treated with 25 mmol/L cisplatin and 3
wells left untreated. After 24 hours, cells caspase activation
was measured by caspaseGlo 3/7 assay (Promega) and
viable cell numbers inferred by MTT assay as described
elsewhere (11). Caspase activity was normalized to cell
density for each treatment.
Immunofluorescent microscopy
Coverslips (VWR International) were treated with 1 mol/L
HCl before cell seeding and incubation for 24 hours at 37C/
5% CO2. After indicated treatment, cells were washed with PBS
then fixed/permeabilized at 37C for 30 minutes with 4%
paraformaldehyde/1.8% TritonX-100/PBS. Coverslips were
blocked in 10% goat serum/2% bovine serum albumin
(BSA)/PBS for 30 minutes, then washed with PBS, and incu-
bated with primary antibodies overnight at 4C. Coverslips
were washed in PBS and incubated with 1:500 dilutions of
fluorochrome-conjugated secondary antibodies [fluorescein
isothiocyanate (FITC) anti-goat IgG, FITC anti-rabbit IgG,
Alexa Fluor 555 anti-mouse IgG, and Alexa Fluor 488 goat
anti-rabbit IgG; Invitrogen] and directly labeled actin stain
(Alexa Fluor 633 phalloidin; Invitrogen) in blocking buffer for 1
hour. Cells were rinsed 3 times in PBS for 5 minutes and
mounted onto slides using Vectashield media containing 40,6-
diamidino-2-phenylindole (DAPI; Vector Laboratories). Slides
were visualized on an inverted confocal microscopy system
(Axiovert 200M, Zeiss and TCS SP5, Leica).
Pharmacologic inhibition of HDAC4
PEO4 and SKOV3 cells were seeded at 25,000 cells per well
in 96-well plates in a volume of 50 mL per well. After 24 hours,
cells were either treated with 40 mL of fresh culture media
(untreated control) or 40 mL fresh media containing HDAC
inhibitor (HDACi) aroyl-pyrrolyl-hydroxy-amide 4a (APHA4a)
at final concentration, calculated for 50 mL final volume, of 5
mmol/L and 10 mmol/L. After 1 hour, 10 mL of cisplatin was
added to a final concentration of 25 mmol/L in 50 mL; 10 mL of
fresh culture media was added to control cells. Caspase 3/7
and MTT assays were conducted at 24 hours post–cisplatin
treatment as described above.
Additional methods
See Supplementary Data for additional methods.
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Results
Coupled gene expression and functional analysis of
upregulated transcripts in clinically acquired platinum
resistance
To confirm that acquired clinical resistance to platinum-
based chemotherapy was maintained in long-term platinum-
free cell culture, we carried out in vitro cisplatin sensitivity
assays (Fig. 1A). Average values from at least 3 replicate
experiments revealed a between 4- and 9-fold increase in
cisplatin IC50 values on acquisition of clinical resistance.
Stable resistance in the absence of cisplatin suggests that
clinical mechanisms of resistance are genetically or epigen-
etically determined: consistent with the description of distinct
genomic differences between the sensitive and resistant
paired lines studied here (5). Mutations in BRCA2 have been
described previously in the cell lines PEO1 and PEO4 (7). We
sequenced BRCA1 and BRCA2 in all paired cell lines and
identified previously described alterations in our stocks of
PEO1 and PEO4 that are associated with functional BRCA2
(discussed in detail in Supplementary Fig. S1). No further
mutations were seen in BRCA1 or BRCA2 in other cell lines
indicating that the clinical platinum resistance phenotype
here is not accounted for by BRCA mutation/reversion. RNAs
from cell line pairs were cohybridized to cDNA microarrays.
Normalized data were filtered as described identifying 91
unique upregulated and 126 downregulated genes in associa-
tion with clinically acquired platinum resistance (Supplemen-
tary Fig. S2 and Supplementary Table S1A and B). We
hypothesized that silencing of genes overexpressed in resis-
tant cells might lead to resensitization by re-engaging apop-
totic response to cisplatin treatment and thus may directly
reveal novel therapeutic targets for clinical reversal of resis-
tance. Hence, the overexpressed genes formed the focus of our
onward strategy. Thirteen upregulated candidate genes were
selected on the basis of either magnitude of overexpression or
cellular function and were taken forward for functional assess-
ment (Supplementary Table S2). We combined an siRNA-
based approach, using the platinum-resistant PEO4 cell line,
to a caspase 3/7 activation–based apoptosis assay to evaluate
the effect of each gene on the cellular response to platinum. To
quantify the difference in platinum-induced apoptosis
between control and test genes, the ratio of caspase3/7
induction in control transfected cells on cisplatin treatment
was compared with that of target gene siRNA-transfected
cells. Six of the 13 genes showed a 1.5-fold or greater increase
in the ratio of caspase induction in the target gene siRNA
compared with the control gene siRNA (platinum resensitiza-
tion ratio; Supplementary Table S2) and these were taken
forward for further analysis. Assays were repeated a further 3
times for these 6 genes and the average values plotted
(Fig. 1B). The platinum resensitization ratios were calculated
and averages subjected to Student's t test for statistical
significance (Table 1). Knockdown of control and test genes
was confirmed by Western blotting (Fig. 1C). Four genes,
FOLR2, PIK3R1, HDAC4, and STAT1, emerged as significantly
resensitizing platinum-resistant ovarian cancer cells. We




















































































































Figure 1. Identification of platinum resistance modulators. A, IC50 values
for platinum-sensitive and -resistant paired cell lines were calculated
based on SRB assay data (n ¼ 3). This analysis confirmed an in vitro
resistance to cisplatin in all clinically platinum-resistant cell lines relative to
their sensitive parent lines [fold changes in IC50 between sensitive and
matched resistant cells: PEO4-8.7 (P ¼ 0.016), PEO6-4.6 (P ¼ 0.004),
PEA2-4.1 (P¼ 0.0002), PEO23-4.5 (P¼ 0.00002)]. B, following microarray-
based expression analysis, candidate genes were assessed for a role in
acquired platinum resistance by a first round of siRNA knockdown
followed by cisplatin treatment identifying 6 genes that enhanced
apoptotic induction by cisplatin. Following replication, 4 of these genes
[FOLR2 (P ¼ 0.004), HDAC4 (P ¼ 0.02), PIK3R1 (P ¼ 0.04), and STAT1
(P ¼ 0.0002)] passed statistical analysis (see also Table 1) as enhancing
apoptotic induction on cisplatin treatment when compared with control
siRNA treated cells. Data are represented as means  SEM of 4 replicate
experiments. C, specificity of siRNA was confirmed by Western blot. All
t tests throughout are 2-tailed and assume unequal variances.
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reports indicate that the transcription factor STAT1 can be
regulated by acetyl modifications (12, 13) suggesting the
possibility that STAT1 may transcriptionally control the
switch from sensitivity to resistance in a manner that may
be modulated clinically using HDACi, which are well devel-
oped and indeed approved for use in cutaneous T-cell lym-
phoma (14).
HDAC4 knockdown resensitizes a panel of clinically
derived platinum-resistant ovarian cancer cell lines
We used quantitative real time PCR (qRT-PCR) and
Western blotting to validate the upregulation of HDAC4 seen
in the gene expression analysis (Fig. 2A). This indicated an
increase in expression between sensitive and resistant cells
in each pair tested. We showed that the effect seen in the 24-
hour caspase3/7 activation assay is maintained at 72 hours by
SRB assay following HDAC4 siRNA knockdown (Fig. 2B). We
then considered the effect of siRNA knockdown of HDAC4 in
the clinically derived platinum-resistant cell lines PEA2,
PEO23, and SKOV3. Figure 2C and Supplementary Figure
S4 show significantly increased apoptotic response to cisplatin
following siRNA knockdown of HDAC4, compared with con-
trol siRNAs. Conversely, silencing of HDAC4 expression in
sensitive cells (PEO1, PEA1, PEO14) did not significantly
enhance platinum sensitivity, in keeping with their already
relatively low HDAC4 expression levels (Supplementary
Fig. S3). However, overexpression of HDAC4 in platinum-
sensitive PEO1 cells resulted in decreased apoptotic response
to cisplatin (P ¼ 0.032) indicating that the platinum-resistant
phenotype can be, at least partially, recapitulated by over-
expression of HDAC4 alone (Fig. 2D). Deconvolution of the
pool of 4 HDAC4 siRNAs confirmed target specific knockdown
(Supplementary Fig. S4B).
Demonstration of a novel role for HDAC4 in acquired
platinum resistance led us to consider possible targets for
HDAC4-mediated deacetylation. Posttranslational modifica-
tion of the transcription factor STAT1 by acetylation at lysine
residues 410 and 413 has been reported previously in mela-
noma cells (12) and shown to promote dephosphorylation at
tyrosine residue 701 (13) thereby acting as a control mechan-
ism for this protein in the IFN response. Because STAT1 was
identified as upregulated in resistant cells in our analysis and
knockdown significantly resensitized cells to platinum (see
above), we considered that STAT1 might be subject to acetyl
regulation in acquired resistance and hence explored whether
a functional interaction occurs between HDAC4 and STAT1.
STAT1 is activated and translocated to the nucleus in
response to cisplatin treatment in acquired platinum-
resistant but not -sensitive ovarian cancer cells
We examined the broader role of STAT1 in platinum
resistance prior to more detailed mechanistic studies. STAT1
exists as 2 distinct isoforms, full-length STAT1a and STAT1b,
a truncated form considered to act as a dominant-negative
inhibitor of STAT1a. qRT-PCR in platinum-sensitive and
-resistant lines showed that both STAT1a and STAT1b were
upregulated to the same extent in the resistant lines (Fig. 3A),
suggesting that differences between isoforms did not explain
the alteration in platinum sensitivity.
Next, we carried out RNA interference (RNAi) knockdown of
STAT1 in additional platinum-resistant ovarian cancer cell
lines: PEA2, PEO23, and SKOV3. Figure 3B and Supplementary
Figure S5A depict the enhanced apoptotic response following
STAT1 siRNA knockdown. Deconvolution of the pool of 4
siRNAs to STAT1 validated target-specific phenotype (Sup-
plementary data Fig. S5B).
We explored whether STAT1 is activated in response to
cisplatin and thus examined the subcellular localization of
STAT1. Immunofluorescence microscopy of platinum-sensi-
tive and matched, resistant cells showed that in the absence of
platinum, STAT1 is predominantly unphosphorylated and
cytoplasmic. However, nuclear STAT1, phosphorylated at
Y701, is observed following cisplatin treatment in resistant
cells (PEO4/PEA2) but not matched, sensitive cells (PEO1/
PEA1) where STAT1 remains largely unphosphorylated and
cytoplasmic (Fig. 3C and Supplementary Fig. S6A). This is in
keeping with the canonical pathway of STAT1 activation by
phosphorylation, dimerization and nuclear translocation and
suggests a platinum-induced, STAT1-mediated transcrip-
tional response occurring specifically in acquired platinum-
resistant cells. To corroborate these findings, we also looked at
pSTAT1 Y701 levels in the sensitive and resistant cells by
Western blotting. Figure 3D shows striking discordance
between the phospho-STAT Y701 levels in the paired sensi-
tive/resistant cell lines PEO1 and PEO4, with no detectable
Y701 phosphorylation in sensitive cells. In contrast, phospho-
STAT1 Y701 is detectable at baseline and is induced following
platinum treatment in PEO4 cells. Expression of the STAT1
regulated gene IRF1 was measured in platinum-resistant
PEO4 cells and showed cisplatin-mediated induction of
IRF1 transcription which was abolished by STAT1 knockdown
Table 1. Knockdown and resensitization
assays were carried out a total of 4 times by
using cisplatin-resistant PEO4 cells for genes
selected following first round analysis (see












NOTE: Platinum resensitization ratio is defined. Quadrupli-
cate data were analyzed by Student's t test for significant
difference in cisplatin-induced caspase 3/7 induction
between test gene siRNA-transfected cells and siRNA
controls.
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confirming functional activity of STAT1 in response to cis-
platin exposure in resistant cells (Supplementary Fig. S6B).
We hypothesized that if HDAC4 and STAT1 had indepen-
dent roles in the platinum-resistant phenotype, we would
expect additivity or synergy in platinum resensitization if
both were inhibited simultaneously. Therefore, we carried
out dual knockdown of HDAC4 and STAT1 in resistant
PEO4 cells. Data indicated no additional effect in apoptotic
response to cisplatin over that seen following knockdown of
either gene alone (Fig. 4A), implying redundancy between
these 2 genes and supporting the notion that they may act
in the same pathway in this phenotype.
Having shown a clear role for STAT1 in platinum resistance,
we considered the hypothesis outlined above, that HDAC4
may be acting as a STAT1 deacetylase, altering the impact of
cisplatin on STAT1 signaling.
HDAC4 interacts with STAT1, modulating its
acetylation, phosphorylation, and nuclear
translocation, thereby abrogating sensitivity to
cisplatin
Toassess STAT1 acetylation and the potential role ofHDAC4
in STAT1 deacetylation, we carried out coimmunoprecipita-



























































































































































































Figure 2. HDAC4 contributes to cisplatin resistance. A, overexpression of HDAC4 in platinum-resistant cells was confirmed at the RNA (left) and protein level
(right; ***, P < 0.005 t test). B, the effect of HDAC4 knockdown on cisplatin response was validated by SRB assay, 72 hours post cisplatin exposure of
siRNA-treated PEO4 cells. Data are mean SEM (n¼ 3). C, clinically derived platinum-resistant cell lines (PEA2/PEO23) were assessed for the contribution of
HDAC4 to acquired resistance. Data in the top panes represent the mean caspase 3/7 induction relative to control siRNA SEM (n¼ 3), whereas bottom pane
shows confirmation of HDAC4 knockdown byWestern blot. *, P < 0.05 t test comparing caspase 3/7 activation between siRNA-treated and siRNA control cells
following cisplatin exposure. D, overexpression of HDAC4 in the platinum-sensitive PEO1 cell line as described in the Supplementary Methods.
Overexpression of protein (bottom) was confirmed byWestern blot and accompanying caspase activation data (top) shows attenuated apoptotic response to
cisplatin in cells overexpressing HDAC4 (n ¼ 4; P ¼ 0.032) comparing caspase 3/7 activation between pcDNA3.1-empty vector (EV) transfected and
pcDNA3.1-HDAC4-treated cells.
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resistant cells (PEO4, PEA2, and SKOV3: Fig. 4B). We assayed
for the presence of acetyl-STAT1 (ac-STAT1) by immunopre-
cipitation with anti-acetyl lysine antibody and Western blot-
ting for STAT1. Ac-STAT1 was present in the platinum-
sensitive cell lines PEO1 and PEA1 (expressing low levels of
HDAC4) but was undetectable in their HDAC4 overexpressing
matched platinum-resistant counterparts PEO4 and PEA2 and
was similarly undetectable in platinum-resistant SKOV-3 cells.
However, following HDAC4 knockdown, ac-STAT1 was detect-
able in all resistant lines (Fig. 4C) indicating that HDAC4 is
required for the deacetylation of STAT1 and providing a novel
mechanistic link between these 2 modulators of platinum
resistance. Next, we considered the consequence of HDAC4-
mediated deacetylation of STAT1 on its protein function and
on the phenotype of clinically acquired platinum resistance.
We hypothesized that because acetylation of STAT1 has
been shown to abrogate IFN-induced phosphorylation at Y701
(13), and that because the knockdown of HDCA4 has been
shown here to increase acetylation of STAT1, that HDAC4
may influence the phosphorylation, and hence nuclear accu-
mulation, of STAT1. Figure 4D shows that the cisplatin-
induced accumulation of phospho-STAT1 observed in the
presence of HDAC4 is abrogated following HDAC4 knock-
down in platinum-resistant PEO4, PEA2, and SKOV3 cells.
Figure 3. STAT1 contributes to
cisplatin resistance and is
phosphorylated at Y701 in
resistant cells following platinum
treatment. A, cDNA from sensitive
and resistant cell lines was
quantified for expression of total
STAT1 and the a and b isoforms of
STAT1 individually *, P < 0.05, **, P
< 0.01 t tests comparing resistant
cells with their sensitive matched
line). B, siRNA to STAT1 in further
platinum-resistant cell lines
revealed a general effect of
resensitization to cisplatin
following STAT1 knockdown as
measured by caspase 3/7
induction. Effective knockdown
was confirmed by Western blot
(See also Supplementary Fig. S5)
*, P < 0.05 t test comparing
caspase 3/7 activation between
siRNA-treated and siRNA control
cells following cisplatin exposure.
C, subcellular location of total-
and phospho-STAT1 was
determined in sensitive and
resistant cells by
immunofluorescence microscopy
as described. Nuclei were
revealed using DAPI stain and
actin cytoskeleton visualized by
Alexa 633 nm conjugated
phalloidin stain (see also
Supplementary Fig. S6). D,
identical matched cells were
treated with cisplatin over 72
hours at 5 mmol/L for sensitive
PEO1 cells and 25 mmol/L for
resistant PEO4. Protein lysates
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Immunofluorescence staining of PEO4 cells showed that
knockdown of HDAC4 is linked to loss of cisplatin-induced
nuclear phospho-STAT1 accumulation (Fig. 5A).
Acquired platinum resistance can be reversed by
treatment with pharmacologic inhibitors of HDACs
To consider the potential therapeutic utility of inhibiting
HDAC4 or STAT1, we treated-platinum resistant cells with the
hydroxamic acid–based HDACi APHA4a (15). This treatment
elicited a restoration of platinum sensitivity, as determined by
induction of caspase 3/7 activity, in the resistant cell lines PEO4
and SKOV3 when combined with platinum at concentrations
that had little or no single agent effect in the same assay
(Fig. 5B). Treatment with HDACi resulted in a similar blockade
on the phosphorylation of STAT1 shown at the morphologic
level by immunofluorescencemicroscopy.We also show loss of
cisplatin-induced STAT1 Tyr701 phosphorylation following
cotreatment with cisplatin/HDACi or HDAC4 siRNA and a
loss of nuclear phospho-STAT1 localization indicating func-
tional loss of transcription factor activity (Fig. 5A).
HDAC4 is significantly overexpressed following
acquired platinum-resistant relapse in clinical samples
To validate the observed increase in HDAC4 expression in
platinum-resistant cells, we measured HDAC4 expression by

























































































































































Figure 4. HDAC4 and STAT1 act
in a single, novel pathway in which
HDAC4 is required for
deacetylation and
phosphorylation of STAT1 in
response to cisplatin. A, STAT1
and HDAC4 were knocked down
alone and in combination by using
siRNA and induction of caspase 3/
7 assessed  cisplatin treatment
in platinum-resistant PEO4 cells. *,
P < 0.05 t test comparing caspase
3/7 activation between siRNA-
treated and siRNA control cells
following cisplatin exposure (left).
Western blot confirmed
knockdown at protein level (right).
B, immunoprecipitates from
untreated platinum-resistant
PEO4, PEA2, and SKOV3 cells
were made by using anti-HDCA4
antibody and probed for the
presence of STAT1. C,
immunoprecipitates from the
platinum-sensitive cell lines PEO1
and PEA1, the resistant paired
lines PEO4 and PEA2 and the
resistant line SKOV-3 were
prepared by using anti-acetyl
lysine antibody and probed for the
presence of STAT1 both before
and after siRNA-based
knockdown of HDAC4. D, control
and HDAC4 siRNA-treated PEO4
(top), PEA2 (middle), and SKOV3
(bottom) cell lysates  cisplatin
were probed for phosphorylation
of STAT1 at tyrosine 701. For B
and C, lysates–-whole cell extract
preimmunoprecipitation; beads—
protein G sepharose beads
without primary antibody; HDAC4/
Ac-lysine—specific
immunoprecipitates; wash—
whole-cell lysate column flow-
through; -ve—primary antibody/
lysate without protein G
sepharose beads.
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platinum-sensitive ovarian cancer patients matched to second
biopsies from the same patients subsequent to development
of acquired platinum resistance. In addition, we utilized
paired biopsies from 14 patients with platinum refractory
disease; those biopsies obtained before and after platinum-
based chemotherapy. Sections were stained and scored,
blinded by 2 pathologists. Intensity of staining was scored
on a 0 to 3 scale and percentage cells stained scored on a 0 to 4
scale. The product score was derived and used for further
statistical analysis. This revealed an increase in HDAC4 pro-
tein expression in 7 of 16 (44%) acquired platinum-resistant
biopsies compared with their matched platinum-sensitive
biopsies (Fig. 6A and B; P ¼ 0.0413; Wilcoxon rank-sum test).
Interestingly, the analysis of 14 paired sections from patients
with platinum refractory disease revealed no increase in
HDAC4 expression between the paired biopsies taken before
and after ineffective first-line platinum treatment indicating
that upregulation of HDAC4 is specifically an acquired resis-
tance mechanism and is not involved in refractory disease
(Supplementary Fig. S7). Clinical parameters are shown in
Supplementary Table S4. This analysis suggests that up to 44%
of patients with acquired platinum resistance may have an
HDAC4-mediated resistance pathway.
Discussion
Resistance to platinum chemotherapy continues to be a
major obstacle in the treatment of ovarian and other cancers.
A recent genomic analysis of the cell lines used in this study
has shown that resistance to platinum seems not to arise by
mutational adaptation of the sensitive tumor cells in the
presence of chemotherapy: rather the resistant cells are pre-
sent in the initial prechemotherapy tumor as a minor popula-
tion (5). The implication is therefore, that clinical mechanisms
of acquired resistance may not be recapitulated in vitro by
adaptive responses following exposure of homogeneous sen-
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Figure 5.HDAC inhibition prevents nuclear localization of phospho-STAT1
and resensitizes resistant cells to cisplatin. A, immunofluorescent
microscopy of platinum-resistant SKOV3 cells reveals induction and
nuclear localization of pSTAT1-Y701 on 24 hours stimulation with 25 mmol/
L cisplatin and shows that HDAC4 knockdown by using siRNA or inhibition
by using 5 mmol/L APHA4a prevents accumulation of pSTAT1. B,
treatment of the resistant cells PEO4 or SKOV3 with the HDACi APHA4a at
5 mmol/L or 10 mmol/L enhances the apoptotic response to treatment with
25 mmol/L cisplatin measured after 24 hours incubation *, P < 0.05,
**, P < 0.01 t test comparing caspase 3/7 activation between vehicle





















Figure 6. HDAC4 expression increases on acquisition of cisplatin
resistance in matched clinical specimens. A, sections cut from FFPE
ovarian tumor blocks from before and after acquisition of platinum
resistance in individual patients were stained for HDAC4 expression and
intensity and frequency of staining. Photomicrographs indicate increased
expression of HDAC4 (brown staining) in resistant (right) compared with
sensitive (left) biopsies from the same patient. Magnifications are
indicated. B, HDCA4 expression scores were produced for each section as
described and the change in score on acquisition of platinum resistance
analyzed by Wilcoxon rank sum test. Scores for 16 paired sections,
grouped as sensitive and resistant are indicated (P ¼ 0.0413).
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in vitromay reflect the artificial environment of the monolayer
culture: a suggestion underscored by the lack of correlation
between gene expression changes detected in a cisplatin-
resistant cell line, PEO1cddp (16), produced in vitro from
sensitive PEO1 cells and those seen in the clinically derived
resistant PEO4 and PEO6 lines (r2 values: PEO1cddp vs. PEO4
¼ 0.25; PEO1cddp vs. PEO6 ¼ 0.23; PEO4 vs. PEO6 ¼ 0.81;
Supplementary Fig. S8). Interestingly, most in vitro derived
platinum-resistant cell lines require periodic retreatment with
platinum to maintain resistance, indicating that the mechan-
isms affecting drug response are transient and adaptive rather
than being genomically established. Conversely, the clinically
derived resistant cell lines used here exhibit stable platinum
resistance in vitro, implying that the genomic differences
reported between sensitive and resistant cells from the same
patient (5) are likely to underpin the resistant phenotype. Such
alterations between these cell line pairs are extensive, how-
ever, and preclude efficient identification of resistance
mechanisms by DNA-level candidate selection. We therefore
used transcriptional profiling to indicate changes in gene
activity relating to acquired resistance.
Gene expression profiling has been used previously to
attempt identification of better predictive biomarkers for
clinically acquired platinum resistance and novel targets for
therapy and has been applied to clinical material (17–19) and
cell lines (20, 21). Jazaeri and colleagues identified expression
changes related to chemoresistance and, although underpow-
ered for statistical significance, suggested that distinct
mechanisms may be responsible for intrinsic and acquired
chemoresistance, as we have also indicated here (17). Spent-
zos and colleagues developed a 93-gene signature predictive of
response to platinum-based chemotherapy (18). Helleman and
colleagues identified a set of 9 genes, predictive of intrinsic
platinum resistance. These studies were focused on frozen
clinical samples and as such were correlative rather than
functional; however, they suggest that gene expression mea-
surements are informative in this context (19). Cheng and
colleagues compared global gene expression levels between
isogenically matched, platinum-sensitive and -resistant ovar-
ian cancer cell line pairs (21). The analysis identified a number
of dysregulated genes; however, no functional validation was
reported. Of note, the platinum-resistant cell lines used were
not clinically derived but were created by in vitro exposure of
sensitive cells to cisplatin (21).
Our analysis identified 4 genes, HDAC4, STAT1, FOLR2, and
PIK3R1 as overexpressed in clinically resistant cells, each of
which also significantly potentiated cisplatin response when
knocked down by siRNA. We were prospectively interested in
whether our approach would identify unrelated mechanisms
or common pathways of acquired resistance. It is of note that
by using this discovery-based approach, we identified a novel
relationship between HDAC4 and STAT1 whereby they phy-
sically interact to create conditions under which STAT1 can be
activated following cisplatin treatment in cells with acquired
clinical platinum resistance but not in matched sensitive cells
from the same patient. As a surrogate of this resistance-
specific activation, we observed phosphorylation and nuclear
translocation of STAT1 upon platinum treatment in resistant
cells only. We showed that overexpression of HDAC4 pro-
motes deacetylation of STAT1 which facilitates STAT1 phos-
phorylation at Y701 and its subsequent nuclear translocation.
In contrast, matched cisplatin-sensitive cells have lower endo-
genous HDAC4 levels and readily detectable ac-STAT1: con-
sequently, cisplatin treatment is unable to induce
phosphorylation of STAT1 (Y701) or STAT1 nuclear relocali-
zation (model summarized in Supplementary Fig. S9).
The role of HDACs in deacetylation of nonhistone proteins
is not a new concept. HDAC6, a class IIb HDAC found
exclusively in the cytoplasm, deacetylates tubulin, contractin,
and Hsp90 affecting cell morphology, adhesion, and migration
(22). A sumoylation/acetylation cross-talk has been described
for p53 that affects the transcriptional activity of this tumor
suppressor (23), whereas activity of the FOXO proteins, down-
stream targets of AKT, can be modulated by p300/CBP-
mediated acetylation and deacetylation by the class III HDAC,
SIRT1 (24). Kramer and colleagues reported acetylation of
STAT1 at K410 and K413 in melanoma cells and showed
increased acetylation following HDAC inhibition or IFN-a
treatment (12) although, HDAC4 was not analyzed in their
study. Following activation at the cell surface, nuclear trans-
location of STAT1 occurs which has been reported to follow
binding of STAT1 to importin-a5 via critical K410 and K413
(25, 26): the same residues as identified by Kramer and
colleagues as the acetyl sites on STAT1 (12). This suggests
a potential interference with the nuclear import machinery in
platinum-sensitive cell lines shown here to have constitutively
acetylated STAT1 and to remain in the cytoplasm following
platinum treatment (Figs. 3C and 4C). Subsequent to their
report of acetyl control of STAT1 (12), Kramer and colleagues
described a cyclical control system whereby phosphorylated,
nuclear STAT1 is acetylated by the histone acetyl transferase
CBP marking it for subsequent dephosphorylation by the
phosphatase TCP45 resulting in decreased DNA binding
and target gene transcription (13). Deacetylation by HDAC3
and nuclear–cytoplasmic translocation returns STAT1 to a
latent cytoplasmic state in readiness for reactivation by sub-
sequent IFN stimulation (13, 27). Our data suggest a similar
but distinct set of effects. In contrast to previous studies,
which identified the involvement of the class I HDACs, HDAC1
and HDAC3 in STAT1 deacetylation, we identify the class II
deacetylase, HDAC4, as having a key role in the cisplatin-
mediated activation of STAT1, specifically in platinum-resis-
tant cells that overexpress this HDAC. Importantly, we see that
in both platinum-sensitive and -resistant lines, IFN treatment
induces strong phosphorylation of STAT1 Y701 despite the
observed differences in basal STAT1 acetylation levels
between those platinum-sensitive and -resistant cells (Sup-
plementary Fig. S10). In contrast, we only see STAT1 Y701
phsophorylation in response to cisplatin treatment in resis-
tant lines. Our data indicate that both sensitive and resistant
cells activate STAT1 in response to IFN-g (Supplementary
Fig. S10); however, only resistant cells activate STAT1 in
response to cisplatin-induced DNA damage (Fig. 3D), suggest-
ing that this effect is not mediated via IFN-g .
The work presented here shows a novel mechanism invol-
ving HDAC4 and places this interaction at the centre of the
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response to platinum chemotherapy revealing clinically rele-
vant phenotypic differences resulting from within-patient
changes in HDAC4 gene expression. Our data indicate that
an HDAC4 threshold level exists that creates a dichotomous
STAT1 response that differentiates clinical platinum sensitiv-
ity from acquired clinical platinum resistance. Pharmacologic
and clinical data (Figs. 5 and 6) suggest that this mechanism
may be a frequent event and can be targeted to reverse
resistance using HDACi, many of which are either in or near
the clinic. It further suggests that HDAC4/class II HDACi may
be more appropriate than pan-HDACi in this indication, with
potentially lower toxicity/nonspecificity. This has implica-
tions for management of platinum-resistant disease, as a
relatively modest reduction in HDAC4 can cause resistant
cells to behave like their sensitive parental cells with respect to
both the control of STAT1 and the cytotoxic effects of cispla-
tin. HDAC4 has not previously been shown to functionally
modulate clinically acquired resistance to platinum-based
treatment.
Although STAT1 is most commonly associated with proa-
poptotic signaling, it is also associated with cell survival in
certain contexts. STAT1 is relocalized to the nucleus of breast
cancer cells following doxorubicin treatment and is associated
with increased apoptotic response (28) and enhances apop-
totic response to DNA damage in mouse fibroblasts via down-
regulation of mdm2, a negative regulator of p53 (29).
Conversely, STAT1 can induce docetaxel resistance in prostate
cancer cells (30) and cisplatin resistance in A2780 ovarian
cancer cells (20). Roberts and colleagues carried out expres-
sion profiling of ovarian cancer cell lines with predefined
response to a number of chemotherapeutics (20). Gene expres-
sion was correlated with drug IC50 values across the cell lines
used and this identified an association between STAT1 and
response to cisplatin and AMD473. Overexpression of STAT1
by transfection was shown to increase resistance to both
agents; however, inhibition of upstream Janus kinase by
treatment with AG490 (31) increased sensitivity to AMD473
but not cisplatin, perhaps suggesting that cisplatin-mediated
activation of STAT1 may be independent of Janus-activated
kinase (JAK) 2/3. The study included the cell line pair PEO1
and PEO4, however, interestingly the analysis did not take
advantage of the matched nature of these lines. Our study
shows that the behavior of STAT1 can differ fundamentally,
even within a single patient's tumor before and after the onset
of clinical resistance to platinum, thus highlighting the impor-
tance of the cellular context in understanding STAT1
responses following stimulus.
In summary, we have shown that molecular profiling of
appropriate, clinically derived model systems coupled to
functional assays can reveal novel biological mechanisms
underlying acquired platinum resistance. The identification
of an HDAC4-mediated STAT1 response "switch" represents a
novel mechanism of in vivo acquired platinum resistance that
is demonstrably amenable to therapeutic modulation and can
result in resensitization to platinum-based chemotherapy.
The recent report that platinum-resistant clones exist within
the platinum-sensitive presenting tumor also raises the pos-
sibility of therapeutically targeting these cells in front-line
therapy to increase survival and/or delay the onset of resis-
tance. Further work will determine the most appropriate
predictive biomarker(s) for identifying patients who might
benefit from this approach. Drug development and clinical
trials around HDAC4 or STAT1 inhibition will address the
therapeutic potential of re-engaging response to platinum-
based treatment in resistant cells by disrupting this specific
mechanism in ovarian and potentially other platinum-treated
cancers. Further work is required to identify the downstream
mechanistic functions of STAT1 that confer this resistant
phenotype and to further integrate this novel mechanism
in the context of other parallel signaling changes in acquired
resistance identified here and elsewhere. In addition, it
remains unclear how platinum-induced DNA damage leads
to STAT1 activation. A comprehensive screen of ligands,
receptors, and associated kinases (JAKs and others) in the
context of platinum treatment would help to address this
question. Establishment of a system-level understanding of
acquired platinum resistance will allow us to better predict
the behavior of each tumor and identify rational means of
targeting it for re-engagement of apoptotic response to pla-
tinum chemotherapy.
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